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vCHEMICAL ABBREVIATIONS
25B-NBOMe 1-(4-Bromo-2,5-dimethoxyphenyl)-
N-[(2-methoxyphenyl)methyl]
ethanamine
25C-NBOMe 1-(4-Chloro-2,5-dimethoxyphenyl)-
N-[(2-methoxyphenyl)methyl]
ethanamine
25I-NBOMe 1-(4-Iodo-2,5-dimethoxyphenyl)-N- 
[(2-methoxyphenyl)methyl]ethanamine
3,4-MDP-2-P 3,4-Methylenedioxyphenylpropan-
2-one
2-AI 2-Aminoindane 
2C-B 4-Bromo-2,5-dimethoxyphenethyl-
amine
2C-E 4-Ethyl-2,5-dimethoxyphenethylamine
2C-I 4-Iodo-2,5-dimethoxyphenethylamine
5-MeO-DMT 5-Methoxy-N,N-dimethyltryptamine
5-MeO-DPT 5-Methoxy-N,N-dipropyltryptamine 
AKB-48/
APINACA
1-Pentyl-N-tricyclo[3.3.1.13,7]
dec-1-yl-1H-indazole-3-carboxamide
APAAN alpha-Phenylacetoacetonitrile
-PVP alpha-Pyrrolidinopentiophenone 
ATS Amphetamine-type stimulants 
bk-MBDB 1-(1,3-Benzodioxol-5-yl)-
2-(methylamino)butan-1-one
BTCP Benzothiophenylcyclohexylpiperidine
BZP 1-Benzylpiperazine 
DMT Dimethyltryptamine
GHB Gamma-hydroxybutyrate 
JWH-018 (1-Pentyl-1H-indol-3-yl)-1-naphthale-
nyl-methanone
LSD (+)-Lysergide 
mCPP 1-(3-Chlorophenyl) piperazine 
MDA 3,4-Methylenedioxyamphetamine
MDAI 5,6-Methylenedioxy-2-aminoindane
MDEA/MDE 3,4-Methylenedioxyethylamphetamine
MDMA 3,4-Methylenedioxymethamphetamine
MDPBP 3,4-Methylenedioxy--
pyrrolidinobutyrophenone
MDPV 3,4-Methylenedioxypyrovalerone
MN-24 1-Pentyl-N-(naphthalen-1-yl)-1H- 
indole-3-carboxamide
NPS New Psychoactive Substances
P-2-P/PMK 1-Phenyl-2-propanone
PB-22 Quinolin-8-yl-1-pentyl-1H-indole-
3-carboxylate
PCP Phencyclidine
PMMA para-Methoxymethamphetamine,
TFMMP 1-(3-Trifluoromethylphenyl)piperazine
THC delta-9-Tetrahydrocannabinol
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EXPLANATORY NOTES
The designations employed and the presentation of the 
material in this publication do not imply the expression 
of any opinion whatsoever on the part of the Secretariat 
of the United Nations concerning the legal status of any 
country, territory, city or area or of its authorities, or con-
cerning the delimitation of its frontiers or boundaries. 
Countries and areas are referred to by the names that were 
in official use at the time the relevant data were 
collected.
The following notes describe certain terms, data sources 
and timeframes used throughout this document.
ATS – Amphetamine-type stimulants (ATS) are a group 
of substances comprised of synthetic stimulants, including 
amphetamine, methamphetamine, methcathinone, and 
ecstasy-type substances (e.g. MDMA and its analogues). 
In various sections of the present report, amphetamine and 
methamphetamine are also referred to as amphetamines. 
In cases where countries reported to UNODC without 
indicating the specific ATS they are referring to, the term 
non-specified ATS was used. Often drug use surveys in 
South America, Central America and the Caribbean do 
not differentiate between the use of amphetamines (meth-
amphetamine and amphetamine) and non-medical use of 
prescription ATS, by using the term "stimulants".
Ecstasy –Tablets which are marketed to contain an ecstasy-
type substance, but may actually contain a variety of other 
substances, are referred to as “ecstasy” in inverted commas. 
Use of ecstasy-type substances was usually reported sepa-
rately in drug use surveys and is therefore not included in 
the non-specified ATS group.
NPS – New psychoactive substances are substances of 
abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Single Convention on Narcotic 
Drugs or the 1971 Convention on Psychotropic Sub-
stances, but which may pose a public health threat. In this 
context, the term ‘new’ does not necessarily refer to new 
inventions but to substances that have been recently 
become available.
Synthetic drugs – For the purpose of this report, the term 
synthetic drugs includes both Amphetamine-Type Stimu-
lants (ATS) and New Psychoactive Substances (NPS). 
Maps – The origins of the drug flow arrows do not neces-
sarily indicate the source/manufacture of the drug in ques-
tion, but instead represent the flows as perceived by 
recipient countries. The boundaries and names shown and 
the designations used on maps do not imply official 
endorsement or acceptance by the United Nations. Dashed 
lines represent undetermined boundaries. A dotted line 
represents approximately the Line of Control in Jammu 
and Kashmir agreed upon by India and Pakistan. The final 
status of Jammu and Kashmir has not yet been agreed upon 
by the parties. The final boundary between the Sudan and 
South Sudan has not yet been determined.
Data Sources – Unless indicated specifically, data con-
tained in this report draws upon official sources as reported 
in the UNODC Annual Reports Questionnaire (ARQ), 
the UNODC questionnaire on new psychoactive sub-
stances by Member States and the International Collabo-
rative Exercises (ICE) network of drug analysis laboratories, 
annual and technical reports of the International Narcotics 
Control Board (INCB) and the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), offi-
cial government and inter-governmental entities (e.g., 
Interpol/ICPO, Europol, Inter-American Drug Abuse 
Control Commission of (CICAD), UNODC Field Offices 
and HONLEA and HONLAF reports, data systems (e.g., 
DAINAP, DAINLAC) and scientific literature.
Data Timeframes – The statistical data contained in this 
report covers the period 2008-2012, except in instances 
where a longer historical timeframe is necessary to provide 
a clear explanation of manufacture/emergence, use and 
trafficking of ATS and NPS. Data related to seizures of 
ATS, their precursors and clandestine laboratories are sub-
ject to change for a variety of reasons, such as new or late 
data being added or revisions in data already provided by 
Member States. Thus, some figures may differ from previ-
ously published figures. All data reported herein reflect the 
most up-to-date and accurate information available at the 
time of writing.

11. GLOBAL OVERVIEW
This report provides an analysis of the global synthetic 
drugs market and for this purpose includes both Amphet-
amine-Type Stimulants (ATS) and New Psychoactive Sub-
stances (NPS). The expansion of global ATS markets is of 
increasing concern, conveyed by the 2009 Political Decla-
ration and Plan of Action on International Cooperation 
towards an Integrated and Balanced Strategy to Counter 
the World Drug Problem. This report aims to provide an 
improved understanding of the problem based on scientific 
evidence and experiences that show the complex interplay 
between the demand for and the supply of ATS in different 
contexts. Previous reports have focused on ATS, but given 
the growing presence of NPS on illicit drug markets, this 
report takes a more comprehensive view of the situation. 
Plant-based psychoactive substances, such as khat, have also 
been included in discussions on emerging NPS, as these 
have become of increasing concern in certain regions.
While the NPS issue is not new, it has gained in impor-
tance on an international level at the fifty-fifth session of 
the Commission on Narcotic Drugs (CND) in March 
2012, when Member States decided to monitor emerging 
trends in the composition, production and distribution of 
NPS as well as patterns of use, and to share that informa-
tion and adopt appropriate measures aimed at reducing 
supply and demand.1 The use of NPS that pose a health 
threat, has grown rapidly over the past decade and there 
have been increasing reports of the availability and manu-
facture of such substances. Given the fast-paced nature of 
the NPS market, there is a continued need for analysis of 
the scope and magnitude of the global synthetic drugs 
problem based on forensic and scientific data and qualita-
tive information for effective policy decision-making.
Growing global markets for ATS
Based on 2010 figures, the last Global ATS Assessment 
published in 2011, confirmed that ATS were firmly estab-
lished on global illicit drug markets and that use levels 
often exceeded those of heroin and/or cocaine. Since 2010, 
however, surging ATS seizures point to a rapid expansion 
of the global market, with total ATS seizures rising by more 
than 80 per cent to more than 135 tons in 2012. The 
increase of ATS seizures is primarily attributable to the 
1 This is reflected in CND resolution 55/1 on promoting international 
cooperation in responding to the challenge posed by new psychoactive 
substances. In March 2013, CND Resolution 56/4 further encour-
aged UNODC to share and exchange ideas, efforts, good practices 
and experiences in adopting effective responses to address the unique 
challenges posed by new psychoactive substances.
growing amount of global methamphetamine seizures, 
which have more than doubled over the same period, 
reaching 107 tons in 2012. The growing importance of 
methamphetamine is a new feature of the global ATS 
market.
The high level of global methamphetamine seizures in 
recent years has been primarily due to the rise of seizures 
in East and South-East Asia and North America. Preva-
lence figures and treatment data indicate that metham-
phetamine is a major problem in several countries in East 
and South-East Asia, such as Brunei Darussalam, Cambo-
dia, the Philippines, Singapore and Thailand.2 Extensive 
methamphetamine manufacture has been reported in 
Mexico and the United States and increasing amounts are 
being smuggled from Mexico to the United States.3 Already 
prior to 2011 there were indications of an expansion of 
the ATS market in Europe in terms of use and manufac-
ture. This trend was confirmed by recent data.
2 Drug Abuse Information Network for Asia and the Pacific (DAINAP); 
United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brunei Darussalam, the Philippines and 
Singapore 2012.
3 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2007-2012; US Department of Justice, Drug 
Enforcement Administration (DEA), National Drug Threat Assessment 
Summary 2013, November 2013.
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Over the years, global amphetamine seizures have fluctu-
ated, ranging between about 20 tons and 33 tons annually 
since 2008. Amphetamine continues to be the main ATS 
of use in the Middle East and amphetamine seizures in this 
region have been steadily increasing, annually accounting 
for more than 55 per cent of amphetamine seized world-
wide.4 Although global “ecstasy”5 seizures are compara-
tively low remaining below 6 tons annually, “ecstasy” 
continues to be the main ATS of use across Europe and 
the Oceania region.6 However, amphetamine is still a 
major problem in large parts of Europe, particularly in 
Northern Europe.7 In South and Central America, com-
paratively little data is available with regards to ATS, given 
that cannabis and cocaine continue to dominate the drug 
market and law enforcement efforts. Although ATS use 
among the general population remains at low levels, some 
countries in the region have reported high levels of use 
among youths, sometimes even exceeding cannabis and/
4 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2004-2012
5 In this report “ecstasy” is in inverted commas to indicate that pills are 
marketed to contain MDMA or other ecstasy-group substance, which 
may actually contain a variety of other substances.
6 United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2013, New York, May 2013.
7 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Denmark, Latvia and Sweden in 2010-2012.
or cocaine use.8 Generally, ATS use figures in Africa remain 
limited and, until a few years ago, ATS use appeared to be 
largely confined to South Africa. However, in the last few 
years, ATS use has been reported in some other African 
countries, particularly in West Africa.
Expansion of global methamphetamine 
trafficking
The last global ATS assessment in 2011 reported on how 
ATS manufacture has spread beyond established markets 
in Europe, North America and Oceania to East and South-
East Asia, West Africa and Central and South America. 
This trend has continued over the last few years. Particu-
larly methamphetamine trafficking has expanded in terms 
of scope and quantity. The risk of ATS manufacture in 
several countries has also been heightened by the extensive 
availability of ATS precursor chemicals.
West Africa has become a prominent region for metham-
phetamine manufacture which is then trafficked to East 
and South-East Asia. According to seizure reports, ATS, 
in particular methamphetamine, has been trafficked from 
West Africa either directly or via Southern Africa and West-
ern Europe to East and South-East Asia and Oceania, 
8 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Bolivia, Honduras, Costa Rica and Jamaica 
2008-2012.
Map 1: Methamphetamine flows as perceived by recipient countries, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012; Data reported by National Drug 
Law Enforcement Agency (NDLEA), Nigeria, July 2009 – July 2013; Data derived from ‘Illicit Drug seizures with relation to European  
Airports’ (IDEAS) database, 2009-2012; Australian Crime Commission (ACC), Illicit Drug Data Report 2009-2010, Canberra, June 2011; 
“Turkish Report of Anti-Smuggling and Organised Crime 2011”, Turkish National Police, Ankara, March 2012; International Narcotics  
Control Board (INCB), Report of the International Narcotics Control Board for 2012, Vienna, January 2013.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived 
by recipient countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent 
undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status 
of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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mostly to Australia, Japan, Malaysia and Thailand.9 Since 
2009, about 86 per cent of ATS originating from West 
Africa seized at Western European and Japanese airports, 
were destined for countries in East and South-East Asia, 
predominantly Japan as well as Malaysia.10 From Southern 
Africa, ATS is also being trafficked to Australia.11
According to the Turkish authorities, Turkey serves as a 
transit point for methamphetamine smuggled from the 
Islamic Republic of Iran to East and South-East Asian 
countries.12 Between 2010 and 2012, methamphetamine 
seizures perceived to have originated in the Islamic Repub-
lic of Iran were reported by Indonesia, Malaysia and Thai-
land.13 However, there have been no reports of dismantled 
methamphetamine laboratories in the Islamic Republic of 
Iran in recent years.14 Recently, there has been an emer-
gence of methamphetamine trafficking from the Islamic 
Republic of Iran to Europe.15 There have also been reports 
of methamphetamine (including other drugs under inter-
national control) trafficked from the Islamic Republic of 
Iran to other regions of the world, such as Central Asia16 
and the Middle East17.
Recent trends in precursor chemicals used 
in the manufacture of ATS and  
synthetic drugs
As a result of the increased awareness of the main precur-
sor chemicals used for the manufacture of ATS and syn-
thetic substances, a number of Member States have 
introduced and/or amended their legislation to more 
9 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2008-2012; Data reported by National Drug 
Law Enforcement Agency (NDLEA), Nigeria, July 2009 – July 2013; 
Data derived from ‘Illicit Drug seizures with relation to European Air-
ports’ (IDEAS) database, 2009-2013; Australian Crime Commission 
(ACC), Illicit Drug Data Report 2009-2010, Canberra, June 2011.
10 Data derived from ‘Illicit Drug seizures with relation to European 
Airports’ (IDEAS) database, 2009-2013.
11 Australian Crime Commission (ACC), Illicit Drug Data Report 2009-
2010, Canberra, June 2011.
12 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012; “2012 National 
Report (2011 data) to the EMCDDA by the Reitox National Focal 
Point” European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Turkey, 2012.
13 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia, Malaysia and Thailand 2010-
2012.
14 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Islamic Republic of Iran 2010-2012. 
15 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Bulgaria, Germany, the Russian Federa-
tion and Turkey 2010-2012; “Turkish Report of Anti-Smuggling and 
Organised Crime 2011”, Turkish National Police, Ankara, March 
2012.
16 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Tajikistan 2012.
17 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012; United Nations Office 
on Drugs and Crime (UNODC), Annual Report Questionnaire for 
the Syrian Arab Republic 2011.
closely monitor shipments of precursor chemicals, leading 
to an increase in the number of countries reporting seizures 
of these chemicals to the International Narcotics Control 
Board (INCB).18
A second trend in recent years is the increased use of alter-
nate forms of known precursors such as pharmaceutical 
preparations containing pseudoephedrine/ephedrine in 
certain regions of the world and the use of alternate pre-
cursor chemicals in the manufacture of ATS. Phenylacetic 
acid, one such alternate precursor used for the manufacture 
of amphetamine and methamphetamine was recently 
rescheduled from Table II to Table I of the 1988 United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances which invokes stricter 
import and export controls. The illicit manufacture of ATS 
is flexible, and drug traffickers are increasingly using non-
controlled precursors such as certain phenylacetic acid 
derivatives as well as novel precursor chemicals such as 
alphaphenylacetoacetonitrile (APAAN)19 for the manu-
facture of amphetamine/methamphetamine and other 
18 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
19 At the time of preparation of this report, alpha-phenylacetoacetonitrile 
(APAAN) was on the agenda of the fifty-seventh session of the Com-
mission on Narcotic Drugs (CND) for the inclusion in Table I of the 
United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988.
Fig. 2: Number of NPS reported at the global level, 
2009 to 2013 (cumulative)
Source: United Nations Office on Drugs and Crime (UNODC) ques-
tionnaire on new psychoactive substances, 2012; United Nations 
Office on Drugs and Crime (UNODC), “UNODC Early Warning 
Advisory on New Psychoactive Substances (NPS) October 2013 
update”, October 2013; Submissions to UNODC and laboratories 
participating in the International Collaborative Exercises (ICE) pro-
gramme.
Note: For some substances reported in 2013 the reference period may have 
been August to December 2012.
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non-controlled chemicals that can be used to manufacture 
ecstasy-group substances.20
Responding to the rapid expansion of NPS
A recent feature of global drug markets is the unprece-
dented pace at which new psychoactive substances (NPS) 
have been developed and at which these have emerged 
worldwide. By 2013, the emergence of 348 NPS had been 
reported to UNODC globally, the majority of which were 
identified between 2008 and 2013. Although UNODC 
has detected 348 NPS, the actual number of NPS available 
worldwide may be significantly higher, given that this figure 
only reflects reports of official sources and does not take 
unofficial sources into account. However, the NPS market 
is very dynamic and a number of NPS are transient in their 
nature. Therefore, the fact that certain NPS are present, 
does not mean that they have an established market.
Currently, 234 psychoactive substances (excluding esters 
and isomers) are under the governance of the 1961 Single 
Convention on Narcotic Drugs and the 1971 Convention 
on Psychotropic Substances. And yet, the variety of sub-
stances available on illicit drug markets is higher than ever. 
Over the last century, there has been an upward trend in 
the number of internationally scheduled substances. In 
20 For more detailed information on the precursors used for the illicit 
manufacture of controlled substances, see the upcoming 2014 World 
Drug Report which will contain a chapter dedicated to the topic.
spite of the significant increase in NPS reported over the 
last few years and growing concerns about the health risks 
associated with them, no psychoactive substances have 
been internationally scheduled since 2009.21
In the absence of an international framework, Member 
States have developed different national legislative 
responses to NPS.22 There is not yet sufficient evidence 
available to fully understand the effect of different legisla-
tive approaches on NPS markets. However, there are some 
cases that have shown a decline in NPS use after the imple-
mentation of national regulatory measures. In New Zea-
land, for example, BZP use declined sharply after it had 
been scheduled as a Class C drug in 2007 and in the 
United Kingdom there may have been a decline in the 
market for mephedrone following its classification as a class 
B substance under the Misuse of Drugs Act in 2010.23 The 
21 The World Health Organisation (WHO) Expert Committee on Drug 
Dependence has considered the control of some substances since 2009, 
such as ketamine, but so far there has been no decision to schedule any 
of these substances.
22 For a detailed analysis and overview of national legislative responses to 
NPS see the UNODC Early Warning Advisory on New Psychoactive 
Substances: www.unodc.org/nps
23 C. Wilkins and P. Sweetsur, “The impact of the prohibition of Ben-
zylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal 
highs and other drug use in New Zealand”, Drug and Alcohol Depen-
dence 127, no. 1-3 (2013): 72-80; United Kingdom, Home Office, 
Drug Misuse Declared: Findings from the 2011/12 British Crime Survey 
for England and Wales, 2nd ed., London, July 2012.
Fig. 3: Number of new psychoactive substances not under international control and substances controlled 
under the international drug conventions, 1961-2013
Source: I. Bayer and H. Ghodse,“Evolution of international drug control, 1945-1995”, Bulletin on Narcotics, vol. LI, Nos. 1 and 2, 1999 
(United Nations publication) (for natural drugs until 1995 and synthetic drugs until 1948); The International Drug Control Conventions 
(United Nations publication, Sales No. E.09.XI.20); International Narcotics Control Board, list of narcotic drugs under international control 
(“Yellow List”), 50th ed., December 2011; International Narcotics Control Board, list of psychotropic substances under international con-
trol (“Green List”), 24th ed., May 2010; United Nations Office on Drugs and Crime (UNODC) questionnaire on new psychoactive sub-
stances, 2012; United Nations Office on Drugs and Crime (UNODC), “UNODC Early Warning Advisory on New Psychoactive Substances 
(NPS) October 2013 update”, October 2013; Submissions to UNODC and laboratories participating in the International Collaborative Exer-
cises (ICE) programme.
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Emergence of NPS
effects of national control measures in the long run remain 
unknown since more time is needed to study the prevalence 
of NPS on the market.
Diverse markets for NPS
By 2013, NPS had emerged in every region of the world, 
in a total of 94 countries worldwide.24 Though there were 
a number of countries that did not provide any informa-
tion on the emergence of NPS to UNODC, this does not 
24 Countries and territories reporting emergence of NPS: Albania, 
Andorra, Angola, Argentina, Australia, Austria, Bahrain, Belarus, Bel-
gium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, 
Cambodia, Canada, Cabo Verde, Chile, China, Colombia, Costa Rica, 
Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Egypt, Eritrea, 
Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Hong 
Kong (China), Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, 
Jordan, Republic of Korea, Latvia, Lebanon, Liechtenstein, Lithu-
ania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Republic of 
Moldova, Mongolia, Myanmar, Netherlands, New Zealand, Norway, 
Oman, Panama, Philippines, Poland, Portugal, Qatar, Romania, Rus-
sian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, South 
Africa, Spain, Sudan, Sweden, Switzerland, Syrian Arab Republic, 
Tanzania, Thailand, Togo, Turkey, Ukraine, United Arab Emirates, 
United Kingdom, United States of America, Uruguay, Viet Nam, 
Yemen, Zambia, Zimbabwe. The presence of khat was established for 
Djibouti, Ethiopia, Kenya and Somalia based on information from 
various official sources.
mean that such substances were not present on these mar-
kets. NPS is a phenomenon that is difficult to detect 
because NPS identification requires an advanced level of 
forensic laboratory capacity.
Between 2008 and 2013, the majority of NPS in terms of 
the number of reports worldwide to UNODC, were syn-
thetic cannabinoids at 28 per cent and synthetic cathinones 
at 25 per cent, followed by phenethylamines at 17 per cent. 
Together these three groups of NPS made up over two-
thirds of the total number of reports of NPS at 70 per cent. 
By 2013, the total number of synthetic cannabinoids 
surged to 110 from 60 in mid-2012.
However, given that the largest number of NPS reports to 
UNODC were made by European and North American 
countries, the break-down of identified substances is gen-
erally representative of the trends in these regions and does 
not provide a clear global overview. On a region by region 
basis, trends somewhat vary. For instance, in South and 
Central America and the Caribbean, between 2008 and 
2013, synthetic cannabinoids were the third most fre-
quently reported NPS at about 17 per cent, after pipera-
zines which made up the largest share at about 33 per cent 
Map 2: Global emergence of NPS, 2008 to 2013
Source: United Nations Office on Drugs and Crime (UNODC) questionnaire on new psychoactive substances, 2012; United Nations Office 
on Drugs and Crime (UNODC), Annual Report Questionnaire for Canada, Eritrea, Sweden, Tanzania and Zambia 2009-2012; United 
Nations Office on Drugs and Crime (UNODC), “UNODC Early Warning Advisory on New Psychoactive Substances (NPS) October 2013 
update”, October 2013; Submissions to UNODC and laboratories participating in the International Collaborative Exercises (ICE) pro-
gramme; United Nations Office on Drugs and Crime (UNODC), World Drug Report 2013, New York, May 2013; World Bank, Comprendre 
la dynamique du khat à Djibouti: Aspects Sociaux, économiques et de santé, report No. 62823-DJ, Washington DC, 2011; United States 
Department of State, Bureau for International Narcotics and Law Enforcement Affairs, International Narcotics Control Strategy Report, vol. 
1, Drug and Chemical Control, March 2012; “Khat use in Europe: implications for European policy”, Drugs in focus briefing of the Euro-
pean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg, 2011.
Note: The information presented in this map portrays the emergence of NPS among Member States which have been reported to UNODC in the questionnaire 
on new psychoactive substances in 2012 or in the UNODC Annual Report Questionnaire (ARQ) in 2008 to 2012. The presence of khat was established for 
Djibouti, Ethiopia, Kenya and Somalia based on information from various official sources. The fact that information with regards to NPS in some countries is not 
indicated does not mean that there is no NPS present in these countries; The boundaries shown on this map do not imply official endorsement or acceptance 
by the United Nations. Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed 
upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and 
South Sudan has not yet been determined.
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and phenethylamines which accounted for a 26 per cent 
share. Over the same period, synthetic cannabinoids were 
the most frequently reported substance group in East and 
South-East Asia, Oceania and the Pacific at about 25 per 
cent, closely followed by ketamine and phencyclidine-type 
substances at 24 per cent.
NPS are being sold on illicit drug markets
Many NPS available on the market contain molecules that 
might share similar effects and profiles of substances under 
international control that they are designed to mimic.25 
For instance, synthetic cannabinoids, which include the 
JWH series (eg. JWH-01826), are mimetics of THC (delta-
9-tetrahydrocannabinol), which is the main psychoactive 
substance in cannabis. Synthetic cathinones, which include 
substances such as mephedrone, methylone and MDPV, 
can evoke stimulant and empathogenic effects similar to 
ATS, including MDMA.27 Phenethylamines include sub-
25 So-called mimetics are substances that are chemically different but 
mimic the pharmacological effects of a particular substance, notably by 
acting on the same receptors of the brain; See United Nations Office 
on Drugs and Crime (UNODC), World Drug Report 2013, New York, 
May 2013.
26 JWH-018 is the chemical abbreviation of (1-pentyl-1H-indol-3-yl)-
1-naphthalenyl-methanone, a synthetic cannabinoid not under inter-
national control.
27 For more information on the stimulant and empathogenic effects 
of mephedrone see Brunt, Tibor M. et. al. “Instability of the ecstasy 
stances such as the 2C series (eg. 2C-I) and NBOMe com-
pounds (eg. 25I-NBOMe), which can exhibit effects 
ranging from stimulant to hallucinogenic.28 Only a few 
substances of this group are already controlled under the 
1971 Convention on Psychotropic Substances such as 
amphetamine, methamphetamine and MDMA.
A recent feature has been that there have been several cases 
in which NPS have been sold on ATS and other illicit drug 
markets. For instance, in the United States, synthetic can-
nabinoids first emerged on the drug market in 2008 and 
were marketed as “legal alternatives to marijuana”, as the 
use of these produce effects similar to those of cannabis.29 
In recent years, countries in Europe, Latin America and 
East and South-East Asia, as well as Canada and New Zea-
land, have reported of NPS, such as mephedrone, sold as 
“ecstasy”, which is traditionally synonymous with 
MDMA.30 Therefore, reports of high level “ecstasy” use 
market and a new kid on the block: mephedrone” Journal of Psycho-
pharmacology September 2010 (25): 1543-1547; Schifano, Fabrizio, et. 
al. “Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, 
pharmacological and clinical issues”, Journal of Psychopharmacology 
April 2011 (214): 593-602.
28 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
29 US Department of Justice, Drug Enforcement Administration (DEA), 
National Drug Threat Assessment Summary 2013, November 2013.
30 European Monitoring Centre for Drugs and Drug Addiction 
Fig. 4: Total number of NPS reports to UNODC by 
countries worldwide, 2008 to 2013
Source: United Nations Office on Drugs and Crime (UNODC) ques-
tionnaire on new psychoactive substances, 2012; United Nations 
Office on Drugs and Crime (UNODC), “UNODC Early Warning 
Advisory on New Psychoactive Substances (NPS) October 2013 
update”, October 2013; Submissions to UNODC and laboratories 
participating in the International Collaborative Exercises (ICE) pro-
gramme.
NPS groups Examples
Aminoindanes 2-AI, MDAI
Phencyclidine-type  
substances
Ketamine,  
methoxyeticyclidine
Phenethylamines 25B-NBOMe, PMMA
Plant-based substances Khat
1, kratom2,  
salvia divinorum3
Piperazines BZP, TFMPP
Synthetic cannabinoids JWH-018, AKB-48
Synthetic cathinones Mephedrone, MDPV
Tryptamines 5-MeO-DMT, 5-MeO-DPT
Aminoindanes
1%
Ketamine & 
Phencyclidine-
type substances
4%
Other substances 
5%
Phenethylamines
17%
Piperazines
9%
Plant-based 
substances
7%
Synthetic 
cannabinoids
28%
Synthetic 
cathinones
25%
Tryptamines
4%
Table 1: NPS groups
Source: United Nations Office on Drugs and Crime (UNODC).
1 The khat shrub (catha edulis) of the celastraceae family is a plant native to 
the horn of Africa and the Arabian peninsula and a plant-based NPS not 
under international control; United Nations Office on Drugs and Crime 
(UNODC), The challenge of new psychoactive substances. Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, Vienna, 
March 2013.
2 Mitragyna speciosa Korth (of the Rubiaceae family) is a large tree known as 
"kratom" found in the tropical and sub-tropical regions of South-East Asia. 
Kratom is a plant-based NPS and neither kratom nor any of its active alka-
loids are listed under the 1961 and 1971 UN Conventions; United Nations 
Office on Drugs and Crime (UNODC), The challenge of new psychoactive 
substances. Global Synthetics Monitoring: Analyses, Reporting and Trends 
(SMART) Programme, Vienna, March 2013.
3 Salvia divinorum (of the mint family Lamiaceae), is a psychoactive plant 
indigenous to forest areas in Oxaca, Mexico and a plant-based NPS not 
under international control; United Nations Office on Drugs and Crime 
(UNODC), The challenge of new psychoactive substances. Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, Vienna, 
March 2013.
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in some of countries may be misleading. Similarly, various 
NBOMe compounds have been sold as LSD in South 
America, in countries, such as Chile and Colombia, and 
there have been reports of high LSD use among certain 
population groups in the region.31 Overall, it remains 
unclear whether these new substances are replacing other 
controlled substances, in either the short or long term, or 
whether they are simply being used as a supplement to the 
range of existing drugs under international control.
A large market for ketamine in East and 
South-East Asia
Ketamine32 is a widely used anasthetic often used in vet-
erinary as well as human medicine. However, ketamine is 
also widely misused for recreational purposes at clubs and 
raves, such as in South-East Asia, where it was also found 
(EMCDDA), “Risk assessment report of a new psychoactive substance: 
4-methylmethcathinone (mephedrone)”; United Nations Office on 
Drugs and Crime (UNODC), Annual Report Questionnaire 2010-
2012.
31 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013; United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012; “II Estudio Epidemiológico 
Andino sobre Consumo de Drogas en la Población Universitaria, 
Informe Colombia 2012”, Proyecto Programa Anti-Drogas Ilícitas en 
la Comunidad Andina (PRADICAN), Inter-American Observatory 
on Drugs (OID)/ Inter-American Drug Abuse Control Commission 
(CICAD), Observatorio de Drogas de Colombia, Enero 2012.
32 At the time of preparation of this report, China submitted a notifica-
tion to the Secretary-General of the United Nations on scheduling 
ketamine under the 1971 Convention on Psychotropic Substances.
in seized tablets sold as “ecstasy”.33 Side-effects of chronic 
ketamine use can include high blood pressure, abdominal 
pain, lower urinary tract symptoms, disorientation, 
impaired vision and confusion.34
Ketamine is more widely misused in East and South-East 
Asia than in the Americas and Europe. Among people held 
in prisons in Macau, China, in 2012 ketamine was the 
second most used drug in terms of annual prevalence at 
18.3 per cent, after methamphetamine at 41.6 per cent.35 
Extensive ketamine use has also been reported in Brunei 
Darussalam, India, Japan, Myanmar and Singapore.36
High levels of ketamine seizures have been reported in 
China, including Hong Kong, China, over the years which 
have also accounted for a significant share of ketamine 
seizures reported worldwide. Between 2008 and 2011, 
ketamine seizures in mainland China and Hong Kong, 
China, almost made up 60 per cent of global ketamine 
33 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia and Singapore 2010-2011.
34 United Christian Hospital, “Emergency department presentation of 
ketamine abusers in Hong Kong: a review of 233 cases”, Hong Kong 
Med J 16 (2010):6-11; United Nations Office on Drugs and Crime 
(UNODC), The challenge of new psychoactive substances. Global Syn-
thetics Monitoring: Analyses, Reporting and Trends (SMART) Pro-
gramme, Vienna, March 2013; T. Okon, “Ketamine: an introduction 
for the pain and palliative medicine physician”, Pain Physician, vol. 10, 
no. 3 (2007): 493-500.
35 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Macau, China 2012.
36 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
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Map 3: Ketamine seizures reported worldwide, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and 
Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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seizures.37 Ketamine manufacture has been reported by 
countries in East Asia, particularly in China, where large 
numbers of ketamine laboratories were dismantled in 2007 
and 2012.38 From China and India, including Cambodia 
and the Taiwan Province of China, ketamine is reportedly 
trafficked to other countries within the region, as well as 
to countries in Europe and North America.39 
37 Except for 2010 when ketamine seizures accounted for about 42 per 
cent of the global total; United Nations Office on Drugs and Crime 
(UNODC), Annual Report Questionnaire for China 2010.
38 A total of 44 ketamine laboratories were discovered in mainland China 
in 2007 and another 81 laboratories in 2012; United Nations Office 
on Drugs and Crime (UNODC), Annual Report Questionnaire for 
China 2007-2012.
39 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada, Indonesia, Italy, Japan, Thailand 
and the United States 2008-2011.
The global spread of the khat market
Khat, a plant-based NPS, is largely cultivated in East Africa 
and parts of the Middle East, where it has had a long tra-
dition of use at communal festivities. High levels of preva-
lence have been recorded in Yemen and the Jazan region 
of Saudi Arabia. A general population survey among people 
aged 16 and above in Yemen, where khat is not under 
national control and is being cultivated, showed a lifetime 
prevalence of 52 per cent, which, with the exception of 
alcohol, tobacco and caffeine, is the highest lifetime preva-
lence rate recorded for any psychoactive substance in any 
country in the world.40 In the Jazan region of Saudi Arabia, 
where khat is under national control, this substance appears 
40 World Bank, “Yemen toward qat demand reduction”, Report no. 
39738-YE, June 2007; United Nations Office on Drugs and Crime 
(UNODC), World Drug Report, New York, June 2012.
Map 4: Khat flows as perceived by recipient countries, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012; “Khat use in Europe: implications 
for European policy”, Drugs in focus briefing of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg, 
2011.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of khat. These arrows represent the flows as perceived by recipient 
countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and 
Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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to be wide-spread among youths.41 Over the last few years, 
Saudi Arabia has also reported by far the largest amount 
of khat seizures in the Middle East.42
In the last several years, khat has been increasingly trans-
ported from East Africa to other regions, to mostly supply 
migrant communities from sub-Saharan Africa.43 Khat 
starts to decompose quickly, 72 hours after harvesting, so 
that a high frequency and short time-span between harvest 
and delivery are key for transport. Large amounts of khat 
are smuggled from Ethiopia and Kenya to the United 
Kingdom and the Netherlands by plane, where until 
recently it has not been under national control in either 
country. Onward trafficking to other countries in Western 
and Northern Europe and even as far as North America 
has also been reported. High levels of khat seizures also 
indicate an emerging threat in East and South-East Asia 
and Oceania, heightened by recent reports of khat cultiva-
tion in Indonesia in 2013.44
Global monitoring and  
information-sharing
The global expansion of the ATS market and the dynamic 
nature of the NPS situation enhance the need for global 
monitoring and knowledge-sharing from the experiences 
of individual Member States. The examination of scientific 
evidence, forensic data and information are essential to 
generate an effective response to the rapidly growing syn-
thetic drug market. To complement the currently available 
mechanism for global synthetic drugs monitoring, such as 
the Global SMART (Synthetics Monitoring: Analyses, 
Reporting and Trends) Programme, the UNODC Early 
Warning Advisory on NPS was launched in June 2013.45 
In accordance with CND resolution 56/4 adopted in 
March 2013, the Early Warning Advisory is designed “to 
enable timely and comprehensive sharing of information 
on new psychoactive substances including analytical meth-
odologies, reference documents and mass spectra, as well 
41 Ageely, Hussein M., “Prevalence of Khat chewing in college and sec-
ondary (high) school students of Jazan region, Saudi Arabia” Harm 
Reduction Journal June 2009 (6): 11; Alsanosy, Rashad Mohammed, 
et. al. “Khat Chewing among Students of Higher Education in Jazan 
Region, Saudi Arabia: Prevalence, Pattern, and Related Factors” 
BioMed Research International 2013, accessed on 4 December 2013 at 
http://www.hindawi.com/journals/bmri/2013/487232/abs/.
42 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Saudi Arabia 2008-2010.
43 “Khat use in Europe: implications for European policy”, Drugs in 
focus briefing of the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Luxembourg, 2011; Drug Enforcement 
Administration (DEA), “Khat”, Office of Diversion Control, Drug 
and Chemical Evaluation Section, August 2013.
44 In February 2013, the National Narcotics Board (NNB) Police dis-
covered a 7 hectare khat plantation in Cisarua of Bogor in West Java, 
Indonesia; “Comparison Analysis of Red and Green Khat Leaves Fresh, 
Dried and After Two Months Frozen”, Drugs Testing Laboratory 
National Narcotics Board Republic of Indonesia, April 2013.
45 For further information on the UNODC Early Warning Advisory on 
NPS website see www.unodc.org/nps.
as trend analysis data, with a view to providing a global 
reference point and early warning advisory”.
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2. AFRICA
Regional Overview
In the last few years, ATS use and production has extended 
beyond South Africa, primarily to West Africa. However, 
South Africa continues to report the largest number of 
dismantled ATS laboratories in Africa. In terms of traffick-
ing, methamphetamine is increasingly being smuggled 
from West Africa to other parts of Africa as well as to East 
and South-East Asia, which is a growing market for meth-
amphetamine. East Africa appears to be used for diverting 
ATS precursor chemicals and it is emerging as an ATS 
transit trafficking hub. Data on NPS use and trafficking 
remains limited, but the traditionally used psychoactive 
substance, khat, is highly prevalent in some African coun-
tries. More recently, the non-medical use of prescription 
medicines, such as tramadol, a synthetic opioid pain-killer 
not under international control, has been reported in 
Egypt.
Illicit ATS manufacturing spreading from 
South Africa to West Africa
For some time, illicit ATS manufacture had been limited 
to Southern Africa. Particularly, South Africa continues to 
annually report the largest number of illicit ATS laborato-
ries in Africa, even though these have been steadily declin-
ing since 2005. As of 2007, methamphetamine laboratories 
made up the largest share of annually dismantled ATS 
laboratories in the country, surpassing the number of 
detected methcathinone laboratories. 
ATS manufactured in South Africa are destined for domes-
tic use as well as for onward trafficking to other countries. 
According to a household survey in 2008, the annual ATS 
prevalence rate (excluding ecstasy) of the population aged 
15 to 64 in South Africa was 1.02 per cent, higher than 
that of cocaine use at 0.78 per cent and opiates at 0.41 per 
cent, but below that of cannabis use at 4.26 per cent.46 
According to expert perception, methcathinone (locally 
known as “cat”) and crystalline methamphetamine (locally 
known as “tik”) are currently the most abused ATS47 in 
South Africa.48 In 2012, methamphetamine users also 
accounted for the second largest share of people treated 
46 United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2013, New York, May 2013.
47 Moreover, South Africa is possibly the world’s largest illicit market for 
methaqualone (Mandrax). Mandrax is a sedative-hypnotic, which is 
often abused in combination with cannabis. According to INCB, the 
use of this drug has also been reported in other countries in East and 
Southern Africa, notably Kenya and Mozambique.
48 “Country Report South Africa”, presented at the Twenty-first Meet-
ing of Heads of National Drug Law Enforcement Agencies, Africa 
(HONLAF), Addis Ababa, Ethiopia, 5-9 September 2011.
for drug use at treatment centres in South Africa, at 22.9 
per cent, below the share of people treated for cannabis 
use at 38.3 per cent.49 According to the South African 
Community Epidemiology Network on Drug Use 
(SACENDU), 35 per cent of the patients in the Western 
Cape Province reported methamphetamine as their pri-
mary substance of abuse in 2011.50
Until a few years ago, the ATS market appeared to be 
largely confined to South Africa. However, in 2010, a 
methamphetamine laboratory was discovered in Egypt.51 
Moreover, since 2009 there is increasing evidence to sug-
gest that West Africa is developing into a key region for 
methamphetamine production. The first indications of 
possible methamphetamine manufacture in West Africa 
were reported in 2010, when the United States Govern-
49 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for South Africa 2012.
50 Dada, Siphokazi et.al., “Monitoring Alcohol & Drug Abuse Trends 
in South Africa (July 1996 – June 2011)”, South African Commu-
nity Epidemiology Network on Drug Use (SACENDU), SACENDU 
Research Brief Vol. 14(2), 2011.
51 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 6, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, October 2011.
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Fig. 5: Reported laboratories dismantled in South 
Africa, 2005-2010
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2010; United Nations Office on 
Drugs and Crime (UNODC) Database on Estimates and Long Term 
Trend Analysis; “Country Report South Africa”, presented at the 
Twenty-first Meeting of Heads of National Drug Law Enforcement 
Agencies, Africa (HONLAF), Addis Ababa, Ethiopia, 5-9 September 
2011.
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ment indicted members of a large international cocaine 
trafficking organisation that had also intended to illicitly 
produce methamphetamine in Liberia.52 Between 2011 
and 2012, a total of 5 methamphetamine laboratories have 
been dismantled in Nigeria, in Lagos and Anambra State.53 
So far, Nigeria is the only West African country to officially 
report illicit methamphetamine manufacture. Establishing 
the full extent of methamphetamine manufacture in West-
ern Africa remains difficult, due to weak data collection 
mechanisms and processes.
Similarly as in South Africa, ATS manufacture in Nigeria 
may have led to a spread of ATS use. In Nigeria, the only 
country in West Africa for which recent annual ATS preva-
lence rates are available, the results of a national alcohol 
52 United Nations Office on Drugs and Crime (UNODC), West Africa – 
2012 ATS Situation Report, Global Global Synthetics Monitoring: Analy-
ses, Reporting and Trends (SMART) Programme (SMART) Programme, 
June 2012.
53 “16th Liaison Officers Meeting”, UNODC Regional Office for West 
and Central Africa, Dakar, 17 April 2013; United Nations Office 
on Drugs and Crime (UNODC), Global SMART Update Volume 9, 
Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) 
Programme, Vienna, March 2013.
and drug use survey in 2012, showed that methamphet-
amine was the most used ATS in terms of lifetime preva-
lence at 4.1 per cent followed by “ecstasy” at 3.8 per cent 
and amphetamine at 2.6 per cent.54 On the whole, higher 
levels of use were reported in the urban northern-central 
parts of Nigeria for both, amphetamine and methamphet-
amine. These use figures would rank Nigeria’s ATS preva-
lence higher than most European countries.55
According to expert perception, ATS are among the pri-
mary drugs of use for people receiving drug treatment in 
Burkina Faso in 2011 and Niger in 2010.56 Moreover, 
according to a report of the National Authority for the 
Campaign against Alcohol and Drug Abuse (NACADA), 
the lifetime use of amphetamines/mandrax (methaqualone) 
among secondary school children in Nairobi in 2010, in 
Kenya, is 2.6 per cent.57 Also in Cabo Verde, the prelimi-
nary results of a national drug use survey in 2012 display 
a lifetime use of amphetamine at 0.1 per cent.58 In a 
number of African countries, amphetamine use has also 
been reported in recent years, including Algeria, Egypt, 
Côte d’Ivoire, Niger, Tunisia and Mozambique.59 For most 
other African countries there is either limited or no recent 
or reliable data available. Lack of capacity for the collec-
tion and analysis of drug-related data, in particular drug 
use data, remains a serious challenge in several countries 
of the region.
Are precursor chemicals being diverted for 
ATS manufacture in Africa?
According to the International Narcotics Control Board 
(INCB) there has been a marked increase in the diversion 
of ATS precursor chemicals to Africa, particularly West 
Africa, in recent years, after controls over ephedrine and 
pseudoephedrine60 had been strengthened in other regions 
of the world. For instance, according to the National Drug 
Law Enforcement Agency (NDLEA), since 2009 there 
have been a number of ephedrine and pseudoephedrine 
54 “Substance Abuse in Perspective in Nigeria – Report of a National 
Survey on Alcohol and Drug Use in Nigeria”, Federal Neuropsychiatric 
Hospital, Aro, Abeokuta, Nigeria, 2012.
55 For more information on ATS use in Europe, see the Regional Over-
view on Europe in this report.
56 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2011.
57 “Role of School Environment in Alcohol and Drug Abuse among Stu-
dents: Evidence from Public Secondary School Students in Nairobi”, 
Promotion of Evidence-Based Campaign-National Alcohol and Drug 
Abuse Research Workshop 2011 Report, National Campaign Against 
Drug Abuse (NACADA) Authority and P. Koome, March 2011, pp 
28-30.
58 United Nations Office on Drugs and Crime (UNODC), Inquérito 
Nacional sobre a prevalência de consumo de substâncias psicoactivas na 
população geral, Ministério da Justiça, April 2013.
59 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2011.
60 These are the main precursor chemicals used in the manufacture of 
ATS such as methamphetamine and methcathinone.
Methamphetamine 
laboratories
Methcathinone 
laboratories
Possible ecstasy 
manufacture
Map 5: Dismantled ATS laboratories reported in  
Africa, 2009-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
“West Africa – 2012 ATS Situation Report”, Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, 
June 2012; United Nations Office on Drugs and Crime (UNODC), 
Global SMART Update Volume 6, Global Synthetics Monitoring: 
Analyses, Reporting and Trends (SMART) Programme, Vienna, 
October 2011; United Nations Office on Drugs and Crime 
(UNODC), Annual Report Questionnaire 2009-2012.
Note: The boundaries shown on this map do not imply official endorsement 
or acceptance by the United Nations. The final boundary between the Sudan 
and South Sudan has not yet been determined.
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seizures at Murtala Muhammed International Airport 
(MMIA) in Nigeria, including reports of ephedrine seized 
in Côte d’Ivoire since 2008, reaching about 0.6 tons in 
2012.61 
East African countries have also reported significant thefts 
and/or losses of such ATS precursor chemicals since 2009. 
Many of these diversions were reported by the Kenyan 
authorities, while Tanzanian authorities have also begun 
to report thefts of pseudoephedrine in 2010. According to 
the INCB, all thefts of such precursor chemicals between 
September 2009 and December 2011 in Kenya and the 
United Republic of Tanzania totaled over 3.2 tons (2,062 
kg of pseudoephedrine and 1,183 kg of ephedrine).62 Over 
the same period, Kenya reported 31 thefts of mostly pseu-
doephedrine, as well as ephedrine, to the Pharmacy and 
Poisons Board.63
More recently, Uganda has also reported some prevented 
attempts of ATS precursor chemical diversions. In 2011, 
shipments of 0.1 tons of ephedrine destined for Uganda 
and 0.3 tons of ephedrine heading for Sudan were reported 
to INCB, the ultimate destination of which remains 
unclear.64 It is still unknown, as to whether the significant 
61 Annual Report, National Drug Law Enforcement Agency (NDLEA), 
Nigeria, 2012; Rapport de la Côte D’Ivoire, Ministère de l’Intérieur de 
la République de Côte d’Ivoire, Comité Interministériel de Lutte Anti-
Drogue (CILAD), 2009; Récapitulatif des Saisies pour l’Année 2012, 
Ministère de l’Intérieur de la République de Côte d’Ivoire, Comité 
Interministériel de Lutte Anti-Drogue (CILAD), 2012.
62 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
63 Official Communication with the Pharmacy and Poisons Board (PPB) 
of Kenya, Nairobi, 2012.
64 International Narcotics Control Board (INCB), Report of the Interna-
thefts or losses of ephedrine and pseudoephedrine in pre-
dominantly East and West African countries over the last 
few years were intended for illicit ATS manufacture in the 
region or for other parts of Africa. So far, there have been 
no reports of ATS being illicitly being manufactured in 
East Africa.
Is ATS trafficking from Africa increasing?
Overall, annual ATS seizures reported to UNODC from 
Africa continue to be moderate, with individual seizures 
ranging between 60 grams to 50 kg, which may be due to 
limited law enforcement controls. Between 2005 and 
2012, by far the largest amounts of ATS seizures were 
reported by Niger, followed by South Africa, Ghana and 
Benin.
West Africa has become a prominent region for metham-
phetamine trafficked to East and South-East Asia. Accord-
ing to seizure reports, ATS, in particular methamphetamine, 
is trafficked from West Africa either directly or via South-
ern Africa and Western Europe to East and South-East 
Asia and Oceania, mostly to Australia, Japan, Malaysia and 
Thailand.65 INCB has reported that methamphetamine 
tional Narcotics Control Board for 2012, Vienna, January 2013.
65 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2008-2012; Data reported by National Drug 
Law Enforcement Agency (NDLEA), Nigeria, July 2009 – July 2013; 
Data derived from ‘Illicit Drug seizures with relation to European Air-
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Fig. 6: Thefts of ephedrine and pseudoephedrine 
reported in Kenya, 2009-2011
Source: Official communication with the Pharmacy and Poisons 
Board (PPB) of Kenya, Nairobi, 2012.
Note: Data for 2009 only covers September-December.
Map 6: ATS seizures reported in Africa, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2012.
Note: The boundaries shown on this map do not imply official endorsement 
or acceptance by the United Nations. The final boundary between the Sudan 
and South Sudan has not yet been determined.
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transits East Africa from West Africa at Addis Ababa in 
Ethiopia and Nairobi in Kenya for onward trafficking by 
plane.66 According to seizures reports included in the data-
base of Illicit Drug seizures with relation to European Air-
ports’ (IDEAS), about 85 per cent of ATS seized at Western 
European and Japanese airports originating from West 
Africa since 2009, were destined for countries in East and 
South-East Asia, predominantly Japan as well as 
Malaysia.
According to the National Drug Law Enforcement Agency 
(NDLEA) in Nigeria, Malaysian nationals made up the 
largest share of foreign nationals arrested for ATS traffick-
ing at around 46 per cent (44 people), at Murtala 
Muhammed International Airport (MMIA), between July 
2009 and July 2013. Over the same period, a number of 
nationals of Asian countries, such as China, India, Japan, 
South Korea, Thailand and Viet Nam were also arrested 
for ATS trafficking at MMIA.
Moreover, according to expert perception, there have been 
increasing arrests of West African and Kenyan nationals 
related to methamphetamine trafficking in Japan, Malaysia 
and the Philippines.67 In 2010, Malaysia also reported to 
ports’ (IDEAS) database, 2009-2013; Australian Crime Commission 
(ACC), Illicit Drug Data Report 2009-2010, Canberra, June 2011.
66 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
67 “International Cooperation Against the Threat of ATS Globaliza-
tion and West African Drug Syndicates” National Police Agency 
(NPA) of Japan, presented at the seventeenth Asia-Pacific Operational 
Drug Enforcement Conference (ADEC), Tokyo, Japan, 14-16 Febru-
ary 2012; “Malaysia Country Presentation”, Royal Malaysian Police 
(RMP), presented at the seventeenth Asia-Pacific Operational Drug 
have seized methamphetamine that was perceived to have 
originated in Nigeria.68 
Trafficking groups are also smuggling ATS from West 
Africa to other parts of the continent, mostly South Africa. 
For instance, according to the National Drug Law Enforce-
ment Agency (NDLEA), about 0.2 tons of ATS seizures 
Enforcement Conference (ADEC), Tokyo, Japan, February 2012.
68 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Malaysia 2010.
Fig. 7: Reported destination of ATS seized at 
Western European and Japanese airports 
originating from West Africa, 2009-2013
Source: Data derived from ‘Illicit Drug seizures with relation to 
European Airports’ (IDEAS) database, 2009-2013.
Fig. 8: Foreign nationals arrested for ATS traffick-
ing reported at Murtala Muhammed  
International Airport (MMIA) in Nigeria,  
July 2009-July 2013
Source: Data reported by National Drug Law Enforcement Agency 
(NDLEA), Nigeria, July 2009-July 2013.
Fig. 9: Destination of ATS seizures reported at 
Murtala Muhammed International Airport 
(MMIA) in Nigeria, July 2009-July 2013
Source: Data reported by National Drug Law Enforcement Agency 
(NDLEA), Nigeria, July 2009-July 2013.
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reported at MMIA in Nigeria since 2009, were destined 
for South Africa. During this period, large amounts of ATS 
seizures at MMIA were also destined for countries in East 
and South-East Asia, such as Malaysia and Japan as well 
as other countries within Africa, including Mozambique 
and Zimbabwe.
From Southern Africa, ATS is also being trafficked to Aus-
tralia. According to the Australian Crime Commission 
(ACC), seizures of ATS shipments that had embarked from 
South Africa accounted for the largest share, of about 28 
per cent, of all ATS detected at the Australian border in 
2009 and 2010, while Zambia was also reported as the 
embarkation point for some cases.69 Both Australia and 
New Zealand have also reported that West African organ-
ized criminal groups are involved in ATS trafficking to 
these countries.70
69 Australian Crime Commission (ACC), Illicit Drug Data Report 2009-
2010, Canberra, June 2011.
70 “Country Report New Zealand”, presented at the Thirty-fifth Meeting 
In spite of increasing evidence for methamphetamine traf-
ficking from Africa to other regions, there continues to be 
severe lack of data from the African region. More particu-
larly, there is a general lack of awareness of ATS and law 
enforcement authorities in Africa tend to focus on the 
interception of drugs such as cannabis and cocaine.
Khat
Even though there is only limited data available on NPS 
in Africa, the problem generally appears to be less prevalent 
in African countries than in some other parts of the world. 
In total, 11 of all surveyed African countries71 reported 
the emergence of NPS to UNODC between 2008 and 
2013. By far the largest number of NPS reports were made 
by Egypt which reported up to 20 NPS that included syn-
of Heads of National Drug Law Enforcement Agencies, Asia and the 
Pacific (HONLAP), Agra, India, 22-25 November 2011.
71 These included Angola, Cabo Verde, Egypt, Eritrea, Ghana, South 
Africa, Sudan, the United Republic of Tanzania, Togo, Zambia and 
Zimbabwe.
Map 7: ATS flows in and from Africa as perceived by recipient countries, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012; Data reported by National Drug 
Law Enforcement Agency (NDLEA), Nigeria, July 2009-July 2013; Data derived from ‘Illicit Drug seizures with relation to European Air-
ports’ (IDEAS) database, 2009-2013; Australian Crime Commission (ACC), Illicit Drug Data Report 2009-2010, Canberra, June 2011; Inter-
national Narcotics Control Board (INCB), Report of the International Narcotics Control Board for 2012, Vienna, January 2013.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of ATS. These arrows represent the flows as perceived by recipient 
countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and 
Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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thetic cannabinoids, plant-based substances and pipera-
zines. However, plant-based psychoactive substances, such 
as khat, which are traditionally extensively used and pro-
duced in Africa are a particular NPS of concern.
Khat (catha edulis) is a plant whose leaves contain cathi-
none and cathine.72 It is largely cultivated and used for its 
stimulant effects in countries along the Red Sea and the 
Indian Ocean. In Africa, chewing khat leaves has had a 
particularly long tradition in parts of Ethiopia, Kenya, and 
Somalia where it was mostly used by men at communal 
festivities. High prevalence rates were recorded by a study 
conducted in Djibouti, in 2011, which found that the 
annual prevalence of use among the population aged 12 
and above was at 28.3 per cent and that almost half of the 
households (49.7 per cent) had at least one khat user.73
In the last several years, khat has been increasingly trans-
ported from East Africa to other regions so as to predomi-
nantly supply migrant communities from sub-Saharan 
Africa.74 So far, there still is insufficient data to provide an 
estimate for khat prevalence rates, though studies carried 
out in some European countries, most of which were con-
ducted among Somali and Yemeni communities in the 
United Kingdom, point to high prevalence rates among 
these communities. According to a study conducted by the 
National Association for the Care and Resettlement of 
Offenders (NACRO) analysing khat use among Somali 
communities in 4 cities in the United Kingdom, 39 per 
cent had used khat at some point in their lives, 34 per cent 
used it in the last year and just under 4 per cent used khat 
on a daily basis.75 Another study of selected persons of 
Somali, Ethiopian and Yemeni communities in the United 
Kingdom conducted by Turning Point, showed a lifetime 
prevalence of 82 per cent, 60 per cent current use and 26 
per cent regular use.76
Since khat can decompose quickly after 72 hours of har-
vesting, it is usually delivered to other countries and regions 
outside of Africa on a frequent and regular basis. The 
national authorities in a number of European countries 
report that large amounts of khat are smuggled from Ethio-
72 Cathinone and cathine and some of their synthetically produced deri-
vates (e.g. methcathinone) are internationally controlled substances 
under the 1971 Convention on Psychotropic Substances, but khat 
leaves are not.
73 World Bank, Comprendre la dynamique du khat à Djibouti: Aspects 
Sociaux, économiques et de santé, report No. 62823-DJ, Washington 
DC, 2011. 
74 Drug Enforcement Administration (DEA), “Khat”, Office of Diver-
sion Control, Drug and Chemical Evaluation Section, August 2013; 
“Khat use in Europe: implications for European policy”, Drugs in 
focus briefing of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), Luxembourg, 2011.
75 Patel Shilpa L., Wright, Sam, and Gammampila Alex. “Khat use 
among Somalis in four English Cities” Home Office Online Report 
47/05, 2005.
76 Turning Point, Home Office. “Khat use in Somali, Ethiopian and 
Yemeni communities in England: issues and solutions”, November 
2004.
pia and Kenya to the United Kingdom and the Nether-
lands, from where they are then trafficked onwards to other 
countries in Western and Northern Europe, as well as 
North America. Between 2009 and 2012, Canada and the 
United States reported of khat seizures that were perceived 
to have primarily originated in Kenya as well as Ethiopia 
and perceived to have been trafficked via the Netherlands 
and the United Kingdom.77 In 2012, khat seizures per-
ceived to have been trafficked from the United Kingdom 
and the Netherlands have been reported by countries in 
Western and Central Europe, such as Germany, Ireland, 
Malta, Switzerland, as well as the United States.78 In 
Europe, khat is often trafficked from Germany onwards 
to other countries in Europe, including Denmark, Malta, 
Sweden and Switzerland.79 According to the EMCDDA, 
an estimated 300 tons of khat are annually transported to 
the United Kingdom and the Netherlands, where until 
recently it has not been under national control in either 
country.80 Though khat is controlled in most European 
countries, the substance is currently under consideration 
for inclusion to the Misuse of Drugs Act 1971 as a Class 
C substance in the United Kingdom, before which khat 
was allowed to be imported, traded and consumed as a 
vegetable product, as it was the case in the Netherlands, 
where it has also recently been placed under national con-
trol in June 2012.81 
Seizure data indicates that khat has increasingly been traf-
ficked to Europe and North America over the last several 
years. Between 2004 and 2011, total khat seizures in these 
regions have more than doubled from about 64 tons in 
2004 to almost 150 tons in 2012, of which by far the larg-
est seizures were reported by the United States, Germany 
and Sweden. Contrary to this evidence, for most years since 
2004, khat seizures in Africa have ranged between 1 ton 
and 10 tons, most of which was seized in Zambia and the 
United Republic of Tanzania. The comparatively low levels 
of khat seizures in Africa could be explained by the fact 
that the substance is not under national control in a 
number of East African countries, including Djibouti, Ethi-
opia, Kenya and Somalia.82 Within Africa, khat is perceived 
to be trafficked from Somalia and Tanzania to Zambia and 
77 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire Canada and United States 2012.
78 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2012.
79 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2012.
80 “Khat use in Europe: implications for European policy”, Drugs in 
focus briefing of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), Luxembourg, 2011.
81 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
82 D. M. Anderson and N.C.M. Carrier, Khat: Social Harms and Leg-
islation – A Literature Review, Occasional Paper 95, London, Home 
Office, July 2011.
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South Africa.83 According to seizure data, the majority of 
khat seized in Eritrea between 2008 and 2012, originated 
in Eritrea and was perceived to be intended for the domes-
tic market, whilst the remaining khat seizures in the coun-
try were perceived to have originated from Yemen.84
Non-medical use of prescription drugs
The synthetic opioid analgesic, tramadol, has appeared on 
illicit drug markets and there are indications of misuse. In 
the last few years, tramadol use has become of increasing 
concern in some African countries, particularly Egypt. Tra-
madol is a synthetic opioid pain-killer not under interna-
tional control, usually obtainable at pharmacies and 
frequently prescribed by doctors after surgery. According 
to expert perception, tramadol use has greatly increased, 
particularly after the Egyptian revolution in 2011, as it is 
available on the black market at low prices.85 The Fund 
for Drug Control and Addiction has reported that trama-
dol users have also been making up a substantial percentage 
of admissions to Egyptian drug treatment centres. A study 
of patients admitted to three major drug treatment centres 
in Cairo (Egypt) between 2007 and 2011, found that the 
percentage of patients reporting tramadol use had increased 
dramatically over these years and made up the majority of 
all persons entering drug treatment in each of the centres 
in 2011.86
83 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Zambia 2008-2012.
84 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Eritrea 2008-2012.
85 Fawzi, Marwa M. “Some medicolegal aspects concerning tramadol 
abuse: The New Middle East youth plague 2010. An Egyptian Over-
view”, Egyptian Journal of Forensic Sciences 2011 (1): 99–102.
86 Presentation by Samir Abou El Magd, MD Professor of Psychiatry 
at the Cairo University in Egypt in September 2012, “Tramadol Use 
in Egypt: Emergence of a Major New Public Health Problem” and 
In response to the growing threat, the Egyptian govern-
ment has placed tramadol, as well as its salts and derivatives 
and preparations containing tramadol, under national con-
trol under the Anti-Narcotics Law in 2012.87 As a result 
of increased law enforcement efforts, seizures of tramadol 
have surged. The Anti-Narcotics General Administration 
(ANGA) in Egypt reported large seizures of up to 375 
million tramadol pills between January and October of 
2012, about eight times the amount reported to have been 
seized in 2011, when tramadol was not under national 
control.88 At Egypt’s seaports, tramadol pill seizures 
increased from 120 million in 2011 to around 320 million 
in the first quarter of 2012.89 The preparations were 
reportedly smuggled from China and India.90
According to the Libyan Anti-Narcotics Agency, Libya is 
also facing large-scale tramadol trafficking and use, though 
exact statistics on the extent of the problem are unavailable 
as the country is currently in the process of restructuring 
its law enforcement institutions.91 In Africa, use of trama-
dol preparations have also been reported, such as in Mau-
ritius and Togo.92 Large amounts of tramadol have been 
recently seized in West Africa. Between February and Octo-
ber of 2012, a total of 24 containers carrying more than 
132 tons of tramadol preparations, all of which had been 
smuggled from India, were seized in West African coun-
tries, including Togo, Benin, Ghana and Senegal.93 Of the 
seized containers, 19 were destined for Niger.
summary of results published in The Canadian Journal of Addiction 
Medicine 4 (1).
87 “Country Report Egypt”, presented at the Twenty-second Meet-
ing of Heads of National Drug Law Enforcement Agencies, Africa 
(HONLAF), Accra, 25-29 June 2012.
88 US Department of State, International Narcotics Control Strategy Report 
(INCSR), Bureau of International Narcotics and Law Enforcement 
Affairs, March 2013.
89 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
90 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
91 US Department of State, International Narcotics Control Strategy Report 
(INCSR), Bureau of International Narcotics and Law Enforcement 
Affairs, March 2013.
92 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
93 Since some of the seized preparations might be counterfeit, forensic 
examinations are still being conducted so as to identify whether the 
seized preparations actually contain tramadol; International Narcotics 
Control Board (INCB), Report of the International Narcotics Control 
Board for 2012, Vienna, January 2013.
Fig. 10: Khat seizures reported in Africa, Europe 
and North America, 2004-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2004-2012.
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3. EAST AND SOUTH-EAST ASIA, OCEANIA 
AND THE PACIFIC
 Regional Overview
Methamphetamine continues to dominate the ATS market 
in East and South-East Asia, Oceania and the Pacific. ATS 
seizures in the region have annually increased from about 
13 tons in 2008 to just under 40 tons in 2012. The rapid 
rise of ATS seizures over the years is primarily attributable 
to the increase of methamphetamine seizures which about 
tripled from less than 12 tons in 2008 to 36 tons in 2012. 
Having increased from about 0.1 tons in 2008 to 2.3 tons 
in 2011, amphetamine seizures in the region have dropped 
again to less than 0.2 tons in 2012. Seizures of "ecstasy" 
have also fluctuated over the years, but have more than 
tripled in 2012 to 1.9 tons. However, both amphetamine 
and “ecstasy” seizures in the region have remained at rela-
tively low levels, whilst methamphetamine seizures have 
annually made up more than 90 per cent of total ATS sei-
zures for a number of years.
There are indications that increasingly large quantities of 
ATS are being manufactured in East and South-East Asia. 
Between 2008 and 2011, the total number of dismantled 
ATS laboratories have risen by almost 90 per cent, pre-
dominantly due to the large increase of both dismantled 
amphetamine and methamphetamine laboratories, which 
rose from about 300 in 2009 to almost 590 in 2010 and 
levelling at around 560 in 2011.94 Though the number of 
94 The data available at the national level for Australia where the major-
ity of ATS laboratories for East and South-East Asia, Oceania and 
dismantled laboratories in the region intended solely for 
methamphetamine manufacture dropped from about 410 
in 2008 to less than 180 in 2009, these have remained at 
about 150 in 2010 and 2011. The annual number of dis-
mantled “ecstasy” laboratories have remained at around 30 
between 2008 and 2010, but have increased to just under 
140 in 2011.
ATS use is a major problem in large parts of the region. 
For instance, according to expert perception, there has 
been a large increase of ATS use in mainland China in 
2012, as well as some increase in the number of people 
receiving treatment for ATS use.95 In 2012, ATS users 
accounted for the second largest share at 19.1 per cent of 
people receiving drug treatment in mainland China, below 
those treated for opioid use accounting for 79.7 per cent.96 
In South-East Asia, Community-Based Treatment services 
in Cambodia in 2012 provided ongoing treatment for an 
estimated 1,300 drug users, of which 86.4 per cent were 
treated for ATS use.97 The number of people receiving 
the Pacific were dismantled does not allow to differentiate between 
dismantled methamphetamine and amphetamine laboratories. 
95 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2012.
96 Drug Abuse Information Network for Asia and the Pacific (DAINAP).
97 Drug Abuse Information Network for Asia and the Pacific (DAINAP).
Fig. 11: Total ATS seizures reported in East and 
South-East Asia, Oceania and the Pacific, 
2008-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2012.
Fig. 12: Dismantled ATS laboratories reported in 
East and South-East Asia, Oceania and the 
Pacific, 2008-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2011.0
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treatment for ATS use in Myanmar accounted for 2.7 per 
cent of the total number of people receiving treatment for 
drug use in 2011 (around 97 per cent of people were 
treated for opioid use), but according to expert perception, 
there has been an annual increase in the number of people 
admitted for treatment relating to ATS use at the Yangoon 
Mental Health Hospital for psychiatric problems over the 
last 5 years.98 According to the National Narcotics Board 
of Indonesia, ATS users were estimated to have accounted 
for the second largest share of drug users receiving drug 
treatment in the country in 2011 at 35.7 per cent (4,884 
people), following those treated for opioid use at 53.1 per 
cent (7,262 people).99
Over the years, amphetamine seizures in the Oceania 
region have remained at comparatively low levels, totaling 
less than 1 ton between 2008 and 2012. However, drug 
treatment admissions indicate that amphetamine is a drug 
of concern in Australia. Between 2011 and 2012, ampheta-
mine users in Australia accounted for the second largest 
share of people receiving drug treatment at 22.6 per cent, 
after cannabis at 43.2 per cent, followed by heroin at 17.3 
per cent and pharmaceutical opioids at about 8.5 per 
cent.100 
98 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Myanmar 2011;  “Myanmar country pres-
entation”, Central Committee for Drug Abuse Control (CCDAC), 
presented at the ASEAN Conference 2013: Road-map to Effective 
Substance Dependence Treatment, Nonthaburi, Thailand, 17-19 July 
2013.
99 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2012.
100 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
A growing market for methamphetamine?
Over the years, methamphetamine seizures have been pre-
dominantly reported in East and South-East Asia, in coun-
tries such as China, Indonesia, the Lao People’s Democratic 
Republic (Lao PDR), Malaysia, Myanmar and Thailand. 
A rapid rise in seizures have particularly been reported in 
mainland China, where detected methamphetamine has 
risen annually from 6 tons in 2008 to more than 16 tons 
in 2012, making up about 45 per cent of total metham-
phetamine seizures for the region that year. Increasing 
methamphetamine seizures have also been reported in 
Thailand, from about 2 tons in 2008 to more than 10 tons 
in 2012 and in Myanmar from 0.1 ton to 2 tons. Except 
for a decrease in methamphetamine seizures in Malaysia 
from 1.1 ton in 2008 to 0.9 tons in 2012, seizures have 
increased in Indonesia from 0.7 tons to more than 2.1 tons 
over the same period, as well as in the Lao PDR from 0.1 
ton to 0.9 tons.
Whilst methamphetamine seizures in East and South-East 
Asia have been rising rapidly, there are also indications of 
high levels of methamphetamine use in this region. For 
instance, according to expert perception, there has been a 
large increase of methamphetamine use in mainland China 
in 2012, as opposed to amphetamine use which has 
remained stable, and “ecstasy” use, which has shown some 
decline.101 Also, among people held in prisons in Macau, 
China, in 2012, methamphetamine was the most used 
drug in terms of annual prevalence at 41.6 per cent.102
101 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2012.
102 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Macau, China 2012.
Fig. 13: Methamphetamine seizures reported in East and South-East Asia, Oceania and the Pacific by  
country, 2008-2012 
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012.
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In South-East Asia, methamphetamine users in Thailand 
accounted for the largest share of people treated for drug 
use at drug treatment centres in 2012 at 88 per cent.103 
Moreover, according to expert perception, methamphet-
amine use in Thailand is on the rise among students at 
secondary school and at university.104 In Myanmar, a study 
on ATS use among high school students in Myitkyina, in 
Kachin State, in 2011, found that methamphetamine was 
the most used drug under international control with a 
lifetime prevalence at 1.5 per cent and an annual preva-
lence of 0.8 per cent.105 Methamphetamine use is also 
reported to be a major problem in Lao PDR where meth-
amphetamine users accounted for over 50 per cent of 
people treated for ATS use in 2012 at the Somsanga Treat-
ment and Rehabilitation Centre in Vientiane.106
Despite an increase of methamphetamine seizures in Indo-
nesia, methamphetamine use in the country on the whole 
is reported to be lower than that of other substances under 
international control and certain ATS. According to a high 
school survey among students aged 15 to 19 in 2011, 
annual methamphetamine prevalence at 0.26 per cent  use 
ranked below “ecstasy” use at 0.34 per cent.107 Although 
ATS users accounted for 35.7 per cent (4,884 people) of 
the total number of people treated for drug use in Indo-
nesia in 2012, this was below the number of people treated 
for opioid use at 53.1 per cent (7,262 people).108 Meth-
amphetamine continues to be manufactured in the coun-
try, but the number of discovered laboratories have recently 
decreased. Therefore, the increase of methamphetamine 
seizures in Indonesia might not necessarily be due to a 
growing domestic market for the drug and could instead 
point to a rise of methamphetamine trafficking.
Some other countries in East and South-East Asia demon-
strate high levels of treatment admissions for methamphet-
amine use indicating that methamphetamine is a major 
problem throughout the region. For instance, in the Phil-
ippines people treated for methamphetamine use by far 
accounted for the largest share of people admitted for treat-
ment of drug use at treatment facilities in 2012 at 63.2 per 
cent (2,167 people).109 Moreover, according to expert per-
103 Drug Abuse Information Network for Asia and the Pacific (DAINAP).
104 Drug Abuse Information Network for Asia and the Pacific (DAINAP).
105 “Study on Use of Amphetamine-Type Stimulants among High-School 
Students at Myitkyina State”, Substances Abuse Control Project, 
Department of Health, Ministry of Health, Republic of Myanmar 
and the World Health Organisation Country Office for Myanmar, 
Myitkyina, Myanmar, 2011.
106 United Nations Office on Drugs and Crime (UNODC), Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for 
Asia and the Pacific. Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, November 2013.
107 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2012.
108 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2011.
109 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Philippines 2012.
ception, the majority of people admitted to Temporary 
Centers for Drug Education and Rehabilitation in Cam-
bodia in 2012 were treated for methamphetamine use.110 
Also, according to expert perception, methamphetamine 
was the second most commonly used drug in Cambodia 
after heroin since 2010.111 In 2012, people admitted to 
Drug Rehabilitation Centers for methamphetamine use in 
Singapore accounted for the second largest share of people 
treated for drug use at 41.5 per cent (585 people), after 
heroin at 44.9 per cent (632 people).112 In Brunei Darus-
salam, methamphetamine users in the country accounted 
for 97.3 (145 people) per cent of all people admitted for 
drug treatment in 2012, similar to the share reported in 
previous years.113
A growing use of NPS in the form of 
“ecstasy”? 
High levels of “ecstasy” use continue to be reported by 
countries in the Oceania region. The Australian 2010 
National Drug Strategy Household Survey found that 
“ecstasy” remains the second most used drug in Australia 
among people aged 15 to 64 at a lifetime prevalence of 
10.3 per cent, after cannabis use at 35.4 per cent.114 Fur-
thermore, the 2010 National Drug Strategy Household 
Survey among people aged 14 to 19, also indicated 
“ecstasy” as the second most used substance in terms of 
lifetime prevalence at 4.7 per cent, after cannabis use at 
21.5 per cent, whilst annual “ecstasy” use ranked third at 
2.8 per cent after cannabis at 15.7 per cent and pharma-
ceuticals at 3.2 per cent.115
The number of detected MDMA laboratories in Australia 
over the years have annually ranged between 10-20 labo-
ratories. However, there are reports of increased “ecstasy” 
trafficking to Australia from European countries, including 
Germany, the Netherlands and the United Kingdom.116 
According to the Australian Crime Commission (ACC), 
the number of small quantity MDMA detections along 
the Australian border is on the rise, most of which occur 
in the postal stream.117
110 “Country Report on Drug Situation in Cambodia”, National Author-
ity for Combatting Drugs (NACD), presented at the Seventeenth Asia-
Pacific Operational Drug Enforcement Conference (ADEC), Tokyo, 
14-16 February 2012. 
111 Drug Abuse Information Network for Asia and the Pacific (DAINAP).
112 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Singapore 2012.
113 Drug Abuse Information Network for Asia and the Pacific (DAINAP); 
United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brunei Darussalam 2012.
114 “2010 National Drug Strategy Household Survey Report”, Australian 
Institute of Health and Welfare (AIHW), Canberra, July 2011.
115 “2010 National Drug Strategy Household Survey Report”, Australian 
Institute of Health and Welfare (AIHW), Canberra, July 2011.
116 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
117 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
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In 2010, New Zealand also reported an increasing trend 
of “ecstasy” use. The latest drug use survey conducted in 
the country between 2007/08 showed that in terms of 
annual prevalence “ecstasy” was the third most used sub-
stances among people aged 16-64 at 2.6 per cent after 
cannabis at 14.6 per cent and hallucinogens at 3.2 per 
cent.118 However, according to law enforcement officials 
in New Zealand, “ecstasy” tablets seized in 2012 have been 
found to contain little or no MDMA and consist mainly 
of a blend of other internationally controlled and non-
controlled substances, such as mephedrone, BZP119, 
TFMPP120 and methylone121.122 Moreover, a laboratory 
believed to be intended for the supply of “ecstasy” tablets 
discovered in New Zealand in November 2012, was in fact 
manufacturing NPS that were sold as “ecstasy”.123 There-
fore, reports of increasing “ecstasy” use in New Zealand 
may in fact point to a growing use of NPS.
This trend of selling NPS as “ecstasy” on ATS markets has 
also been observed by countries in South-East Asia. For 
instance, according to expert perception, in Hong Kong, 
China, “ecstasy” tablets, were reported to contain other 
ATS, as well as NPS such as ketamine, TFMPP and 
PMMA124 in addition to MDMA.125 In Singapore, 
“ecstasy” seizures in 2012 were also found to contain a 
number of controlled and non-controlled substances other 
than MDMA.126 “Ecstasy” seizures in Indonesia have 
increased continuously from 0.1 ton in 2009 to about 1.3 
tons in 2012. The seized tablets have also been reported 
to contain NPS.127 Prevalence data also points to wide-
spread “ecstasy” use in Indonesia. The results of a drug use 
survey among Indonesian workers aged 15 to 60 in 2012, 
118 “Drug Use in New Zealand: Key results of the 2007/08 New Zealand 
Alcohol and Drug Use Survey”, Ministry of Health, Wellington, Janu-
ary 2010.
119 Benzylpiperazine (BZP) is a piperazine not under international con-
trol.
120 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a piperazine not 
under international control, commonly found in “ecstasy” tablets.
121 3,4-methylenedioxy-N-methylcathinone, also known as methylone is 
a synthetic cathinone not under international control.
122 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for New Zealand 2012.
123 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for New Zealand 2012.
124 PMMA is the chemical abbreviation of paramethoxymethampheta-
mine, a phenethylamine not under international control.
125 “Narcotics Bureau Quarterly Report, 3Q – 2012 (July-September)”, 
Narcotics Bureau, Hong Kong Police Force (HKNB), presented at the 
Eighteenth Asia-Pacific Operational Drug Enforcement Conference 
(ADEC), Tokyo, 26-27 February 2013.
126 These substances included ketamine, mephedrone, JWH-018 (a 
synthetic cannabinoid not under international control), MDPV (a 
synthetic cathinone not under international control), TFMPP, methy-
lethcathinone (4-methylethcathinone, a synthetic cathinone not under 
international control),  BZP and pentedrone (a synthetic cathinone 
not under international control); United Nations Office on Drugs and 
Crime (UNODC), Annual Report Questionnaire for Singapore 2012.
127 These NPS included ketamine, methylone and synthetic cannab-
inoids; United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire for Indonesia 2009-2012.
rank “ecstasy” as the third most used drug in terms of life-
time prevalence at 2.50 per cent, after cannabis at 7.11 per 
cent and tranquilizers and sedatives at 4.09 per cent.128 In 
2011, a school survey in Indonesia among students aged 
15 to 19 also indicated the annual prevalence of “ecstasy” 
as the second most used drug together with benzodiaze-
pines at 0.34 per cent, after cannabis at 1.3 per cent.129 
There have also been reports of “ecstasy” manufacture in 
Indonesia, having discovered 24 “ecstasy” laboratories 
including 15 MDMA laboratories since 2008.130
Methamphetamine manufacture
In recent years, an increasing number of ATS laboratories 
have been discovered in the region. Despite a drop in 2009, 
the number of dismantled methamphetamine laboratories 
in the region have remained at around 150 annually for 
the last few years. The majority of these dismantled labo-
ratories between 2008 and 2011 were reported by New 
Zealand at 47 per cent, followed by Australia at 24 per 
cent and Thailand at 18 per cent. Methamphetamine labo-
ratories were also reported to have been discovered in Cam-
bodia, Hong Kong (China), India, Indonesia, Japan, the 
Republic of Korea, Malaysia, Myanmar, the Philippines 
and Sri Lanka, together making up about 11 per cent of 
the total number reported in the region.
128 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2012.
129 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2011.
130 Malaysia has also reported “ecstasy” manufacture, with 19 laboratories 
dismantled between 2008 and 2012; United Nations Office on Drugs 
and Crime (UNODC), Annual Report Questionnaire for Malaysia 
2008-2012.
Fig. 14: Dismantled methamphetamine laboratories 
reported in East and South-East Asia,  
Oceania and the Pacific, by country,  
2008-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2011.
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Although New Zealand has reported by far the largest 
number of methamphetamine laboratories in the region, 
most laboratories have been of relatively small-scale and 
have often been discovered in vehicles or suitcases.132 
Moreover, the number of dismantled methamphetamine 
laboratories in the country has been steadily decreasing 
over the years, from 134 in 2009 to 109 in 2011. Accord-
ing to the National Drug Intelligence Bureau (NDIB) in 
New Zealand, increased law enforcement pressure on ATS 
131 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis, 
Luxembourg, Publications Office of the European Union, 2013.
132 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for New Zealand 2012.
precursor chemical trafficking to the country has led to a 
decline in domestic methamphetamine manufacture. Sei-
zures of ephedrine and pseudoephedrine have been on the 
decline in recent years, dropping by 24.0 per cent in 2011 
and by another 37.6 per cent in 2012 to only around 0.3 
tons.133 Methamphetamine seizures in New Zealand have 
remained at low levels, annually ranging between about 
15 and 30 kg.134
133 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for New Zealand 2012.
134 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for New Zealand 2012.
The changing content of “ecstasy” tablets
In many regions of the world, a large proportion of seized pills marketed as “ecstasy” contain substances other than 
MDMA. This trend may be due to successful controls over the main precursor chemicals used in the manufacture of 
MDMA. In Europe, according to the EMCDDA, amphetamines have been commonly found in “ecstasy” pills in 
Luxembourg, Spain and Turkey.38 In many other cases across the world, drugs sold as “ecstasy” actually contained New 
Psychoactive Substances (NPS). Over the last few years, a wide array of NPS have been discovered in tablets sold as 
“ecstasy” seized in Asia, the Americas, Europe and Oceania.
Substances Asia Americas Europe Oceania
2C-B •
2C-E •
-PVP • •
Amphetamine •
BTCP •
BZP • •
CPP* •
DMT •
Eutylone (bk-EBDB) •
Fluoro-methcathinone •
JWH-018 •
Ketamine • • •
mCPP •
MDA •
MDPBP •
MDPV • •
Mephedrone •
Methamphetamine • • •
Methoxetamine •
Methylethcathinone • •
Methylone •
N-ethylamphetamine •
Pentedrone •
PMMA • • •
TFMPP • • •
Table 2: Substances found in pills sold as “ecstasy”, 2009-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2009-2012; European Monitoring Centre 
for Drugs and Drug Addiction and European Police Office, “EU Drug Markets Report: A Strategic Analysis”, Luxembourg, Publica-
tions Office of the European Union, 2013.
Note: Prescription drugs and cutting agents are not listed in this table and substances in bold letters are substances under international control. Substance 
names are as provided by the respective source and the identification of a substance in “ecstasy” pills does not provided an indication of the quantity 
found. 
* Substance not identified due to a lack of detailed information.
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In Australia, the data available at the national level does 
not allow to differentiate between dismantled metham-
phetamine and amphetamine laboratories. In any case, in 
the state of New South Wales, in Australia, the New South 
Wales (NSW) Police Force reported that the number of 
discovered methamphetamine laboratories increased by 
almost 21 per cent in 2012 alone, to 81 from 67 in the 
previous year.135 According to the Australian Crime Com-
mission (ACC), the Australian ATS market (excluding 
“ecstasy”) appears to be predominantly supplied by rising 
domestic manufacture.136 ATS laboratories dismantled in 
Australia over the years have annually accounted for more 
than 60 per cent of the number of laboratories dismantled 
in East and South-East Asia, Oceania and the Pacific.137 
Between 2008 and 2011 the number of illicit ATS labo-
ratories discovered in Australia more than doubled from 
about 270 to 570.138 
In recent years, there has been a rapid increase in the 
number of methamphetamine laboratories detected in 
Thailand. Whilst only 2 methamphetamine laboratories 
were discovered in Thailand between 2008 and 2010, 109 
had been dismantled in 2011 and another 84 in 2012.139 
Methamphetamine manufactured in Thailand may be 
intended to supply the large domestic market. Indeed, 
most laboratories consisted of small-scale manufacturing 
sites located in the central parts of the country, near Bang-
kok.140 Therefore, methamphetamine may also be traf-
ficked into the country to meet domestic demand, which 
is supported by reports that large amounts of metham-
phetamine seized in Thailand originate from Myanmar.141 
For instance, in 2008 all methamphetamine seized in Thai-
land was perceived to have originated in Myanmar.142 
Since then, methamphetamine seizures reported in Ban-
gladesh, Thailand and Myanmar itself have been perceived 
to have originated in Myanmar.143
135 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
136 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
137 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2008-2011.
138 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2008-2011.
139 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Thailand 2008-2012.
140 Thailand country report, Office of the Narcotics Control Board of 
Thailand (ONCB), presented at the Eighteenth Asia-Pacific Opera-
tional Drug Enforcement Conference (ADEC), 26-27 February 2013.
141 “Thailand country report” Office of the Narcotics Control Board of 
Thailand (ONCB), presented at the Eighteenth Asia-Pacific Oper-
ational Drug Enforcement Conference (ADEC), 26-27 February 
2013; “China country presentation”, China National Narcotics Con-
trol Commission (NNCC), presented at the Eighteenth Asia-Pacific 
Operational Drug Enforcement Conference (ADEC), Tokyo, 26-27 
February 2013.
142 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Thailand 2008.
143 United Nations Office on Drugs and Crime (UNODC), Annual 
In Indonesia, a number of methamphetamine laboratories 
have been dismantled over the years rising to 17 in 2009, 
but dropping to 4 in 2012, most of which were again 
small-scale kitchen-type facilities discovered in Jakarta and 
Sumatra.144 Given that Indonesia had licit requirements 
for ephedrine at about 7 tons and pseudoephedrine at 
more than 38 tons (precursor chemicals which can be used 
for the manufacture of ATS) in 2012, there is a high 
potential risk of these substances being diverted for illicit 
ATS manufacture.145 Though there have been no reports 
of ATS manufacture in Singapore and ATS seizures on the 
whole remain limited, the country has high licit require-
ments for ephedrine at 12 tons and pseudoephedrine at 
53 tons.146
There have been large numbers of drug manufacturing 
laboratories dismantled in China over the years. Up until 
2011, the number of laboratories intended for ATS manu-
facture or any other substances under international control 
remains unclear.147 In 2009, around 390 unspecified drug 
manufacturing laboratories were dismantled in China, 
declining to 378 in 2010 and 357 in 2011.148 However, 
in 2012, China reported that the 228 dismantled meth-
amphetamine laboratories accounted for the largest share 
of all 326 drug laboratories dismantled that year.149 In 
Hong Kong, China one methamphetamine laboratory was 
also reported to have been dismantled in that same year.150 
China has the highest licit requirements for ephedrine in 
the world at 155 tons and has the second highest licit 
requirements for pseudoephedrine at 200 tons after India 
at more than 300 tons,151 which may again heighten the 
risk of diversion for ATS manufacture.
Otherwise, methamphetamine manufacture has also been 
reported over the years in Japan, the Republic of Korea, 
Malaysia, Myanmar, the Philippines and Sri Lanka. 
Report Questionnaire for Bangladesh, Myanmar and Thailand 2008-
2011.
144 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2009-2012.
145 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
146 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Singapore 2012; International Narcotics 
Control Board (INCB), Precursors and chemicals frequently used in the 
illicit manufacture of narcotic drugs and psychotropic substances, New 
York, January 2013.
147 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2012.
148 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2012; Drug Abuse Information Net-
work for Asia and the Pacific (DAINAP).
149 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2012.
150 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Hong Kong, China, 2012.
151 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
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Between 2008 and 2011, there had been 30 methampheta-
mine laboratories dismantled in Malaysia and 19 in the 
Philippines, though most laboratories in the Philippines 
consisted of relatively small facilities.152 Moreover, most 
methamphetamine seized in Japan and the Republic of 
Korea was perceived to have been trafficked from other 
countries and only 2 methamphetamine laboratories were 
dismantled in Japan and 4 in the Republic of Korea 
between 2008 and 2011, while one methamphetamine 
laboratory was discovered in Sri Lanka. In Myanmar, 6 
methamphetamine laboratories have been discovered, 
sometimes in small, mobile facilities.153 This number is 
relatively small in view of the fact that there have been 
reports of sizeable amounts of methamphetamine seized 
in a number of countries in the region, among them China 
and Thailand, that originate in Myanmar.154
Methamphetamine trafficking to  
and within East and South-East Asia  
and Oceania
Though large amounts of methamphetamine are manu-
factured in the region, the drug continues to be trafficked 
from many other parts of the world to supply markets in 
East Asia, South-East Asia and Oceania. In addition, meth-
amphetamine manufactured in countries in East and 
South-East Asia is also trafficked to other countries within 
the region.
Between 2010 and 2012, methamphetamine seizures 
reported in Indonesia, Malaysia and Thailand were per-
ceived to have originated in the Islamic Republic of Iran.155 
According to expert perception, Thailand is primarily a 
transit country for methamphetamine en route from the 
Islamic Republic of Iran to Japan, Malaysia, the Philippines 
and Hong Kong, China.156 In 2012, Iranians were also 
152 Only one large-scale manufacturing facility was dismantled in the Phil-
ippines in 2012, which was capable of producing more than 50 kg of 
methamphetamine in a single production cycle; “Philippine Country 
Report”, Dangerous Drugs Board (DDB), presented at the Global 
SMART Programme Regional Workshop, Jakarta, 28-29 August 2013.
153 United Nations Office on Drugs and Crime (UNODC), Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for 
Asia and the Pacific. Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, November 2013.
154 “Thailand country report” Office of the Narcotics Control Board of 
Thailand (ONCB), presented at the Eighteenth Asia-Pacific Opera-
tional Drug Enforcement Conference (ADEC), 26-27 February 2013; 
“China country presentation”, China National Narcotics Control 
Commission (NNCC), presented at the Eighteenth Asia-Pacific Oper-
ational Drug Enforcement Conference (ADEC), Tokyo, 26-27 Febru-
ary 2013; United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire for Thailand 2008.
155 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia, Malaysia and Thailand 2009-
2011.
156 Thailand country report, Office of the Narcotics Control Board of 
Thailand (ONCB), presented at the Eighteenth Asia-Pacific Opera-
tional Drug Enforcement Conference (ADEC), 26-27 February 2013; 
“Thailand country report”, Office of the Narcotics Control Board of 
Thailand (ONCB), presented at the Twenty-second Anti-Drug Liaison 
Officials’ Meeting for International Cooperation (ADLOMICO), 
the most common foreign nationality to be reported in 
connection with ATS trafficking in Indonesia.157
According to seizure reports, ATS, in particular metham-
phetamine, is trafficked from West Africa either directly 
or via Southern Africa and Western Europe to East and 
South-East Asia, mostly to Australia, Japan, Malaysia and 
Thailand.158 Moreover, according to seizure reports 
included in the database of Illicit Drug seizures with rela-
tion to European Airports’ (IDEAS), about 85 per cent of 
ATS seized at Western European and Japanese airports 
originating from West Africa since 2009, were destined for 
countries in East and South-East Asia, predominantly 
Japan as well as Malaysia.159 The National Drug Law 
Enforcement Agency (NDLEA) in Nigeria also reported 
that large amounts of ATS seizures at Murtala Muhammed 
International Airport (MMIA) were destined for countries 
in East and South-East Asia, such as Malaysia and Japan 
as well as other countries within Africa.160 According to 
expert perception, there have been increasing arrests of 
West African and Kenyan nationals related to metham-
phetamine trafficking in Japan, Malaysia and the Philip-
pines.161 In 2010, Malaysia also reported to have seized 
methamphetamine that was perceived to have originated 
in Nigeria.162
According to expert perception, methamphetamine is also 
trafficked via the Middle East to countries in East and 
South-East Asia.163 East and South-East Asian countries, 
such as Japan, the Republic of Korea, Malaysia, Singapore 
Busan, Republic of Korea, 12-14 September 2012.
157 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2012.
158 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2008-2012; Data reported by National Drug 
Law Enforcement Agency (NDLEA), Nigeria, July 2009 – July 2013; 
Data derived from ‘Illicit Drug seizures with relation to European Air-
ports’ (IDEAS) database, 2009-2013; Australian Crime Commission 
(ACC), Illicit Drug Data Report 2009-2010, Canberra, June 2011.
159 Data derived from ‘Illicit Drug seizures with relation to European 
Airports’ (IDEAS) database, 2009-2013.
160 Data reported by National Drug Law Enforcement Agency (NDLEA), 
Nigeria, July 2009-July 2013.
161 “International Cooperation Against the Threat of ATS Globaliza-
tion and West African Drug Syndicates” National Police Agency 
(NPA) of Japan, presented at the seventeenth Asia-Pacific Operational 
Drug Enforcement Conference (ADEC), Tokyo, Japan, 14-16 Febru-
ary 2012; “Malaysia Country Presentation”, Royal Malaysian Police 
(RMP), presented at the seventeenth Asia-Pacific Operational Drug 
Enforcement Conference (ADEC), Tokyo, Japan, February 2012.
162 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Malaysia 2010.
163  "International Cooperation against the Threat of ATS Globalization 
and West African Drug Syndicates", National Police Agency (NPA) 
of Japan, presented at the Seventeenth Asia-Pacific Operational Drug 
Enforcement Conference (ADEC), Tokyo, Japan, 14-16 February 
2012; "Thailand Country Report", Office of the Narcotics Control 
oard of Thailand (ONCB), presented at the Seventeenth Asia-Pacific 
Operational Drug Enforcement Conference (ADEC), Tokyo, Japan, 
14-16 February 2012; "Malaysia Country Presentation", Royal Malay-
sian Police (RMP), presented at the Seventeenth Asia-Pacific Opera-
tional Drug Enforceme nt Conference (ADEC), Tokyo, February 
2012.
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and Thailand, have reported of methamphetamine seizures 
that had been trafficked via Middle Eastern countries, 
including Qatar and the United Arab Emirates as well as 
Western European countries, such as France and 
Germany.164
From Southern Africa, ATS is also being trafficked to Aus-
tralia. According to the Australian Crime Commission 
(ACC), seizures of ATS shipments that had embarked from 
South Africa accounted for the largest share, of about 28 
per cent, of all ATS detected at the Australian border in 
2009 and 2010, while Zambia was also reported as the 
164 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012.
embarkation point for some cases.165 Both Australia and 
New Zealand have also reported that West African organ-
ized criminal groups are involved in ATS trafficking to 
these countries.166
Methamphetamine seized in Australia, trafficked via Thai-
land and China by the postal services, is also perceived to 
have originated in Germany.167 Though Australian law 
enforcement authorities report an increase of domestic 
165 Australian Crime Commission (ACC), Illicit Drug Data Report 2009-
2010, Canberra, June 2011.
166 “Country Report New Zealand”, presented at the Thirty-fifth Meeting 
of Heads of National Drug Law Enforcement Agencies, Asia and the 
Pacific (HONLAP), Agra, India, 22-25 November 2011.
167 “Illicit Drug Data Report 2011-12”, Australian Crime Commission 
(ACC), Canberra, May 2013.
Map 8: Methamphetamine flows as perceived by recipient countries to East and South-East Asia, Oceania 
and the Pacific, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012; Data derived from the ‘Illicit Drug 
seizures with relation to European Airports’ (IDEAS) database, 2009-2013;
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived 
by recipient countries. The origins of the flow arrows do not necessarily indicate the sources/manufacture of methamphetamine. These arrows represent the 
flows as perceived by source countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines 
represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The 
final status of Jammu and Kashmir has not yet been agreed upon by the parties.
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ATS manufacture, rising amounts of ATS have recently 
been seized along the Australian border pointing to an 
increase of trafficking to the country.168
In recent years, there have also been reports of metham-
phetamine trafficked from countries in North and South 
America to East and South-East Asia. In 2012, Japan and 
Australia reported that a large share of seized metham-
phetamine was perceived to have originated from Mexico 
and trafficked in shipping containers.169 Furthermore, 
168 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
169 United Nations Office on Drugs and Crime (UNODC), Annual 
methamphetamine perceived to have originated in Peru 
and Brazil have been reported seized in the Philippines in 
2012, possibly intended for onward trafficking to main-
land China and Hong Kong, China.170 In addition, 
according to Malaysian law enforcement there are indica-
tions that Iranian drug trafficking groups may be smug-
gling Mexican manufactured methamphetamine to 
Malaysia by plane.171
Report Questionnaire for Japan 2012; Drug Abuse Information Net-
work for Asia and the Pacific (DAINAP).
170 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Philippines 2012.
171 “Malaysia country report”, Narcotics Crime Investigation Depart-
Map 9: Methamphetamine flows as perceived by recipient countries within East and South-East Asia,  
Oceania and the Pacific, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived 
by recipient countries. The origins of the flow arrows do not necessarily indicate the sources/manufacture of methamphetamine. These arrows represent the 
flows as perceived by source countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines 
represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The 
final status of Jammu and Kashmir has not yet been agreed upon by the parties.
China
Hong Kong    
Singapore
Thailand
Japan
Malaysia
Indonesia
Australia
South
Korea
Philipines
New Zealand
Bangladesh
Myanmar
0 2,0001,000 km
Methamphetamine flows
28
2014 GLOBAL SYNTHETIC DRUGS ASSESSMENT
According to reports from Hong Kong, China, metham-
phetamine seized in Hong Kong is mainly perceived as 
being intended for trafficking to other parts of the region, 
such as Australia, Cambodia, Japan, Malaysia and Thai-
land.172 Large amounts of methamphetamine seized in 
China and originating in the country are perceived to be 
intended for the domestic market, and some countries, 
such as Indonesia, the Republic of Korea, Malaysia and 
the Philippines, have reported seizures of methampheta-
mine in 2012 that were perceived to have originated in 
China.173
According to expert perception, some methamphetamine 
originating in Myanmar is intended for the domestic 
market, but most is intended for trafficking to neighbour-
ing countries.174 All methamphetamine seized in Bangla-
desh and Thailand in 2008 was perceived to have originated 
in Myanmar.175 Since then, methamphetamine seizures 
reported in Bangladesh, Thailand and Myanmar itself con-
tinue to be perceived to have originated in Myanmar.176 
According to expert perception, methamphetamine is traf-
ficked from Myanmar to Thailand, Vietnam and Cambo-
dia, via Lao PDR, though the drug also continues to be 
trafficked to these countries directly from Myanmar by 
sea.177 There are indications that large quantities of the 
substance are also smuggled to China. According to expert 
perception, a large share of methamphetamine pills seized 
in China in 2012 originated from Myanmar.178 Moreover, 
there have been reports that increasing amounts of meth-
amphetamine originating from Myanmar have been seized 
in Yunnan province in south-western China along the 
border to Myanmar.179
ment, Royal Malaysia Police (RMP), presented at the Eighteenth Asia-
Pacific Operational Drug Enforcement Conference (ADEC), Tokyo, 
26-27 February 2013.
172 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Hong Kong, China 2012.
173 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia, the Republic of Korea, Malaysia 
and the Philippines 2009-2012.
174 United Nations Office on Drugs and Crime (UNODC), Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for 
Asia and the Pacific. Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, November 2013.
175 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Myanmar and Thailand 2008.
176 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Bangladesh, Myanmar and Thailand 2008.
177 United Nations Office on Drugs and Crime (UNODC), Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for 
Asia and the Pacific. Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, November 2013.
178 “China country presentation”, China National Narcotics Control 
Commission (NNCC), presented at the Eighteenth Asia-Pacific Oper-
ational Drug Enforcement Conference (ADEC), Tokyo, 26-27 Febru-
ary 2013.
179 “Current Drug Situation and Trends of ATS in China”, China National 
Narcotics Control Commission (NNCC), presented at the Eighteenth 
Asia-Pacific Operational Drug Enforcement Conference (ADEC), 
Tokyo, 26-27 February 2013.
A large and established market for NPS
Although the total number of NPS reports in the region 
has fluctuated over the years, reports of NPS on the whole 
have increased from 11 in 2008 to a total of almost 210 
in 2013. The largest increases of NPS reports in the region 
have been observed with synthetic cannabinoids which 
have risen from just one observed substance in 2009 to 52 
in 2013, and ketamine and phencyclidine-type substances 
rising from 11 in 2008 to 50 in 2013. In 2013, synthetic 
cannabinoids and ketamine and phencyclidine-type sub-
stances  together accounted for almost 50 per cent of NPS 
reports. The number of reports of synthetic cathinones, 
phenethylamines, plant-based substances and piperazines 
also increased in recent years. Between 2009 and 2013, 
the number of reported synthetic cathinones increased 
from one to 37, phenethylamines increased from 2 to 23, 
piperazines from 3 to 20 and plant-based substances from 
2 to 8 over the same period. The number of aminoindanes 
reported remained at low levels over the years with only 
one reported since 2009.
On the whole, about one-third of the number of NPS 
reports in the region between 2008 and 2013 have been 
reported by Australia accounting for 31 per cent of the 
total, followed by New Zealand at 17 per cent, Singapore 
at 12 per cent, Japan and China (including Hong Kong, 
China) at both 7 per cent. Other NPS in the region were 
also reported by Brunei Darussalam, Cambodia, Indonesia, 
India, the Republic of Korea, Malaysia, Mongolia, Myan-
mar, the Philippines, Sri Lanka, Thailand and Viet Nam, 
together making up around 26 per cent of the total number 
of NPS reports in the region.
A particularly large NPS market appears to be present in 
the Oceania region, where countries have reported some of 
the highest NPS prevalence rates in the world. In 2007/08, 
before BZP, a piperazine, was classified in New Zealand as 
a Class C drug, a household survey among people aged 15 
to 64, showed that BZP was the second most used drug at 
5.6 per cent, after cannabis at 14.6 per cent in terms of 
annual prevalence, which is more than twice as high as the 
rate for amphetamines at 2.1 per cent.180 However, once 
BZP was scheduled as a Class C drug in 2007, prevalence 
rates for BZP sharply declined, together with several other 
NPS that were placed under national controls.181 In Aus-
tralia, ketamine is the only NPS included in the national 
household survey of people aged 14 and above, and in 2010 
it had an annual prevalence rate at 0.2 per cent use, the 
same as that of heroin, methadone or buprenorphine, and 
180 Ministry of Health, Drug Use in New Zealand; Key results of the 
2007/08 New alcohol and Drug Survey, January 2010.
181 C. Wilkins and P. Sweetsur, “The impact of the prohibition of Ben-
zylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal 
highs and other drug use in New Zealand”, Drug and Alcohol Depen-
dence 127, no. 1-3 (2013): 72-80.
29
Asia
higher than that of GHB at 0.1 per cent.182 However, 
according to the Australian Crime Commission (ACC), 
drug users consume a number of NPS as substitutes to ATS. 
This can be evidenced in the results of a study conducted 
among frequent “ecstasy” and amphetamine users in Aus-
182 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report. Drug Statistics Series No. 25, Canberra, 
July 2011. 
tralia, where 33 per cent had used an “emerging psychoac-
tive substance” (excluding synthetic cannabinoids) in 2012, 
increasing from 28 per cent in 2011.183 
A large market for ketamine appears to be present in a 
number of Asian countries, notably in East Asia. Among 
people held in prisons in Macau, China, in 2012 ketamine 
was the second most used drug in terms of annual preva-
lence at 18.3 per cent, after methamphetamine at 41.6 per 
cent.184 High levels of ketamine seizures have been 
reported in China, including Hong Kong, China, over the 
years which have also accounted for a significant share of 
ketamine seizures reported globally. Between 5 to 6 tons 
of ketamine have been annually seized in mainland China 
and Hong Kong, China, since 2009 and seizures have 
accounted for almost 60 per cent of global ketamine sei-
zures between 2008 and 2011, except for 2010 when keta-
mine seizures accounted for about 42 per cent of the global 
total.
Relatively high levels of ketamine use have also been 
reported in the Southern Asian region where ketamine was 
identified as the fifth most widely used substance in India 
and Myanmar in 2011, while the substance was the fourth 
most widely used substance in Brunei Darussalam in 
2011.185 Though ketamine seizures have remained at low 
levels in Brunei Darussalam and Myanmar, ketamine sei-
183 University of New South Wales, National Drug and Alcohol Research 
Centre, “Australian drug trends 2012: findings from the Ecstasy and 
Related Drugs Reporting System” Drug Trends Conference hand-out 
(Sydney, 2012).
184 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Macau, China 2012.
185 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
Fig. 16: Total number of NPS reports to UNODC in  
East and South-East Asia, Oceania and the 
Pacific, by country, 2008-2013
Source: United Nations Office on Drugs and Crime (UNODC), “The 
challenge of new psychoactive substances”. Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, 
Vienna, March 2013; United Nations Office on Drugs and Crime 
(UNODC), “UNODC Early Warning Advisory on New Psychoactive 
Substances (NPS) October 2013 update”, October 2013; Submis-
sions to UNODC and laboratories participating in the International 
Collaborative Exercises (ICE) programme.
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Fig. 15: Total number of NPS reports to UNODC in East and South-East Asia, Oceania and the Pacific  
(2008-2013)
Source: United Nations Office on Drugs and Crime (UNODC), “The challenge of new psychoactive substances”. Global Synthetics Monitor-
ing: Analyses, Reporting and Trends (SMART) Programme, Vienna, March 2013; United Nations Office on Drugs and Crime (UNODC), 
“UNODC Early Warning Advisory on New Psychoactive Substances (NPS) October 2013 update”, October 2013 Submissions to UNODC 
and laboratories participating in the International Collaborative Exercises (ICE) programme.
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zures in India have been increasing over the years, from 
about 0.8 tons in 2009 to 1.5 tons in 2011.
In 2008, ketamine was identified as the fifth most widely 
used substances in Japan, while Singapore identified keta-
mine as the sixth most widely used substance in 2011, 
followed by the seventh most used substance in Indonesia 
in 2009.186 However, there have been no ketamine seizures 
reported from Japan to UNODC for a number of years, 
and seizures in Indonesia and Singapore have together 
made up less than 1 per cent of ketamine seized globally 
between 2008 and 2011.
Over the years, illicit ketamine manufacture has been 
reported by countries in East Asia, such as in China and 
Hong Kong China. A total of 81 ketamine laboratories 
were discovered in mainland China in 2012, prior to which 
another 44 ketamine laboratories were dismantled in 
2007.187 In 2012, Hong Kong, China, also reported the 
discovery of a ketamine laboratory.188 Ketamine seized in 
China, is perceived to have been intended for trafficking 
to Malaysia, as well as to Hong Kong, China, by sea from 
where it is also perceived to be trafficked onwards to Sin-
186 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
187 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China 2007-2012.
188 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Hong Kong, China, 2012.
gapore by plane.189 Around 2.2 tons of ketamine have 
been seized in Malaysia between 2009 and 2011 and 
according to expert perception, ketamine is among the 
most used NPS in the country.190
Recently, ketamine has also been found in tablets sold as 
methamphetamine in some countries in the region. In 
Indonesia, seizures of tablets sold as methamphetamine in 
2012, reportedly contained methamphetamine as well as 
ketamine and other NPS, under national control.191 In 
the same year, ketamine and other NPS were also found 
in seized tablets sold as methamphetamine in Australia, in 
addition to methamphetamine.192
Most ketamine seized in countries world-wide is perceived 
to originate from China and India, as well as Cambodia 
and the Taiwan Province of China. Canada, the United 
States and countries in Western Europe such as Italy have 
reported of ketamine seizures that were perceived to have 
originated from India as well as China.193 To North Amer-
189 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Hong Kong, China, and Singapore 2012.
190 United Nations Office on Drugs and Crime (UNODC), Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for 
Asia and the Pacific. Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, November 2013.
191 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia 2012.
192 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Australia 2012.
193 United Nations Office on Drugs and Crime (UNODC), Annual 
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Map 10: Ketamine flows as perceived by recipient countries, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of ketamine. These arrows represent the flows as perceived by recipient 
countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and 
Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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ica, ketamine is also trafficked from or via Western Europe. 
Within East and South-East Asia, seized ketamine per-
ceived to have originated in China and/or India between 
2008 and 2012, was reported by Indonesia and Japan.194 
However, ketamine seized in Thailand was perceived to 
have originated in Cambodia and in Japan ketamine sei-
zures were reportedly traced to the Taiwan Province of 
China.195 Most ketamine seized in India over the years 
was perceived to have been intended for the supply of the 
domestic market as well as for onward trafficking.196 Large 
amounts of ketamine seized in mainland China, Hong 
Kong, China, Singapore and Thailand over the years were 
perceived to be intended for the domestic market.197
High levels of khat seizures also indicate an emerging threat 
in East and South-East Asia and Oceania. Between 2008 
and 2012, about 6.4 tons of khat had been seized in China 
and Hong Kong, China and in 2012 more than half of all 
khat seized in the United States that year was reported to 
Report Questionnaire for Canada, Italy and the United States 2008-
2012.
194 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Indonesia and Japan 2008-2012.
195 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Thailand and Japan 2008-2012.
196 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for India 2008-2012.
197 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China, Hong Kong, China, Singapore and 
Thailand 2008-2012.
have been trafficked via China and Hong Kong, China.198 
In February 2013, the Indonesian National Narcotics 
Board (NNB) Police also discovered a 7 hectare khat plan-
tation in Cisarua of Bogor in West Java, in Indonesia.199 
Khat manufacture in the region may heighten the risk of 
an expanding market in the future.
198 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for China and Hong Kong, China, and the 
United States, 2008-2012.
199 “Comparison Analysis of Red and Green Khat Leaves (Fresh, Dried 
and After Two Months Frozen”, Drugs Testing Laboratory National 
Narcotics Board Republic of Indonesia, April 2013.
Fig. 17: Global ketamine seizures and ketamine sei-
zures reported in East and South-East Asia, 
by country, 2008-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2011.
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4. EUROPE
Regional Overview
Amphetamine continues to be the most commonly avail-
able synthetic stimulant in Europe, followed by “ecstasy” 
and methamphetamine. Since 2008, amphetamine seizures 
have annually made up more than 65 per cent of ATS sei-
zures, whilst “ecstasy” seizures have had an annual share of 
less than 22 per cent and methamphetamine seizures have 
annually remained below 13 per cent. Particularly, large 
amounts of amphetamine were seized in 2008 and in 2009, 
when amphetamine seizures made up about 80-85 per cent 
of ATS seizures in Europe.
On the whole, amphetamine is a major problem in Europe, 
particularly in Northern Europe, in countries such as Den-
mark, Latvia and Sweden. Amphetamine users make up a 
substantial portion of those seeking drug treatment in 
Sweden, where the largest number of persons receiving 
drug treatment for the first time were amphetamine users 
in 2010, making up a share of 28.6 per cent (1,473 people), 
and in Latvia, where about 18.9 per cent (380 people) of 
persons were treated for amphetamine use in 2011, making 
up the second highest share of people receiving drug treat-
ment, after those treated for heroin use at 39.8 per cent 
(799 people).200 In Denmark, amphetamine users made 
up the third largest share of people receiving drug treat-
200 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Latvia in 2011 and Sweden in 2010.
ment in 2012 at 9.7 per cent (358 people), after cannabis 
at 64.7 (2,397 people) per cent and heroin at 11.3 per cent 
(420 people).201
While the methamphetamine market appears to have 
picked up somewhat over the last several years, falling 
“ecstasy” seizures and drug law offenses related to “ecstasy” 
in Europe indicate a decline in the “ecstasy” market. 
Between 2007 and 2012, the quantity of “ecstasy” seized 
in Europe decreased by 72 per cent,202 whilst the number 
of “ecstasy”-related offenses203 between 2007 and 2011 
have annually decreased.204 According to the EMCDDA, 
the shrinking popularity for this substance in Europe may 
be due to the fact that many of the pills sold as “ecstasy” 
did not contain MDMA or were of a lower purity.205 
MDMA was often substituted with other substances when 
controls over 3,4-MDP-2-P206 (the main precursor 
chemical used in the manufacture of MDMA) were 
heightened.207
Though ATS continues to be manufactured in Europe, the 
number of ATS laboratories dismantled in the region has 
declined in the last few years. Between 2008 and 2011, 
the total number of dismantled ATS laboratories declined 
by about 34 per cent. Dismantled ATS laboratories con-
tinue to be predominantly methamphetamine laboratories, 
followed by amphetamine, and only few ecstasy laborato-
ries. For instance, in 2011, methamphetamine laboratories 
almost made up 85 per cent of all dismantled ATS labo-
ratories, while amphetamine laboratories made up 16 per 
cent and ecstasy just around 0.5 per cent.
Between 2009 and 2012, large numbers of amphetamine 
201 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Denmark 2012.
202 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2007-2012
203 According to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) “Drug law offences usually refer to offences 
such as drug production, trafficking and dealing as well as drug use 
and possession for use. Although in some countries, drug use and/or 
possession for use are not considered as criminal offences and attract 
administrative sanctions, reports for these were included in the data”.
204 Reported to the EMCDDA by the Reitox National Focal Points in the 
European Union, European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), 2007-2011.
205 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, “EU Drug Markets Report: A Strategic Analy-
sis”, Luxembourg, Publications Office of the European Union, 2013.
206 The full name of the chemical abbreviation is 3,4-Methylenedioxyphe-
nyl-2-propanone.
207 For more information see chapter on “Precursor trends and manufac-
turing methods” of this report.
Fig. 18: Total ATS seizures reported in Europe, 
2005-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2012.
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Poland, including several in Belarus, Bulgaria, Estonia and 
Germany.208 In Germany and Poland, some amphetamine 
laboratories have been reported of medium size, but most 
others reported in Belarus, Bulgaria and Estonia have been 
of a small or “kitchen” size. The size of amphetamine labo-
ratories dismantled in the Russian Federation is unknown. 
On the whole, the sheer number of discovered ampheta-
mine laboratories in these countries is not an indication 
of the quantity produced. In 2011, just over 90 per cent 
of methamphetamine laboratories dismantled in Europe 
were reported in the Czech Republic. However, over the 
last several years methamphetamine production has also 
been reported by other countries, such as in Austria, Bul-
garia, Germany and Slovakia.209
A rapidly evolving marketplace for drugs
During the past few years, a range of NPS have emerged 
on ATS markets. So far, the NPS problem appears to be 
particularly prevalent in Europe. Most of the question-
208 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2009-2012.
209 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2009-2012.
Fig. 19: Dismantled ATS laboratories reported in  
Europe, 2005-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2011.
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Map 11: Reported ATS laboratories dismantled in Europe, 2009-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2009-2012.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
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naires received by UNODC on NPS in 2012 were from 
countries in Europe.210 In 2012, a total of 73 NPS were 
officially identified by European Union (EU) Member 
States through the EU Early Warning System (EWS), 
which is more than triple the number reported in 2009.
In 2011 and 2012, synthetic cannabinoids made up the 
largest share of NPS formally identified within the EU. 
Whilst 74 synthetic cannabinoids have been reported since 
2008, 30 of these were reported in 2012 alone.211 In addi-
tion, 14 new phenethylamines were reported to the EWS 
in 2012, which is more than twice the number detected 
in any previous year. The number of phenethylamines 
detected in 2012 account for approximately one-third of 
the number detected since 2005.212 In contrast, the impor-
tance of synthetic cathinones seems to have decreased 
somewhat recently. Only 5 synthetic cathinone derivatives 
were formerly notified in 2012, which marks about a 70 
per cent drop in the number reported since 2010.213
210 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, March 2013.
211 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and European Police, “New Drugs in Europe, 2012: 
EMCDDA–Europol 2012 Annual Report on the implementation of 
Council Decision 2005/387/JHA” Luxembourg: Publications Office 
of the European Union, 2013.
212 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and European Police, “New Drugs in Europe, 2012: 
EMCDDA–Europol 2012 Annual Report on the implementation of 
Council Decision 2005/387/JHA” Luxembourg: Publications Office 
of the European Union, 2013.
213 European Monitoring Centre for Drugs and Drug Addiction 
The trend in Europe towards synthetic cannabinoids, and 
to a lesser extent phenethylamines and synthetic cathi-
nones, observed in the EWS until 2012, was confirmed 
by a UNODC survey on NPS in 2013. Between July and 
October 2013, European countries reported 225 NPS to 
UNODC,214 of which 40 per cent consisted of synthetic 
cannabinoids, but 20 per cent were phenethylamines and 
17 per cent synthetic cathinones.
Although NPS are by definition not controlled at a global 
level, a number of such substances are controlled on a 
national level and/or EU-wide so that NPS are in fact often 
seized in Europe. Between 2009 and 2012, European 
countries reported a large number of seizures of synthetic 
cannabinoids, but total annual seizures greatly fluctuated 
dropping from 2.6 tons in 2010 to 0.3 tons in 2011, after 
which they surged to 8.8 tons in 2012.215 A number of 
synthetic cannabinoid manufacturing laboratories have 
also been dismantled in Europe over the last few years. In 
2012, a total of 4 synthetic cannabinoid laboratories were 
discovered in Turkey and another laboratory prior to that 
in Germany in 2010.216 Other NPS manufacturing sites 
(EMCDDA) and European Police, “New Drugs in Europe, 2012: 
EMCDDA–Europol 2012 Annual Report on the implementation of 
Council Decision 2005/387/JHA” Luxembourg: Publications Office 
of the European Union, 2013.
214 New and existing substances in Europe were reported to UNODC by 
Austria, Belgium, Croatia, Estonia, France, Germany, Hungary, Ire-
land, Italy, Latvia, Lithuania, Romania, the Russian Federation, Spain, 
Sweden, Ukraine and the United Kingdom.
215 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012.
216 United Nations Office on Drugs and Crime (UNODC), Annual 
Fig. 20: Total identified new psychoactive  
substances reported to the EU early  
warning system (2005-2012)
Source: European Monitoring Centre for Drugs and Drug Addic-
tion and European Police Office, “EU Drug Markets Report: A Stra-
tegic Analysis”, Luxembourg, Publications Office of the European 
Union, 2013.
Fig. 21: Reports of new and existing NPS  
reported by countries in Europe to UNODC 
(July-October 2013)
Source: United Nations Office on Drugs and Crime (UNODC), 
“UNODC Early Warning Advisory on New Psychoactive Substances 
(NPS) October 2013 update”, October 2013.
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Map 12: Lifetime prevalence of legal substances* that imitate the effects of illicit drugs in the EU among  
persons aged 15-24, 2011
Source: Gallup Organisation, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 330, European Commission, 
July 2011.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
* Legal according to national legislation at the time of the survey.
have mostly been reported in Belarus, where an alpha-
pyrrolidinopentiophenone laboratory and a JWH-018 
laboratory were discovered in 2012, as well as another 
JWH-018 laboratory in 2011.217
The only Europe-wide NPS prevalence survey to-date, 
displays results that are not far from prevalence rates of 
some controlled drugs in Europe. The Eurobarometer 
survey conducted among 12,000 randomly selected youths 
aged 15-24 across the EU in 2011 revealed that the lifetime 
prevalence of youths that had experimented with “legal 
substances that imitate the effects of illicit drugs”218 was 
at 4.8 per cent (2.9 million people)219.220 The lifetime 
Report Questionnaire for Turkey and Germany 2010-2012.
217 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Belarus 2010-2012.
218 Legal according to national legislation at the time of the survey; Gallup 
Organisation, Youth Attitudes on Drugs: Analytical Report, Flash 
Eurobarometer series No. 330, European Commission, July 2011.
219 According to the Eurobarometer survey, the definition of legal sub-
stances that imitate the effects of illicit drugs refers to psychoactive 
substances that are not controlled at the national level. Since more 
substances are controlled on the national than on the international 
level, the survey excludes a number of substances that are officially 
termed as NPS. 
220 Gallup Organisation, Youth Attitudes on Drugs: Analytical Report, Flash 
prevalence rates for “legal substances that imitate the effects 
of illicit drugs” in the EU appear to be slightly lower than 
the use rates for amphetamines shown by the European 
School Survey Project on Alcohol and Other Drugs if 
adjusted to the age group 15 to 18, but of a magnitude 
similar to the rate for “ecstasy” and larger than the corre-
sponding rates for cocaine, LSD or heroin.221 The highest 
prevalence rates were reported by Ireland at 16.3 per cent, 
Poland at 9 per cent, Latvia at 8.8 per cent and the United 
Kingdom at 8.2 per cent.
As in the case of other drugs, the use of “legal substances 
that imitate the effects of illicit drugs” is more wide-spread 
among males than among females, more common in met-
Eurobarometer series No. 330, European Commission, July 2011.
221 Gallup Organisation, Youth Attitudes on Drugs: Analytical Report, Flash 
Eurobarometer series No. 330, European Commission, July 2011; B. 
Hibell and others, The 2011 ESPAD Report: Substance Use among Stu-
dents in 36 European Countries, Stockholm, Swedish Council for Infor-
mation on Alcohol and Other Drugs, 2012; B. Hibell and others, The 
ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 
35 European Countries, Stockholm, Swedish Council for Information 
on Alcohol and Other Drugs and Pompidou Group of the Council 
of Europe, 2004; Council of Europe, Alcohol and Drug Use Among 
European 16-18 Year Old Students – Data from the ESPAD Project, 
February 2007.
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Map 13: European countries reporting larger seizures of methamphetamine or amphetamine, 2010-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2010-2012.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
ropolitan than in rural areas and more wide-spread among 
the unemployed population than among those working. 
Visitors at nightclubs display high use rates, but these find-
ings are not generalisable to other groups and populations 
on a nation-wide scale. For instance, a survey of gay-
friendly nightclubs in South-East London found that the 
NPS mephedrone, had the highest prevalence of last 
month use at 53.0 per cent, surpassing cocaine use at 44.6 
per cent and “ecstasy” at 27.0 per cent.222 While the results 
showed that lifetime prevalence of cocaine use was ranked 
highest at 76 per cent, this was followed by “ecstasy” at 69 
per cent and mephedrone at 64 per cent. Another night-
club survey conducted in Denmark in 2010 initiated by 
the Centre for Drug and Alcohol Research at Aarhus Uni-
versity and the National Research Centre for Welfare, also 
showed that 10 per cent of Danish clubbers reported 
to have tried the NPS ketamine, including GHB,223 and 
some hallucinogenic compounds under international 
control.224
222 Wood, D.M. et. al. “Limited use of novel psychoactive substances in 
South London nightclubs” QJM: An International Journal of Medicine 
October 2012 (105)(10): 959-964.
223 GHB is the chemical abbreviation of Gamma-hydroxybutyrate, a 
substance under international control.
224 “Denmark - New Development, Trends and in-depth information on 
Is the market for methamphetamine  
picking up?
In spite of an increase in methamphetamine seizures over 
the last several years, the amount of methamphetamine 
seized in Europe still remains significantly lower than the 
amount of amphetamine seized annually. In terms of total 
ATS laboratories dismantled in Europe, the number of 
methamphetamine laboratories continues to exceed the 
number of amphetamine laboratories. In 2011, more than 
five times as many methamphetamine than amphetamine 
laboratories were dismantled.225 However, many of the 
methamphetamine laboratories discovered in Europe 
between 2010 and 2012 are reported by the Czech Repub-
lic and consist of small-scale operations intended to supply 
drugs to a narrow market.226 In contrast, a number of 
amphetamine laboratories dismantled in Belgium, Ger-
many, Hungary, Lithuania, Poland and Turkey have been 
selected issues”, 2012 National Report (2011 data) to the EMCDDA 
by the Reitox National Focal Point, European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), Denmark, 2012.
225 Of the 360 methamphetamine laboratories dismantled in Europe in 
2011, 338 were discovered in the Czech Republic.
226 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), European Drug Report: Trends and developments, Lisbon: 
Publications Office of the European Union, 2013.
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of a medium or industrial scale.227 Therefore, the sheer 
number of dismantled methamphetamine laboratories 
might not provide a clear indication of the volume illicitly 
manufactured.
Methamphetamine originating from European countries 
are primarily trafficked to other countries within the 
region. In 2012, seizures of methamphetamine originating 
from Belgium, the Czech Republic, the Netherlands and 
Slovakia were perceived to have been trafficked to coun-
tries across Europe, including Austria, Hungary, Ireland, 
Italy, Poland and the United Kingdom.228 Poland is pre-
dominantly a transit country for methamphetamine origi-
nating from the Czech Republic and the Netherlands 
trafficked to other countries in Eastern Europe, including 
Belarus and Lithuania.229 Seized methamphetamine origi-
nating in Lithuania was also indicated as being primarily 
intended for supplying the domestic market as well as for 
onward trafficking to Scandinavian countries, such as 
Sweden.230
Recent evidence suggests that methamphetamine is begin-
ning to replace amphetamine in some countries. Whilst 
the ATS market in the Czech Republic has long been domi-
nated by methamphetamine, this trend appears to be 
spreading to other European countries particularly in East-
ern Europe and the Baltics. For instance, throughout the 
period of 2010 to 2012, a total of 8 European countries 
reported higher methamphetamine than amphetamine 
seizures, with the highest shares reported in the Czech 
Republic, Romania, Slovakia and Turkey.
According to drug treatment data in the Czech Republic 
in 2012, the number of people treated for methamphet-
amine use made up by far the largest share of people treated 
for drug use that year at 68.2 per cent (5,993 people).231 
Moreover, according to expert perception, ATS are primar-
ily driving the increase for drug treatment demand outside 
of Prague in the Czech Republic.232 Also, in 2012, the 
number of people treated for methamphetamine use in 
Slovakia accounted for the largest share of people treated 
for drug use at 44.5 per cent (892 people).233 In addition 
to locally produced methamphetamine, there were reports 
227 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012.
228 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2012.
229 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Belarus and Lithuania 2012.
230 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2012.
231 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Czech Republic, 2012.
232 “Annual Report: The Czech Republic – 2011 Drug Situation”, Office 
of the Government of the Czech Republic, Prague, Czech Republic, 
September 2012.
233 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Slovakia, 2012.
of methamphetamine (exceeding 80 per cent purity) being 
trafficked to Slovakia from the Czech Republic.234
For some other countries in Europe, an increase in meth-
amphetamine seizures might not necessarily point to an 
increase in the domestic market for the drug. For instance, 
with regards to Turkey, methamphetamine seizures have 
increased from about 0.1 ton in 2010 to 0.5 tons in 
2012.235 It is difficult to estimate the current size of the 
methamphetamine market as use data remains unavailable. 
For the first time in 2011, the Turkish National Police 
(KOM) reported that a very low amount of methamphet-
amine was seized in street operations which might point 
to a small scale domestic market.236 However, whilst some 
methamphetamine seizures in Turkey were reported in the 
provinces along the border to the Islamic Republic of Iran, 
53 per cent of seizures in 2011 occurred in Istanbul, pri-
marily at Ataturk Airport.237 Therefore, the Turkish 
national authorities attributed the high level of seizures in 
the country to Turkey’s increasing role as a transit country 
for methamphetamine trafficking.238
Is there a decline in the “ecstasy” market?
In spite of an overall decrease of “ecstasy” seizures for 2012, 
in several European countries, such as France, Spain and 
the United Kingdom, seizures in Turkey have greatly 
increased since 2009 and almost tripled in 2012 to 1.2 
tons. In 2012, Turkey reported the largest “ecstasy” seizures 
in Europe, having outpaced the level reported in the Neth-
erlands, which use to report the largest "ecstasy" seizures 
up until 2011. Within Europe, large amounts of “ecstasy” 
are trafficked from the Netherlands to other countries in 
the region. In 2012, the Netherlands were identified as a 
perceived country of origin for all “ecstasy” seized in Aus-
tria, Hungary and Sweden.239 A large share of “ecstasy” 
seized in Belgium, Croatia, Cyprus, Estonia, Ireland, Italy, 
Lithuania and Poland between 2010 and 2012 was also 
perceived to have originated from the Netherlands.240 
Over the same period, the Netherlands have also been 
named as a major transit country for “ecstasy” seized in 
234 “Slovakia – New Development, Trends and In-depth Information on 
Selected Issues”, 2012 National Report (2011 data) to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) by the 
Reitox National Focal Point, Slovakia, 2012.
235 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Turkey 2010-2012.
236 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
237 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
238 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
239 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Austria, Hungary and Sweden 2012.
240 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012.
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Belgium, France and Germany.241 “Ecstasy” tablets seized 
in Turkey are generally perceived to originate from the 
Netherlands and Belgium from where these are trafficked 
via Bulgaria and more recently via Greece.242
241 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012.
242 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
According to the National Turkish Focal Point to the 
EMCDDA, the increasing seizures in Turkey are chiefly 
attributable to the growing domestic “ecstasy” market. A 
pilot study by the Adult Investigation and Evaluation Form 
(Y-ARDEF) that surveyed 10 penal institutions in Turkey 
in 2011, showed that after cannabis at 41.4 per cent, 
“ecstasy” use had the second highest prevalence rate among 
inmates at 26.6 per cent.243 Moreover, drug-related deaths 
243 Adult Investigation and Evaluation Form (Y-ARDEF) cited in “2012 
Background on regional differences in ATS use
Generically known as amphetamines, methamphetamine 
and amphetamine are closely related synthetic stimulants. 
And yet, of the two, amphetamine has always been more 
common in Europe and the Middle East, whilst metham-
phetamine has dominated the ATS market in East and 
South-East Asia and has had a large presence in North 
America. The high availability of amphetamines in these 
regions primarily has its origins in the Second World War, 
when large quantities of amphetamines were manufac-
tured to supply troops and workers to act as a stimulant 
in strenuous times.1 Military personnel in the United 
States and Japan were predominantly supplied with meth-
amphetamine, while soldiers in Europe were commonly 
given amphetamine.2 Stockpiles of amphetamines after 
the war led to their widespread availability followed by 
the non-medical use of amphetamines in these regions.3 
A surge in the recreational use of methamphetamine was 
first recorded between 1945 and 1955 in the United 
States and Japan.4 Most amphetamines at the time were 
not nationally controlled and manufactured by pharma-
ceutical companies which were also prescribed by medical 
practitioners to treat conditions such as depression, atten-
tion-deficit disorder, alcoholism, obesity and anorexia.5 
With the adoption of the International Convention on 
Psychotropic Substances in 1971, amphetamines were 
placed under international control which restricted the 
availability of amphetamines for non-medical use whilst 
illicit manufacture emerged.
 
Nevertheless, it still remains very difficult to explain 
national preferences for amphetamine and methampheta-
mine, since these drugs are often substituted for each 
other. For drug users, it is especially difficult to distin-
guish between the two given that the purity of street 
samples of both drugs can vary considerably. Although the 
use effects of the two drugs are similar, in that they pro-
duce mental and physical stimulation, methamphetamine 
has a more potent effect on the central nervous system and 
unlike other amphetamines is specifically taken by some 
to extend and intensify the sexual experience.6
Unlike amphetamines, the use of which spread following 
the Second World War, the spread of MDMA was pri-
marily a result of rave culture in Europe, North America 
and Oceania in the 1980s.7 The association with MDMA 
and music is important, since the substance can provide 
stamina to dance for long periods of time.8 MDMA acts 
as a stimulant and has some limited hallucinogenic effects 
that heighten sensory awareness. On the whole, “ecstasy” 
users seek to experience a tranquil euphoria coupled with 
a high degree of emotional empathy between associates. 
In the United States, MDMA was already more widely 
used in the 1970s to substitute MDA which was placed 
under national control.9 MDMA was not nationally con-
trolled and used by psychotherapists to aid counselling, 
particularly with regards to assist in improving interper-
sonal relationships and marital partnerships.
1 Wills, Simon. Drugs of Abuse, 2nd ed., Pharmaceutical Press (2005): 
London, Great Britain, pp.119.
2 ACMD, “Methylamphetamine review”, a report by the Advi-
sory Council on the Misuse of Drugs, 2005; Suwaki, H., Fukui, 
S. and Konuma, K., “Methamphetamine abuse in Japan: its 45 
year history and the current situation” (1997), in Klee, H. (ed.), 
Amphetamine misuse. International perspectives on current trends, 
Harwood Academic Publishers, Amsterdam. 
3 Wills, Simon. Drugs of Abuse, 2nd ed., Pharmaceutical Press (2005): 
London, Great Britain, pp.116; Tamura, M., ‘Japan: Stimulant 
epidemics past and present’, Bulletin on Narcotics 1 (1989): 83–93; 
ACMD, “Methylamphetamine review”, a report by the Advisory 
Council on the Misuse of Drugs, 2005; Case, P., The history of 
methamphetamine: an epidemic in context, First National Confer-
ence on Methamphetamine, HIV and Hepatitis, The Harm Reduc-
tion Project, Salt Lake City, August, 2005. 
4 Shrem, M. T. and Halkitis, P. N., ‘Methamphetamine abuse in the 
United States: contextual, psychological and sociological considera-
tions’, Journal of Health Psychology 13 (2008): 669–79; National 
Institute of Mental Health, cited in Ahmad, K., ‘Asia grapples with 
spreading amphetamine abuse’, The Lancet 361 (2003): 1878–9.
5 ACMD, “Methylamphetamine review”, a report by the Advisory 
Council on the Misuse of Drugs, 2005; Case, P., The history of 
methamphetamine: an epidemic in context, First National Con-
ference on Methamphetamine, HIV and Hepatitis, The Harm 
Reduction Project, Salt Lake City, August, 2005; National Drug 
Law Enforcement Research Fund (NDLERF), The governance of 
illicit synthetic drugs, monograph series No. 9, Commonwealth of 
Australia, 2005. 
6 Wills, Simon. Drugs of Abuse, 2nd ed., Pharmaceutical Press (2005): 
London, Great Britain, pp.119.
7 Wills, Simon. Drugs of Abuse, 2nd ed., Pharmaceutical Press (2005): 
London, Great Britain, pp.120.
8 Reynolds, Simon, Generation Ecstasy: Into the World of Techno and 
Rave Culture, Routledge, 1999: 81.
9 Wills, Simon. Drugs of Abuse, 2nd ed., Pharmaceutical Press (2005): 
London, Great Britain, pp.115.
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as a direct cause of "ecstasy" use have been steadily increas-
ing in Turkey from 9 cases in 2010 to 35 in 2011, whilst 
deaths indirectly caused by "ecstasy" increased from only 
one case to 19 over the same period.244
However, the increasing “ecstasy” seizures in Turkey may 
instead point to a growing market for amphetamines in 
the country. Many seizures of tablets sold on the market 
as “ecstasy”, carrying the ecstasy-logo, actually contained 
amphetamine.245 According to the EMCDDA in 2011, 
66 per cent of the analysed “ecstasy” tablets seized in 
Turkey were found to contain amphetamine or metham-
phetamine, while only 20 per cent contained MDMA.246 
In the meantime, according to the Turkish National Police, 
seizures of tablets sold as captagon (which primarily con-
tain amphetamine) have been steadily decreasing, falling 
from about 7.5 million tablets in 2007 to only 1.1 million 
in 2011.247 For the Turkish National Police this evidence 
suggests that the market for amphetamines in Turkey is 
being revitalised by relabeling captagon tablets as 
“ecstasy”.248
National Report (2011 data) to the EMCDDA by the Reitox National 
Focal Point” European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA), Turkey, 2012.
244 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
245 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
246  “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
247 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
248 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
The high amphetamine content of “ecstasy” tablets in 
Turkey contrasts developments in other European coun-
tries, where the availability of MDMA in “ecstasy” tablets 
appears to have increased. According to the EMCDDA, 
countries reporting that MDMA-like substances accounted 
for the largest proportion of analysed “ecstasy” tablets, 
increased from only 3 countries in 2009 to 11 in 2011.249 
Ecstasy producers may have shifted to using ‘pre-precur-
sors’ that can be legally imported as non-controlled sub-
stances and converted into the precursor chemicals needed 
for MDMA production.250 It remains to be seen whether 
this will stimulate a renewed demand for ecstasy in Europe.
How do controls affect the market for 
mephedrone?
Before being placed under EU-wide control in December 
2010, mephedrone had already been under national con-
trol in a number of European countries using various dif-
ferent legislative approaches.251 Some countries, such as 
Finland and the Netherlands classified mephedrone as a 
249 In 2010, only Malta, Italy and the Netherlands reported that MDMA-
like substances accounted for the largest proportion of analysed 
“ecstasy” tablets in 2009, which increased to 11 countries in 2011 
that included Austria, Croatia, Estonia, Finland, France, Germany, 
Malta, the Netherlands, Poland, Portugal and Slovenia; Reported to 
the EMCDDA by the Reitox National Focal Point of Austria, Croatia, 
Estonia, Finland, France, Germany, Malta, the Netherlands, Poland, 
Portugal and Slovenia, European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), 2012. 
250 For more information, see chapter on “Precursor trends and manufac-
turing methods” of this report.
251 At the time of preparation of this report, the United Kingdom submit-
ted a notification to the Secretary-General of the United Nations on 
adding mephedrone to Schedule 1 of the 1971 Convention on Psy-
chotropic Substances and provisionally scheduling mephedrone under 
Article 2 of that Convention.
Fig. 22: “Ecstasy” seizures reported in selected European countries, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012.
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medicine before adding the substance to the list of con-
trolled substances in their national drug legislation.252 
Denmark, Hungary, and the United Kingdom on the other 
hand, issued a temporary ban before placing the substance 
under permanent control.253 This measure ensured a 
prompt response to an imminent public health threat 
whilst providing experts with more time to gather available 
evidence and make a full assessment. At this stage it is still 
too early to say what the general impact of national control 
measures on mephedrone use will be.
By mid-2013, the largest number of countries to control 
mephedrone worldwide were located in Europe. Reports 
to UNODC supported by information available in the 
public domain show that a total of 31 countries have 
placed national legislative controls over mephedrone in 
Europe, 5 of which are outside the EU and include Bela-
rus, Norway, the Russia Federation, Switzerland and 
Turkey. Outside of Europe, only 9 countries are known to 
have placed regulatory measures on mephedrone.254
252 United Nations Office on Drugs and Crime (UNODC), “NPS brief – 
Mephedrone”, Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, October 2013.
253 United Nations Office on Drugs and Crime (UNODC), “NPS brief – 
Mephedrone”, Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, October 2013.
254 United Nations Office on Drugs and Crime (UNODC), “NPS brief – 
It still remains unclear to what extent mephedrone may 
now be competing with ATS in some countries. Since the 
market for “ecstasy” has clearly been in the decline in sev-
eral European countries, mephedrone may particularly be 
serving as a substitute for this substance. According to a 
number of studies mephedrone can evoke stimulant and 
empathogenic effects similar to other amphetamine-type 
stimulants, including MDMA.255 Moreover, there have 
even been cases reported in the Netherlands and France of 
mephedrone pills that were being sold on the market as 
“ecstasy”.256 In Europe, mephedrone laboratories have 
been discovered in some Eastern European countries, 
including Poland and Belarus.257
Mephedrone”, Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, October 2013.
255 For more on the stimulant and empathogenic effects of mephedrone 
see Brunt, Tibor M. et. al. “Instability of the ecstasy market and a new 
kid on the block: mephedrone” Journal of Psychopharmacology Septem-
ber 2010 (25): 1543-1547; Schifano, Fabrizio, et. al. “Mephedrone 
(4-methylmethcathinone; ‘meow meow’): chemical, pharmacological 
and clinical issues”, Journal of Psychopharmacology April 2011 (214): 
593-602.
256 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), “Risk assessment report of a new psychoactive substance: 
4-methylmethcathinone (mephedrone)”.
257 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Poland and Belarus 2010-2012.
Map 14: Legislative responses to mephedrone worldwide by mid-2013
Source: United Nations Office on Drugs and Crime (UNODC), “NPS brief – Mephedrone”, Global Synthetics Monitoring: Analyses, Report-
ing and Trends (SMART) Programme, October 2013.
Note: The information in this map has been provided by Member States to UNODC in the questionnaire on new psychoactive substances in 2012 or are other-
wise available in the public domain. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines 
represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The 
final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been 
determined.
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So far, available seizure data in Europe do not serve as a 
strong enough indicator to illustrate how legislative con-
trols in Europe may have impacted the market for 
mephedrone. Although mephedrone seizures have some-
what fallen in Europe since 2010 from around 0.2 tons to 
just under 0.1 ton in 2011, they picked up again and 
reached more than 0.1 ton in 2012.258 Comprehensive 
mephedrone seizure data prior to 2010 are not available.
However, prevalence data for the United Kingdom suggests 
that controls may have in fact led to a decline of the domes-
tic mephedrone market. Mephedrone was classified as a 
class B substance under the Misuse of Drugs Act in 2010, 
shortly after which, according to the Crime Survey for 
England and Wales (CSEW) conducted for England and 
Wales in 2011/12, annual mephedrone use among the 
general population aged 16 to 59 declined from 1.4 per 
cent of the previous survey in 2010/11 to 1.1 per cent.259 
The results of a non-representative internet survey con-
ducted on behalf of the United Kingdom dance and club-
bing magazine MixMag and The Guardian newspaper also 
indicated that annual use of mephedrone among respond-
ents dropped from 51 per cent in 2010 to 19.5 per cent 
in 2011.260 So far, the United Kingdom is the only country 
in Europe that conducted repeat surveys which included 
mephedrone. Studies from other European countries on 
the impact of mephedrone controls were not available at 
the time this report was written.
In spite of a possible decline in the demand for mephed-
rone in the United Kingdom, some segments of the popu-
lation may still use it as a substitute to other drugs on the 
ATS market. According to the CSEW 2011/12 survey, 
mephedrone had the highest annual prevalence rate of any 
NPS included in the survey and ranked fourth among the 
general population after cannabis at 6.9 per cent, cocaine 
at 2.2 per cent and “ecstasy” at 1.4 per cent.261 Moreover, 
among those aged 16-24 in this survey, annual mephed-
rone use at 3.3 per cent was the same as that of “ecstasy” 
and thereby ranked as the third most prevalent drug for 
258 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2012; European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), 2010-2012 National 
Reports to the EMCDDA by the Reitox National Focal Points of 
Austria, Bulgaria, Croatia, Cyprus, Finland, Hungary, Ireland, Latvia, 
Lithuania, Malta, Netherlands, Poland, Romania, Slovakia, Sweden 
and United Kingdom.
259 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales, 2nd ed., 
London, July 2012.
260 “Mixmag’s Drug Survey: the results”, March 2012. Available from 
www.mixmag.net/drugssurvey. The results of this (non-random) Inter-
net survey were based on information from some 7,700 respondents 
from the United Kingdom with a mean age of 28 (see: Patrick Butler, 
“How the Guardian/Mixmag survey was constructed”, The Guardian, 
15 March 2012).
261 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales, 2nd ed., 
London, July 2012.
this age-group.262 Mephedrone use appears to be particu-
larly common in London dance clubs. In the CSEW 
2011/12 survey, the highest mephedrone use rate at 9.7 
per cent was found among adults who had visited a night-
club on four or more occasions in the last month.263 More-
over, a survey conducted at two dance clubs in London 
displayed 52 per cent annual use of mephedrone, the 
second highest after cocaine at 59 per cent and surpassing 
cannabis at 48 per cent.264 
262 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales, 2nd ed., 
London, July 2012.
263 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales, 2nd ed., 
London, July 2012.
264 Measham, Fiona, et. al. “The rise in legal highs: prevalence and pat-
terns in the use of illegal drugs and first- and second-generation “legal 
highs” in South London gay dance clubs” Journal of Substance Use 2011 
(16) (4): 263-272.
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5. MIDDLE EAST
Regional Overview
For a number of years, there has been a large and growing 
amphetamine market in the Middle East, driven particu-
larly by the Gulf countries. Seizure data indicate an expand-
ing ATS market in Iraq, Saudi Arabia and the Syrian Arab 
Republic. Reports of ATS manufacture in the Middle East 
suggest that ATS is being supplied by countries in the 
region. However, it remains difficult to assess the full extent 
of the demand for ATS in the region, due to a severe lack 
of data. Though “ecstasy” makes up a small fraction of the 
regional ATS market, use and seizure data in some coun-
tries suggest that there is a growing demand for these drugs 
as well.
A diversified ATS market?
The ATS market in the Middle East has long been domi-
nated by amphetamine, where it is primarily sold under 
the brand name “captagon”265. Since 2007, ATS seizures 
of substances other than amphetamine hardly appear at all 
in seizure data for the region and together make up less 
than 1 per cent of total annual ATS seizures. Amphetamine 
seizures in the region have increased considerably since 
2002 and have remained at high levels since 2006, reach-
ing around 20 tons in 2011, in spite of a drop to about 
13.6 tons in 2010.
As there is only limited data available on ATS use in the 
Middle East, it remains difficult to assess the nature of the 
amphetamine market. UNODC estimates of ATS use 
(excluding “ecstasy”) for the general population aged 15 
to 64 are available for Kuwait at 0.27 per cent in 2005 and 
Saudi Arabia at 0.40 per cent in 2006.266 These figures 
appear to be rather low, given that since 2008 ampheta-
mine seizures in the region annually make up the largest 
share of amphetamine seized worldwide of more than 55 
per cent. Therefore, it is likely that prevalence estimations 
currently available for some countries in the region do not 
reflect the extent of amphetamine use. In Saudi Arabia in 
2012, ATS users accounted for the largest share of people 
treated for drug use at drug treatment centres at 51 per 
cent (3,027 people).267 A recent study analysing patient 
265 Captagon was originally the trade name for a pharmaceutical prepara-
tion containing fenetylline, a synthetic stimulant. In the last few years, 
most tablets seized as Captagon essentially contained amphetamine, 
typically in combination with caffeine and sometimes with a few other 
adulterants; United Nations Office on Drugs and Crime (UNODC), 
World Drug Report, New York, 2010.
266 United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2013, New York, May 2013.
267 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Saudi Arabia 2012.
records between 2002 and 2011 in the United Arab Emir-
ates also suggests that amphetamine use has been growing 
in recent years. According to the study, since 2008, an 
increasing number of patients treated for drug use at the 
National Rehabilitation Center (NRC) reported ampheta-
mines as the main substance of abuse.268
On the whole, “ecstasy” seizures remain low. The majority 
of “ecstasy” seizures in the region have been reported in 
Israel, followed by Lebanon and Saudi Arabia. In Israel, 
“ecstasy” seizures accounted for more than 80 per cent of 
all ATS seizures since 2005, which shows that ampheta-
mine plays a far less significant role in the ATS market in 
Israel than in other countries in the region.269 While 
amphetamine use according to expert perception, has 
remained stable in Israel in 2012, there is a perceived 
increase in “ecstasy” use.270 According to the National Epi-
268 Elkashef, Ahmed. “A profile of patients with substance use disorders 
and treatment outcomes: A 10-year retrospective study from the 
National Rehabilitation Center”, International Journal of Prevention 
and Treatment of Substance Use Disorders vol. 1, no. 1 (2013): 62-75.
269 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Israel 2005-2012.
270 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Israel 2012.
Fig. 23: Total ATS seizures reported in the  
Middle East, 2000-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2000-2011.
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demiological Survey conducted among people aged 18 to 
40 in 2009, lifetime “ecstasy” prevalence in Israel ranked 
as the fifth most used drug at 4.48 per cent, higher than 
amphetamine use at 3.12 per cent.271 In the 2010 Health 
Behaviour in School-aged Children (HBSC) survey, annual 
“ecstasy” use in Israel ranked higher among school children 
aged 15 to 16 and ranked third at 4.5 per cent after can-
nabis and “solvents and inhalants”.272 This confirms find-
ings from other countries and regions that ecstasy use is 
especially high among the younger population.
Treatment data suggests that problematic “ecstasy” use 
exists in Lebanon.273 In a survey at non-governmental 
organisations and hospitals in Lebanon in 2012, patients 
receiving drug treatment for the first time, reported ATS 
as the fourth most commonly used substance, after opioids, 
cocaine and cannabis. While 60 per cent of the people 
treated for ATS use in the country in 2012 reported 
amphetamine use (people), the remaining 40 per cent 
reported “ecstasy” use.274 So far, “ecstasy” use in other parts 
of the region cannot be addressed, as “ecstasy” prevalence 
rates for a number of countries in the Middle East remain 
unavailable.
271 Bar-Hamburger, R., Ezrahi Y., Rosiner, I., and Nirel, R., “Illegal use of 
drugs and alcohol in Israel 2009”, Seventh National epidemiological 
Survey, Israeli Anti-Drug Authority (IADA), Jerusalem, Israel, 2009.
272 Health Behaviour in School-aged Children (HBSC), “World Health 
Organisation (WHO) Collaborative Cross-National Survey”, 2010.
273 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Lebanon 2005-2012.
274 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Lebanon 2012.
Is amphetamine being sourced within  
the region?
In previous years, large amounts of captagon were being 
illicitly manufactured in South-East Europe and trafficked 
to the Middle East.275 With the exception of Turkey, Euro-
pean countries have not been identified as a source of 
amphetamine seized by countries in the Middle East since 
2007. Turkey continues to be cited as a perceived country 
of origin by Jordan, the Syrian Arab Republic and the 
United Arab Emirates.276
While there has been a possible decrease in amphetamine 
trafficking from Europe via Turkey to the Middle East in 
recent years, seizure reports indicate that the amphetamine 
market in Middle Eastern countries is on the rise. Amphet-
amine seizures in the region have more than doubled from 
about 10 tons in 2005 to around 20 tons in 2011, the 
majority of which was reported in Saudi Arabia, followed 
by Jordan and the Syrian Arab Republic. In contrast, 
amphetamine seizures in East and South-East Europe, 
excluding Turkey, have been on the decline, falling by 
almost 80 per cent from about 1.1 tons in 2005 to just 
under 0.3 tons in 2011.
The steady rise in amphetamine seizures in the Middle 
East, is primarily attributable to the rapid increase of 
amphetamine seizures reported in Saudi Arabia, where they 
275 United Nations Office on Drugs and Crime (UNODC), World Drug 
Report 2009, New York, 2009, pp. 124.
276 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Jordan, the Syrian Arab Republic and the 
United Arab Emirates 2008-2012.
Fig. 24: “Ecstasy” seizures reported in the  
Middle East, by country, 2005-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2011.
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Fig. 25: Amphetamine seizures reported in  
the Middle East and South-East Europe 
(exclu ding Turkey), 2005-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2011.
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Middle East
increased from about 80 kg in 2002 to their highest point 
of more than 12 tons in 2009. Between 2001 and 2011, 
the Syrian Arab Republic and Jordan each accounted for 
a 13-16 per cent share of amphetamine seizures in the 
Middle East, whilst Saudi Arabia accounted for about a 
65 per cent share.
So far, ATS manufacture in the region has been officially 
reported by Lebanon, with 3 captagon laboratories and 3 
amphetamine laboratories dismantled in the country since 
2007.277 Over the years, the domestic market in Lebanon 
was perceived to have been supplied by amphetamine that 
had originated from within the country as well as from 
other countries.278 There have also been amphetamine 
seizure reports in Lebanon that were perceived to have been 
destined for onward trafficking to other countries in the 
region, such as Kuwait and Saudi Arabia.279 Some coun-
tries in the Middle East, such as the Syrian Arab Republic 
in 2008 and Jordan in 2011, have also reported of amphet-
amine seizures that were perceived to have originated in 
Lebanon.280
277 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Lebanon 2007-2011; United Nations 
Office on Drugs and Crime (UNODC), Global SMART Update 
Volume 6, Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, Vienna, October 2011.
278 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Lebanon 2008-2012.
279 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Lebanon 2008-2012.
280 United Nations Office on Drugs and Crime (UNODC), Annual 
Although other countries in the region did not report the 
discovery of clandestine amphetamine laboratories, risk 
factors for amphetamine manufacture such as the availabil-
ity of precursor substances are still present. Until 2012, 
when Jordan entirely prohibited imports of P-2-P, the 
country had reported the highest legitimate requirement 
for P-2-P worldwide and accounted for more than half of 
the global total.281 P-2-P, a precursor for amphetamine 
and methamphetamine, was allegedly being used for the 
manufacture of cleaning products.282 In recent years, 
amphetamine seized in Israel was perceived to have been 
trafficked from Jordan.283
Other countries, such as the Syrian Arab Republic, might 
also be at risk of being used for illicit ATS manufacture. 
First reports emerged in 2009 when the United Arab Emir-
ates reported a seizure of around 150 kg of captagon that 
were perceived to have originated from the Syrian Arab 
Republic.284 Moreover, the Syrian Arab Republic has com-
paratively high annual legitimate requirements for pseu-
doephedrine (an ATS precursor chemical) of 50 tons, 
which could lead to the diversion of the chemical for use 
in illicit ATS manufacture.285 Moreover, Jordan reported 
that amphetamine seized in 2011 and 2012 was perceived 
to have originated in the Syrian Arab Republic.286 Prior 
to that, Yemen had also reported that amphetamine seized 
in 2008 was perceived to have originated in the Syrian 
Arab Republic.287 According to expert perception, amphet-
amine originating in the Syrian Arab Republic is trafficked 
to Saudi Arabia and Israel via Jordan.288
Significant amphetamine seizures in Iraq might also sug-
gest a growing amphetamine market. In 2010, Iraq 
reported to have seized about 1.6 tons of amphetamine, 
which was significantly higher than the 0.9 tons reported 
in Jordan that year, although still less than the 2.1 tons 
seized in the Syrian Arab Republic and the 8.8 tons 
Report Questionnaire from the Syrian Arab Republic and Jordan 
2008-2011.
281 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
282 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2011.
283 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Israel 2008-2011.
284 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the United Arab Emirates 2009.
285 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
286 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Jordan 2011-12.
287 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Yemen 2008.
288 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Jordan 2012.
Fig. 26: Distribution of amphetamine seizures  
reported in the Middle East, by country, 
2001-2011
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2001-2011.
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reported in Saudi Arabia.289 Furthermore, in 2011, the 
Syrian Arab Republic identified Iraq as a perceived country 
of origin for seized amphetamine.290
NPS are a growing problem
A number of countries in the Middle East reported the 
emergence of NPS to UNODC, including Bahrain, Israel, 
Jordan, Lebanon, Oman, Qatar, Saudi Arabia, the Syrian 
Arab Republic, the United Arab Emirates and Yemen.291 
Though there is limited data available on NPS in the 
Middle East, there may be some substances that are becom-
ing of increasing concern.
Khat, a plant-based NPS, has had a long traditional use in 
Yemen where it is not under national control and is being 
cultivated. A general population survey among people aged 
16 and above in Yemen in 2006 displayed a lifetime preva-
lence of khat use at 52 per cent, which, with the exception 
of alcohol, tobacco and caffeine, is the highest lifetime 
prevalence rate recorded for any psychoactive substance in 
any country in the world.292 According to these survey 
results, men portrayed an especially high level of lifetime 
khat use prevalence at 72 per cent, of which 42 per cent 
reported daily use of the substance, 12 per cent reported 
use at 3-4 days per week and the remainder at 1-2 days per 
week.293 
In the Jazan region of Saudi Arabia, where khat is under 
national control, the use of this substance appears to be 
wide-spread among youths. This is reflected in the results 
of a study among college and secondary school students 
in the Jazan region aged 15 to 25 in 2009, which showed 
a high lifetime prevalence of use at 21.4 per cent, the 
majority of which at around 91 per cent were male.294 
Another survey among undergraduate students at higher 
education institutions of Jazan conducted between 2011 
289 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010.
290 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Syrian Arab Republic 2011.
291 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013; 
United Nations Office on Drugs and Crime (UNODC), “UNODC 
Early Warning Advisory on New Psychoactive Substances (NPS) 
October 2013 update”, October 2013; Submissions to UNODC and 
laboratories participating in the International Collaborative Exercise 
(ICE) programme.
292 World Bank, “Yemen toward qat demand reduction”, Report no. 
39738-YE, June 2007; United Nations Office on Drugs and Crime 
(UNODC), World Drug Report, 2012.
293 Though not to the same extent as men, women also reported repeated 
khat use. According to the survey results, around 13 per cent of women 
reported khat use on most days of the week, 7 per cent reported khat 
use at 3-4 times per week and 4 per cent at 1-2 days per week; World 
Bank, “Yemen toward qat demand reduction”, Report no. 39738-YE, 
June 2007.
294 Ageely, Hussein M., “Prevalence of Khat chewing in college and sec-
ondary (high) school students of Jazan region, Saudi Arabia” Harm 
Reduction Journal June 2009 (6): 11.
and 2012, showed a lifetime prevalence of khat use at 24.8 
per cent, which was higher among males at 40.5 per cent 
than for females at 3.7 per cent.295 Seizure data for Saudi 
Arabia also suggest the presence of a large market for khat. 
Over the last few years, Saudi Arabia reported by far the 
largest amount of khat seizures in the region. Particularly 
large seizures were reported between 2008 and 2010, total-
ling about 540 tons of khat in 2008, just over 180 tons in 
2009 and around 375 tons in 2010.296
Other NPS have also been reported in the region. With 
regards to ketamine for instance, though it is more widely 
used in East and South-East Asia, ketamine use has also 
emerged in countries in the Middle East. In 2010, Saudi 
Arabia identified the drug as the seventh most widely used 
substance, while Israel, where it has been placed under 
national control, reported that ketamine was the ninth 
most widely used substance in the country in 2011.297 
Still, according to the National Epidemiological Survey of 
people aged 18 to 40 in Israel, annual ketamine use remains 
rather low at 0.12 per cent, just below opium at 0.13 per 
cent.298 In recent years, significant seizures of synthetic 
cannabinoids have also been reported by some countries 
in the Middle East pointing to the emergence of a market 
in the region. Prior to 2012, Saudi Arabia was the only 
country in the Middle East to report seizures of synthetic 
cannabinoids totalling more than 1 kg.299 However, 
according to the Dubai authorities, within the first 8 
months of 2012, Dubai Customs in the United Arab Emir-
ates prevented 126 attempts to smuggle synthetic canna-
binoids which were intended for local use and for onward 
trafficking.300 
Non-medical use of prescription drugs
The synthetic opioid analgesic, tramadol, has appeared on 
illicit drug markets and there are indications of misuse. 
Misuse of tramadol has been reported by some countries 
in the Middle East, such as Jordan, Lebanon and Saudi 
Arabia and it is under national control in both Jordan and 
295 Alsanosy, Rashad Mohammed, et. al. “Khat Chewing among Stu-
dents of Higher Education in Jazan Region, Saudi Arabia: Prevalence, 
Pattern, and Related Factors” BioMed Research International 2013, 
accessed on 4 December 2013 at http://www.hindawi.com/journals/
bmri/2013/487232/abs/.
296 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire from Saudi Arabia 2008-2010.
297 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire 2010-2011.
298 Bar-Hamburger, R., Ezrahi Y., Rosiner, I., and Nirel, R., “Illegal use of 
drugs and alcohol in Israel 2009”, Seventh National epidemiological 
Survey, Israeli Anti-Drug Authority (IADA), Jerusalem, Israel, 2009.
299 United Nations Office on Drugs and Crime (UNODC), The challenge 
of new psychoactive substances. Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
300 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 9, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
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Saudi Arabia.301 According to the INCB, increasing 
amounts of seizures of preparations containing tramadol 
are also reported by Saudi Arabia.302 In Iraq, abuse of 
pharmaceuticals has been highlighted as a significant prob-
lem and tramadol is one of the substances for which large 
and increasing use is being reported.303
301 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
302 International Narcotics Control Board (INCB), Report of the Interna-
tional Narcotics Control Board for 2012, Vienna, January 2013.
303 US Department of State, International Narcotics Control Strategy Report 
(INCSR), Bureau of International Narcotics and Law Enforcement 
Affairs, March 2013.  
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6. NORTH AMERICA
Regional Overview
For some years, North America has had a large and grow-
ing ATS market. Particularly methamphetamine manufac-
ture in Mexico and the United States appears to have risen 
significantly and according to the United States, increasing 
amounts are being smuggled to the country from Mexico. 
Nevertheless, methamphetamine use has so far remained 
at relatively low and stable levels across the region. High 
levels of “ecstasy” use have been reported in Canada, 
though seizures of the substance and MDMA manufacture 
have dropped. Therefore, widespread “ecstasy” use in the 
country may instead point to an increased use of various 
NPS which are often found in seized tablets sold as 
“ecstasy”. NPS are generally widely used in the United 
States and Canada and there have been a rising number of 
reports of synthetic cannabinoids in these countries.
Is there a growing market for  
methamphetamine?
Over the years, ATS seizures in the region have been con-
tinuously increasing from about 12 tons in 2007 to almost 
60 tons in 2012. The majority of ATS seizures have con-
sisted of methamphetamine, making up more than 90 per 
cent of seizures annually since 2010. Amphetamine seizures 
have also increased from about 0.1 ton in 2007 to over 2 
tons in 2012. In contrast, “ecstasy” seizures have been 
steadily decreasing and have fallen by more than 85 per 
cent from about 3 tons in 2007 to around 0.5 tons in 2012.
The rapid rise of methamphetamine seizures in the region 
is predominantly driven by the surge of seizures reported 
in Mexico and the United States. Though methampheta-
mine seizures in the United States exceeded those of 
Mexico between 2007 and 2010, larger amounts have 
recently been reported in Mexico in 2011 and 2012, and 
have made up between 57 to 63 per cent of the total meth-
amphetamine seized. In Canada, methamphetamine 
seizures have decreased by about 87 per cent from 1.5 tons 
in 2007 to about 0.2 tons in 2012. The majority of meth-
amphetamine seized in Canada is perceived to be intended 
for the domestic market.304
In Canada, the market for methamphetamine appears to 
be limited. The results of the annual population survey 
among people aged 15 and above in 2012, identified meth-
amphetamine in Canada as the second least used drug in 
terms of lifetime prevalence, which stood at 0.8 per cent 
followed by heroin at 0.5 per cent.305
Methamphetamine use in the United States, in terms of 
annual use displays a stable trend. The annually conducted 
304 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2010-2012.
305 The results of the 2012 survey ranked the lifetime prevalence of canna-
bis as the most commonly used drug at 46.7 per cent, followed by hal-
lucinogens at 14.8 per cent, cocaine at 8.7 per cent; “2012 Canadian 
Alcohol and Drug Use Monitoring Survey (CADUMS)”, Controlled 
Substances and Tobacco Directorate, Health Canada.
Fig. 27: Total ATS seizures reported in North  
America, 2007-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2007-2012.
Fig. 28: Methamphetamine seizures reported in 
North America, by country, 2007-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2007-2012.
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in the United States in 2012, which predominantly con-
sisted of small-scale and “kitchen” laboratories.310 The 
number of laboratories dismantled in Mexico are at a much 
lower level, but there has been a rapid increase from just 
over 20 methamphetamine laboratories in 2007 to about 
260 in 2012.311 However, the size of methamphetamine 
laboratories dismantled in Mexico is unknown. Therefore, 
the sheer number of discovered methamphetamine labo-
ratories is not an indication of the quantity produced in 
the region. The number of dismantled methamphetamine 
laboratories in Canada remain at low levels and between 
2007 and 2012 made up less than 1 per cent of the total 
number of laboratories discovered in North America.312
Methamphetamine has been trafficked from Mexico to the 
United States for a number of years. Between 2010 and 
2012, methamphetamine seized in Mexico was perceived 
to have been intended for the domestic market as well as 
for onward trafficking to the United States, and to a lesser 
extent, Canada and countries in Central America, such as 
El Salvador.313 The United States Drug Enforcement 
Administration (DEA) has reported that the increased 
manufacture of methamphetamine in Mexico has height-
ened the supply of methamphetamine to the United States 
in recent years. Seizures of methamphetamine that had 
been trafficked from Mexico across the south-west border 
of the United States have annually increased, from about 
310 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the United States 2012.
311 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Mexico 2007-2012.
312 However, at the time of this report data on the number of laboratories 
dismantled in Canada was only available for 2010 and 2011; United 
Nations Office on Drugs and Crime (UNODC), Annual Report 
Questionnaire for Canada 2007-2012.
313 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Mexico 2010-2012.
National Survey on Drug Use and Health (NSDUH) 
among people aged 12 and above, showed that the annual 
prevalence of methamphetamine use decreased from 0.5 
per cent in 2009 to 0.4 per cent in 2010, which is the rate 
at which it has remained over the last few years.306 In 2012, 
annual prevalence of methamphetamine use stood at the 
same level as LSD, and only higher than that of sedatives 
at 0.2 per cent use.307
In spite of the rapid increase of methamphetamine seizures 
in Mexico, domestic use of the substance appears to be 
rather low. Recent data for methamphetamine use are not 
available. However, according to government data, annual 
ATS use (excluding ecstasy) among people aged 12 to 65 
in Mexico, stood at 0.12 per cent in 2011, below that of 
cannabis at 1.20 per cent, cocaine at 0.50 per cent and 
opioids at 0.38 per cent.308 A national survey among 
people receiving drug treatment, conducted by the Mexi-
can Information System of the State Council on Addictions 
(SICECA), also revealed that about 9 per cent of people 
were treated for methamphetamine use at drug treatment 
centres in 2011, which is considerably lower than the share 
of people treated for cannabis use that year at 56.7 per cent 
and cocaine use at 29.1 per cent.309 Prevalence and treat-
ment admission data point to a comparatively small market 
for methamphetamine in Mexico. Therefore, the high level 
of seizures may rather suggests that the drug is not intended 
for domestic use but mostly for trafficking to other coun-
tries. On the whole, prevalence data for countries in North 
America do not indicate a growing methamphetamine 
market. This is not consistent with the rapid increase of 
methamphetamine seizures and dismantled laboratories 
reported in the region.
Increased methamphetamine trafficking 
from Mexico
The recent rise in the number of methamphetamine labo-
ratories dismantled in Mexico and the United States sug-
gests a possible increase of methamphetamine manufacture 
in both countries. Over the years, the United States has by 
far reported the largest number of methamphetamine labo-
ratories in the region with an almost 400 per cent surge in 
laboratories reported between 2010 and 2012. Up to 
13,000 methamphetamine laboratories were dismantled 
306 “2009 National Survey on Drug Use and Health (NSDUH)”, Sub-
stance Abuse and Mental Health Services Administration (SAMHSA); 
“2010 National Survey on Drug Use and Health (NSDUH)”, Sub-
stance Abuse and Mental Health Services Administration (SAMHSA); 
“2011 National Survey on Drug Use and Health (NSDUH)”, Sub-
stance Abuse and Mental Health Services Administration (SAMHSA); 
“2012 National Survey on Drug Use and Health (NSDUH)”, Sub-
stance Abuse and Mental Health Services Administration (SAMHSA).
307 “2012 National Survey on Drug Use and Health (NSDUH)”, Sub-
stance Abuse and Mental Health Services Administration (SAMHSA).
308 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Mexico 2012.
309 Government source, Mexico, 2011.
Fig. 29: Dismantled methamphetamine laboratories 
reported in the United States, 2007-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire for the United States 2007-2012.
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Methamphetamine flows
2.3 tons in 2008 to more than 10.6 tons in 2012.314 
According to the DEA, the drop in methamphetamine 
prices by more than 70 per cent and rise in methamphet-
amine purity by almost 130 per cent between the third 
quarter of 2007 and the second quarter of 2012 together 
with increased methamphetamine trafficked from Mexico 
to the United States, points to a rising domestic availability 
of the drug.315
According to the Mexican authorities methamphetamine 
is trafficked through Mexico to the United States along 
land routes and by plane.316 Some of the routes have been 
reported to lead from Guadalajara in the state of Jalisco, 
at the western-central part of Mexico, to Tijuana in Baja 
California, the most north-western state of Mexico, from 
314 US Department of Justice, Drug Enforcement Administration (DEA), 
National Drug Threat Assessment Summary 2013, November 2013.
315 US Department of Justice, Drug Enforcement Administration (DEA), 
National Drug Threat Assessment Summary 2013, November 2013.
316 Drug Abuse Information Network for Latin America and the Carib-
bean (DAINLAC) questionnaire response for Mexico 2013. 
where these are then smuggled across the border to the 
United States. Jalisco is one of the main states in Mexico 
in which methamphetamine laboratories have been dis-
covered, in addition to Michoacan and Sinaloa state.317 
“Ecstasy” and amphetamine are also reported to have been 
trafficked across Mexico along these routes.318
In the United States, increasing amounts of methamphet-
amine are reportedly being trafficked to San Ysidro, in San 
Diego, in the south-west of California in the United States, 
which is across the border of Tijuana in Mexico. Between 
2010 and 2012, methamphetamine seizures reported at 
San Ysidro in the United States more than doubled from 
almost 1.0 ton to around 2.4 tons, making up 40 per cent 
of methamphetamine seized along the south-western 
border of the United States over that period.319 In addi-
317 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Mexico 2012.
318 Drug Abuse Information Network for Latin America and the Carib-
bean (DAINLAC) questionnaire response for Mexico 2013.
319 United Nations Office on Drugs and Crime (UNODC), Global 
Map 15: Methamphetamine flows as perceived by recipient countries, 2010-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2010-2012.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived 
by recipient countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
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tion, about 1.7 tons of methamphetamine had been seized 
at San Diego between October 2012 and March 2013, 
accounting for about 58 per cent of the total amount of 
methamphetamine seized at border crossings along the 
border between the United States and Mexico over the 
same period.320
High levels of “ecstasy” use among youths
Relatively low levels of “ecstasy” use have been reported in 
the United States. For instance, the National Survey on 
Drug Use and Health (NSDUH) ranked annual “ecstasy” 
use in the United States among people aged 15 to 64 at 
1.2 per cent in 2011 below that of cannabis at 14.0 per 
cent, prescription pain relievers at 5.2 per cent, tranquil-
izers and sedatives at 2.6 per cent and both hallucinogens 
and cocaine at 1.9 per cent.321
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013.
320 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013.
321 United Nations Office on Drugs and Crime (UNODC), Annual 
However, particularly high levels of “ecstasy” use have been 
reported among school children in Canada. The national 
Youth Smoking Survey (YSS) among tenth-grade students 
in 2010-2011, ranked the lifetime prevalence of “ecstasy” 
in third place at 8.2 per cent, after cannabis at 30.0 per 
cent and hallucinogens at 10.3 per cent per cent, as well 
as in terms of annual prevalence at 5.8 per cent, after can-
nabis at 25.8 per cent and hallucinogens at 7.4 per cent.322
A general population survey among people aged 15 and 
above in Canada, also showed that “ecstasy” was the most 
used ATS in 2012 in terms of lifetime use at 5.3 per cent, 
followed by amphetamine at 4.6 per cent and metham-
phetamine at 0.8 per cent, though this still remains sig-
nificantly lower than cannabis at 46.7 per cent, 
hallucinogens at 14.8 per cent and cocaine at 8.7 per 
cent.323
Report Questionnaire for the United States 2011.
322 “Youth Smoking Survey (YSS) 2010-2011”, Controlled Substances 
and Tobacco Directorate, Health Canada.
323 “2012 Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS)”, Controlled Substances and Tobacco Directorate, Health 
Canada.
Map 16: Reported methamphetamine flows by mode of transportation in Mexico, 2013
Source: Drug Abuse Information Network for Latin America and the Caribbean (DAINLAC) questionnaire response for Mexico 2013.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. The boundaries shown on this map do not imply 
official endorsement or acceptance by the United Nations.
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Nevertheless, “ecstasy” seizures have been decreasing or 
remained at low levels across the region. Between 2007 
and 2012, “ecstasy” seizures in Canada have declined by 
over 93 per cent, from 1.0 ton to about 0.1 tons, while 
seizures in the United States have fallen by almost 85 per 
cent from almost 3 tons to 0.5 tons. In Mexico, “ecstasy” 
seizures have remained below 3 kg over the last few years.
So far, relatively high levels of “ecstasy” use among some 
segments of the population are not reflected in seizure data 
for the region. Moreover, the number of dismantled labo-
ratories manufacturing MDMA in Canada has dropped 
from an annual average of 13 laboratories between 2007 
to 2010 to only 4 laboratories in 2011 and 2012, which 
points to a possible decline in MDMA manufacture.324 
All “ecstasy” tablets seized in Canada are perceived to origi-
nate from domestic manufacture.325 Therefore, a decline 
in MDMA manufacture, suggests that other substances 
are being manufactured to be sold on the market as 
“ecstasy”. According to the Royal Canadian Mounted 
Police (RCMP), a variety of NPS are often sold as “ecstasy” 
tablets in Canada, so that it is possible that the domestic 
market supplied by tablets sold as “ecstasy” is to a certain 
extent driven by NPS.326 In 2012, “ecstasy” seizures in 
Canada have been found to contain NPS such as BZP327, 
TFMPP328, MDPV329, 2C-E330, BTCP331 and alpha-
324 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2012.
325 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2012.
326 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2012.
327 Benzylpiperazine (BZP) is a piperazine not under international con-
trol.
328 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a piperazine not 
under international control commonly found in “ecstasy” tablets.
329 3,4-Methylenedioxypyrovalerone (MDPV) is a synthetic cathinone 
not under international control.
330 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), a substance not under 
international control that is a member of the 2C class of phenethyl-
amines.
331 Benzothiophenylcyclohexylpiperidine (BTCP) is as of yet an unclassi-
fied substance not under international control.
Fig. 30: Lifetime and annual prevalence rates among tenth-grade students aged 15-16 in Canada,  
2010-2011 
Source: “Youth Smoking Survey (YSS) 2010-2011”, Controlled Substances and Tobacco Directorate, Health Canada.
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Fig. 31: “Ecstasy” seizures reported in  
North America, by country, 2007-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2007-2012.
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PVP332, but also 2C-B333 including various ATS and pre-
scription stimulants.334
A large market for NPS
North America, predominantly the United States and 
Canada are among the largest and most diversified markets 
for NPS in the world. There have been a growing number 
of NPS reports from the United States and Canada, which 
have almost quadrupled between 2010 and 2013. Since 
2008, synthetic cannabinoids have made up an increasing 
share of NPS, making up 31 per cent of the total by 2013, 
followed by synthetic cathinones at 24 per cent and 
phenethylamines at about 22 per cent. Other reports of 
NPS, such as aminoindanes, ketamine and phencyclidine-
type substances, piperazines, plant-based substances and 
tryptamines have been increasing steadily over the years, 
and together have made up less than 25 per cent of the 
annual total since 2009. So far, Mexico has only reported 
one phenethylamine in 2012.335
332 Alpha - Pyrrolidinopentiophenone is a synthetic cathinone not under 
international control.
333 2C-B (4-bromo-2,5-dimethoxyphenethylamine), a substance con-
trolled under schedule II of the United Nations convention on 
Psychotropic Substance 1971, is a member of the 2C class of pheneth-
ylamines.
334 Other substances found within “ecstasy” tablets included caffeine, 
methamphetamine, diphenydramine, procaine, benzocaine, lidocaine; 
United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2012.
335 The NPS reported by Mexico for 2012 was 1-(2-fluorophenyl)propan-
2-amine, a phenethylamine under international control.
In the United States, synthetic cannabinoids first emerged 
on the drug market in 2008 and were marketed as a “legal 
alternatives to marijuana”, since the use of synthetic can-
nabinoids produce effects similar to those of cannabis.336 
The number of calls to poison control centers regarding 
“synthetic marijuana” (i.e. synthetic cannabinoids) 
increased in the United States by almost 80 per cent 
between 2010 and 2012.337 A synthetic cannabinoid labo-
ratory has also been discovered in Canada in 2012.338 
Prevalence data indicates high levels of NPS use among 
youths in the United States. The Monitoring the Future 
drug use survey among twelfth-grade students showed that 
in 2012 annual use of synthetic cannabinoids was the 
second highest most used drug at 11.3 per cent after can-
nabis at 36.4 per cent.339 Annual use for other NPS have 
also been reported, such as salvia divinorum at 4.4 per 
cent, ketamine at 1.5 per cent and “bath salts”340 at 1.3 
per cent. According to these results, NPS use has become 
significantly higher than that of many internationally con-
trolled substances.
336 US Department of Justice, Drug Enforcement Administration (DEA), 
National Drug Threat Assessment Summary 2013, November 2013.
337 American Association of Poison Control Centres, “Synthetic mari-
juana data”, updated 28 February 2013.
338 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Canada 2012.
339 United States, National Institute on Drug Abuse, Monitoring the 
Future survey, 2011.
340 Synthetic cathinones are frequently found in products sold as “bath 
salts”, or even “research chemicals”, “plant food” or “glass cleaner” and 
are usually sold in powder, pill or capsule form; United Nations Office 
on Drugs and Crime (UNODC), The challenge of new psychoactive 
substances. Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, Vienna, March 2013.
Fig. 32: Total number of NPS reports to UNODC in the United States and Canada, 2008-2013 
Source: United Nations Office on Drugs and Crime (UNODC), “The challenge of new psychoactive substances”. Global Synthetics Monitor-
ing: Analyses, Reporting and Trends (SMART) Programme, Vienna, March 2013; United Nations Office on Drugs and Crime (UNODC), 
“UNODC Early Warning Advisory on New Psychoactive Substances (NPS) October 2013 update”, October 2013; Submissions to UNODC 
and laboratories participating in the International Collaborative Exercises (ICE) programme.
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NPS mimic the effects of substances under international control
Many NPS available on the market contain chemicals that share similar structural and/or pharmacological properties 
of substances under international control that they are designed to mimic.1 For instance, synthetic cannabinoids, which 
include the JHW series (eg. JHW-018), are mimetics of THC (delta-9-tetrahydrocannabinol), which is the main psy-
choactive substance in cannabis. Synthetic cathinones, which include substances such as mephedrone, methylone and 
MDPV, can evoke stimulant and empathogenic effects similar to amphetamines, including MDMA.2 Phenethylamines 
include substances such as the 2C series (eg. 2C-I) and NBOMe compounds (eg. 25I-NBOMe), which can exhibit 
effects ranging from stimulant to hallucinogenic.3 Only a few substances of this group are already controlled under the 
1971 Convention on Psychotropic Substances such as amphetamine, methamphetamine and MDMA. Tryptamines 
include a number of different substances that are derivatives of the controlled tryptamines and are designed as such to 
produce similar hallucinogenic effects to the substance while bypassing its control status. Ketamine is also closely related 
to the internationally controlled substance, phencyclidine (PCP), listed in Schedule II of the 1971 Convention on 
Psychotropic Substances.4 Overall, structural similarity does not imply similar pharmacological effects, and NPS 
designed to mimic a controlled substance can have higher or lower biological activity, various stimulatory effects and a 
different toxicological profile than the drug it is designed to mimic.
1 So-called mimetics are substances that are chemically different but mimic the pharmacological effects of a particular substance, notably by acting 
on the same receptors of the brain; See United Nations Office on Drugs and Crime (UNODC), World Drug Report 2013, New York, May 2013.
2 For more on the stimulant and empathogenic effects of mephedrone see Brunt, Tibor M. et. al. “Instability of the ecstasy market and a new 
kid on the block: mephedrone” Journal of Psychopharmacology September 2010 (25): 1543-1547; Schifano, Fabrizio, et. al. “Mephedrone 
(4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues”, Journal of Psychopharmacology April 2011 (214): 593-
602. 
3 United Nations Office on Drugs and Crime (UNODC), The challenge of new psychoactive substances, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
4 United Nations Office on Drugs and Crime (UNODC), The challenge of new psychoactive substances, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2013.
Fig. 33: Annual prevalence by drug, among twelfth-grade students in the United States, 2012 
Source: United States, National Institute on Drug Abuse, Monitoring the Future survey, 2012.
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7. SOUTH AMERICA, CENTRAL AMERICA
 AND THE CARIBBEAN
 Regional Overview
Cannabis and cocaine continue to dominate the drug 
market and law enforcement efforts in South America, 
Central America and the Caribbean, so that comparatively 
little data is available with regards to ATS in the region. 
Although ATS use among the general population remains 
at low levels, some countries, including Bolivia, Honduras, 
Costa Rica and Jamaica, have reported high levels of use 
among youths, sometimes even exceeding cannabis and/
or cocaine use.341 Nevertheless, ATS continues to make 
up a small share of the regional drug market. In recent 
years, “ecstasy” has become the main ATS used in some 
South American countries and people treated for “ecstasy” 
use make up a large share of the total number treated for 
ATS use in the region, at about 63 per cent in Argentina 
and 53 per cent in Colombia. There have been several 
reports of ATS manufacture, particularly in Central Ameri-
can countries, and there are indications that these sub-
stances are being trafficked to Western Europe and Eastern 
Asia. NPS are becoming a growing threat in the region, as 
these are sometimes being sold as “ecstasy” tablets or 
“LSD” on the illicit drug market.
An emerging market for “ecstasy”?
ATS seizures in South America, Central America and the 
Caribbean have somewhat fluctuated over the years, annu-
ally ranging between about 90 kg and 240 kg in the past 
5 years. On the whole, ATS seizures in the region have 
predominantly consisted of amphetamine and “ecstasy”. 
“Ecstasy” seizures have been steadily increasing in the 
region and more than tripled between 2008 and 2012. 
Amphetamine seizures have made up less than a quarter 
of ATS seizures over the years, except in 2009 when sei-
zures surged to more than 160 kg. Methamphetamine sei-
zures have remained low, declining from about 30 kg in 
2008 to just 17 kg in 2012.
The steady increase in seizures points to a possible emer-
gence of an “ecstasy” market in the region. On the whole, 
the majority of “ecstasy” seizures in the region have been 
reported in Brazil accounting for about 47 per cent of the 
total ATS seized in South America, Central America and 
the Caribbean between 2008 and 2012, followed by Argen-
tina at 22 per cent, Peru at 16 per cent, Colombia at 6 per 
cent and Uruguay at 4 per cent.
341 The analysis presented in this report may differ from the report 
titled "Amphetamine-Type Stimulants in Latin America 2014", which 
focusses on differentiating between ATS and other stimulating sub-
stances, and does not incorporate the Caribbean region.
Fig. 34: Total ATS seizures reported in South Ameri-
ca, Central America and the Caribbean,  
2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2012.
*Available data for Argentina in 2011 were incomplete and therefore not 
comparable to 2012 data.
Fig. 35: “Ecstasy” seizures reported in South Amer-
ica, Central America and the Caribbean, by 
country, 2008-2012 
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2008-2012.
*Available data for Argentina in 2011 were incomplete and therefore not 
comparable to 2012 data.
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cent348 after cannabis at 2.60 per cent and tranquilizers 
and sedatives at 1.15 per cent.349 A drug use survey among 
the general population aged 15 to 64 in Chile in 2010, also 
ranked the annual prevalence of ATS (excluding ecstasy) 
use at 0.27 per cent, below that of cannabis at about 4.88 
per cent, sedatives and tranquilisers at 2.61 per cent, 
cocaine at 1.01 per cent and opioids at 0.29 per cent.350 
Despite the fact that ATS use is lower than for cannabis 
and cocaine among the general population, the high level 
of ATS use among students together with seizure evidence 
suggests that ATS are a growing problem in the region.
In the last few years, ATS use in some countries of the 
region has become particularly wide-spread among stu-
dents. In some cases “stimulants”351 are among the most 
widely used drugs under international control, sometimes 
exceeding cannabis and/or cocaine use. For instance, in 
2008, a drug use survey among students aged 10 to 19 in 
Bolivia in 2008, showed that “stimulants” had the highest 
annual prevalence rate at 4.0 per cent, higher than that of 
cannabis at 3.6 and cocaine at 1.9 per cent.352 In that same 
year, a drug use survey among students aged 13 to 25 in 
Honduras, also identified “stimulants” as the most used 
drug at a lifetime prevalence rate of 4.3 per cent, higher 
than cannabis at 3.4 per cent and cocaine at 2.8 per 
cent.353 Furthermore, in Costa Rica, a drug use survey 
among school students aged 15 to 16 in 2012, found that 
annual ATS use at 1.3 per cent, was higher than that of 
cocaine use at 0.9 per cent, but below that of cannabis at 
9.7 per cent.354 In 2010, a drug use survey among school 
students aged 15 to 16 in Jamaica ranked the lifetime prev-
alence of amphetamine use at 2.5 per cent and metham-
phetamine at 1.4 per cent, higher than that of cocaine use 
at 1.0 per cent, and below that of cannabis use at 14.3 per 
cent.355
Is ATS manufacture emerging in the 
region?
Over the years, a number of ATS laboratories have been 
dismantled in the region, particularly in Central America. 
348 This figure includes the use of prescription stimulants (non prescrip-
tion/non-therapeutic use).
349 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Costa Rica 2012.
350 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Chile 2012.
351 Often drug use surveys in South America, Central America and the 
Caribbean do not differentiate between the use of amphetamines 
(methamphetamine and amphetamine) and non-medical use of pre-
scrption ATS, by using the term "stimulants".
352 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Bolivia 2008.
353 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Honduras 2008.
354 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Costa Rica 2012.
355 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Jamaica 2010.
In 2012, “ecstasy” accounted for the largest share of ATS 
seizures in some countries, accounting for more than 95 
per cent of ATS seizures in Brazil and almost 50 per cent 
of ATS seizures in Argentina.342 Moreover, all ATS seizures 
reported in Peru for a number of years have consisted of 
“ecstasy”.343
Though there are indications that “ecstasy” use is higher 
than that of other ATS in some countries, their market share 
still appears to be relatively low in comparison to other 
drugs under international control. In Brazil, a drug use 
survey among students aged 10 to 19 in 2010 indicated a 
higher lifetime “ecstasy” use rate at 1.3 per cent than for 
methamphetamine at 0.3 per cent, which was also higher 
than the lifetime heroin use rate at 0.3 per cent, but below 
that of cocaine at 2.5 per cent and cannabis at 5.7 per 
cent.344 A general survey of treatment centres in Argentina 
also showed that about 63 per cent (74 people) of the people 
treated for ATS use were treated for “ecstasy” use in 2010, 
whilst the remainder was treated for amphetamine use (43 
people).345 However, the total number of people treated 
for ATS use makes up less than 1 per cent of those treated 
for drug use that year. Similarly, Colombia reported that 
the majority of about 53 per cent of people treated for ATS 
use in 2012 were treated for “ecstasy” use (48 people), fol-
lowed by methamphetamine use at 42 per cent (38 people) 
and amphetamine use at about 5 per cent (5 people).346 
Then again, the number of people treated for ATS use only 
make up 10.3 per cent of the total number of people treated 
for drug use in Colombia that year and the share of people 
treated for cannabis use at 33.0 per cent (292 people) and 
cocaine use at 32.1 per cent (181 people), are considerably 
higher.347 These figures show that whilst problematic 
“ecstasy” use exists in some countries of the region, other 
drugs under international control, such as cannabis and 
cocaine, continue to make up a much larger share of the 
market.
A growing ATS market among youths
ATS use among the general population remains relatively 
low in most countries in the region. For instance, in Costa 
Rica, a general drug use survey among people aged 12 to 
70 in 2010 showed that ATS (excluding ecstasy) were the 
third most used drug in terms of annual use at 1.02 per 
342 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brazil and Argentina 2012.
343 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Peru 2005-2011.
344 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brazil 2010.
345 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Argentina 2010.
346 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
347 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
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Since 2009, a total of 3 amphetamine, 3 methampheta-
mine and 2 non-specified ATS laboratories were detected 
in Guatemala, while another 2 methamphetamine and one 
amphetamine laboratory were dismantled in Nicaragua. 
In South America, Brazil reported the discovery of an 
ecstasy and a methamphetamine laboratory in 2009, after 
which, an ecstasy laboratory was found in Argentina in 
2010. Prior to 2009, ATS manufacture had only been 
reported in Argentina and Brazil with the discovery of two 
ecstasy and one methamphetamine laboratory.
Moreover, according to seizure data, large amounts of pre-
cursor chemicals, such as ephedrine and pseudoephedrine, 
used in the manufacture of ATS are being trafficked in the 
region. Between 2007 and 2012, an estimated total of up 
to 79 tons of ephedrine and pseudoephedrine were seized 
in the region, of which 47 tons consisted of ephedrine and 
the remaining 32 tons of pseudoephedrine. Over the years, 
by far the largest amount of these precursor chemicals was 
estimated to have been seized in El Salvador, followed by 
Guatemala, Argentina, Honduras and Panama. Lower 
levels of ephedrine and pseudoephedrine seizures have also 
been reported over the years by Brazil, Chile, Colombia, 
Costa Rica, Nicaragua, Paraguay and Venezuela.
While there have been reports of ATS precursor chemical 
seizures and numerous dismantled ATS laboratories, par-
ticularly in Central American countries, ATS seizures have 
remained at low levels. For instance, since 2008, ATS sei-
zures reported by Guatemala have totalled less than 1 kg 
and in Nicaragua there have been no reports of ATS sei-
zures for a number of years, except for about 55 kg in 
2009.356 Moreover, methamphetamine seizures in some 
countries in South America have only somewhat increased, 
from just over 1 kg in 2010 to more than 12 kg in 2011 
in Brazil, as well in Argentina from 0.02 kg to about 17 
kg over the same period.357 Low ATS seizure reports in 
the region might be because law enforcement focusses their 
efforts on cannabis and cocaine, which continue to domi-
nate the drug market.
356 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Guatemala and Nicaragua 2008-2012.
357 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brazil and Argentina 2009-2012.
Map 17: Dismantled ATS laboratories reported in South America, Central America and the Caribbean,  
2009-2012 
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2009-2012; United Nations Office on Drugs 
and Crime (UNODC), Global SMART Update Volume 7, Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Pro-
gramme, Vienna, March 2012; United Nations Office on Drugs and Crime (UNODC), Global SMART Update Volume 8, Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, Vienna, September 2012; United Nations Office on Drugs and Crime 
(UNODC), Global SMART Update Volume 9, Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme, Vienna, 
March 2013; United Nations Office on Drugs and Crime (UNODC), Global SMART Update Volume 10, Global Synthetics Monitoring: Anal-
yses, Reporting and Trends (SMART) Programme, Vienna, September 2013.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
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It remains unclear to what extent ATS is being manufac-
tured for domestic use or being trafficked to other regions 
of the world. For some time, there have been indications 
that ATS trafficking routes from South America, Central 
America and the Caribbean have been extended to Western 
Europe and Eastern Asia, though these have mostly 
involved the trafficking of amphetamine. In Western 
Europe, Spain reported the arrest of nationals from various 
South and Central American and Caribbean countries 
relating to amphetamine over the years.358 Moreover, 
between 2007 and 2010 small quantities of less than 1 kg 
and up to 2 kg of amphetamine perceived to have origi-
nated in or trafficked via Brazil and Nicaragua were 
reported to have been seized in Italy and Portugal.359 In 
Eastern Asia, methamphetamine perceived to have origi-
nated in Peru and Brazil have been reported seized in the 
Philippines in 2012, possibly intended for onward traf-
ficking to mainland China and Hong Kong, China.360
Are NPS being sold on the illicit drug 
market?
Between 2008 and 2013, there have a total number of 54 
NPS reports to UNODC from Argentina, Brazil, Chile, 
Colombia and Costa Rica, Ecuador, Panama and Uruguay 
in South and Central America, of which the majority con-
358 Between 2008 and 2011, Spain reported the arrest of a Brazilian, 2 
Colombian and 2 Dominican Republic nationals, including a national 
of Uruguay relating to amphetamine; United Nations Office on Drugs 
and Crime (UNODC), Annual Report Questionnaire for Spain 2008-
2012.
359 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Italy and Portugal 2007-2010.
360 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Philippines 2012.
sist of piperazines, followed by phenethylamines and syn-
thetic cannabinoids.
Though there have been comparatively few reports of keta-
mine in the region, some seizures of substances under inter-
national control were also found to contain ketamine. In 
June 2013, Colombia reported the seizure of 7,000 tablets 
Fig. 36: Total estimated ephedrine and pseudoephedrine seizures by country in South America,  
Central America and the Caribbean, 2007-2012 
Source: International Narcotics Control Board (INCB), Report of the International Narcotics Control Board for 2012, Vienna, January 2013; 
United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire for Guatemala and Nicaragua 2007-2012; Official 
sources approved by governments.
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Fig. 37: Total number of NPS reports to UNODC in 
South America, Central America and the 
Caribbean, by substance group, 2008-2013 
Source: United Nations Office on Drugs and Crime (UNODC), The 
challenge of new psychoactive substances. Global Synthetics Moni-
toring: Analyses, Reporting and Trends (SMART) Programme, 
Vienna, March 2013; United Nations Office on Drugs and Crime 
(UNODC), “UNODC Early Warning Advisory on New Psychoactive 
Substances (NPS) October 2013 update”, October 2013; Submis-
sions to UNODC and laboratories participating in the International 
Collaborative Exercises (ICE) programme.
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sold as 2C-B361, an internationally controlled drug, but 
which, according to the Colombian Drug Observatory was 
found to contain ketamine and small quantities of other 
unidentified substances.362 In 2012, Brazil also reported 
to UNODC to have discovered ketamine within sub-
stances sold as “ecstasy”.363
In some countries, ketamine prevalence rates have been 
reported at higher levels than those of some other sub-
stances under international control. In Argentina, a general 
drug use survey among people aged 12 to 65 in 2010 indi-
cated a higher lifetime prevalence rate for ketamine use at 
0.30 per cent than for opiates at 0.07 and prescription 
stimulants at 0.05 per cent.364 Furthermore, a general drug 
use survey among people aged 15 to 65 in Uruguay in 
2011, showed that lifetime ketamine prevalence at 0.60 
per cent was higher than that of methamphetamine use at 
0.20 per cent, opioids at 0.18 per cent and prescription 
stimulants at 0.03 per cent.365 Later, in 2012, survey 
results also showed that ketamine had a higher lifetime 
prevalence rate among students aged 15 to 16 in Colombia 
at 0.26 per cent than for heroin at 0.25 per cent.366
Nevertheless, ketamine use among youths in South Amer-
ica remains at low levels. In 2011, a drug use survey among 
high school students aged 15 to 16 in Argentina indicated 
ketamine use with the lowest lifetime prevalence at 0.6 per 
cent, together with cannabis (resin).367 Another drug use 
survey among students in Brazil aged 10 to 19 in 2010 
also ranked ketamine as the least used drug in terms of 
lifetime prevalence at 0.2 per cent,368 as was the case in 
Costa Rica, where lifetime ketamine use among students 
aged 15 to 16 was reported at 0.36 per cent in 2012.369
NPS are targeting the established LSD 
market
NBOMe370 compounds are a frequently reported NPS in 
361 2C-B (4-bromo-2,5-dimethoxyphenethylamine), a substance con-
trolled under schedule II of the United Nations convention on 
Psychotropic Substance 1971, is a member of the 2C class of pheneth-
ylamines.
362 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013.
363 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brazil 2012.
364 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Argentina 2010.
365 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Uruguay 2011.
366 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
367 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Argentina 2011.
368 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Brazil, 2010.
369 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Costa Rica 2012.
370 NBOMe compounds are a series of hallucinogenic phenethylamine 
the region. By 2013, Brazil, Chile and Colombia reported 
on the emergence of a number of NBOMe compounds. 
Recently, law enforcement authorities in some countries 
in South America have reported that the substance is being 
sold as “LSD” on the illicit drug market. In June 2013, 
the Drug Observatory of Colombia reported through its 
early warning system (SAT) that substances sold as LSD 
were actually found to contain two NBOMe compounds, 
25B-NBOMe and 25C-NBOMe.371 LSD use in Colombia 
has also risen to particularly high levels. Unlike in previous 
years, where prevalence rates for LSD use in Colombia 
were reported to be below 1 per cent, a drug use survey 
among students aged 15 to 16 in 2012 ranks LSD as the 
second most used drug in terms of annual prevalence at 
3.13 per cent, after marijuana at 15.01 per cent.372 The 
lifetime prevalence rate for LSD use among students aged 
15 to 16 has also risen considerably to 4.9 per cent, below 
that of cannabis at 31.2 per cent, cocaine at 7.0 per cent 
and solvents and inhalants at 8.0 per cent.373 In Ecuador, 
lifetime “LSD” prevalence among students aged 12 to 17 
in 2012 at 1.3 per cent is the same as that of cannabis 
(resin) and higher than that of opium at 0.9 per cent and 
amphetamine at 0.8 per cent.374 Given the reports of NPS 
being sold as “LSD”, more research is needed on the poten-
tial connection between NPS and high levels of “LSD” use 
among certain user groups.
Recently, there have also been reports of “ecstasy” and 
“LSD” shipments trafficked to South America from West-
ern Europe which contained NPS. In May 2013, the Chil-
ean National Police seized 800 stamps believed to contain 
the hallucinogenic substance LSD from a consignment 
that had been trafficked from Spain, but which actually 
consisted of 25I-NBOMe.375 In 2012, “ecstasy” seizures 
in Chile were perceived to have originated from Argentina 
and Spain.376 Moreover, between 2008 and 2012, “ecstasy” 
seizures reported in France, Germany and Portugal were 
perceived to have been destined for Brazil.377
substances, which are not under international control.
371 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
372 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
373 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Colombia 2012.
374 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Ecuador 2012.
375 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013.
376 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Chile 2012.
377 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for France, Germany and Portugal 2012.
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8. WESTERN AND CENTRAL ASIA
Regional Overview
Methamphetamine continues to be the most commonly 
available ATS in Western and Central Asia, though use 
and seizure data for the region still remains scarce. Overall, 
levels of methamphetamine use in the region are low, but 
a surge in methamphetamine seizures in the Islamic Repub-
lic of Iran point to a possible increasing domestic market. 
Over the years, some ATS laboratories have been disman-
tled in Central Asia and there are concerns regarding the 
spread of manufacture to Afghanistan. Methamphetamine 
trafficking from the Islamic Republic of Iran to East and 
South-East Asia also appears to have spread to Europe.
Is the ATS market growing in Western 
Asia?
The ATS market in Western and Central Asia predomi-
nantly consists of methamphetamine. Since 2005, meth-
amphetamine seizures made up about 90 per cent of ATS 
seizures in region, followed by amphetamine at 8 per cent 
and “ecstasy” at less than 1 per cent.
Over the years, ATS seizures in the region have greatly 
increased. In 2011, ATS seizures in Western and Central 
Asia almost totalled 4 tons, having previously reached 1.4 
tons in 2010 and less than 60 kg in 2007.
The rapid rise of ATS seizures in Western and Central Asia 
is primarily attributable to the increase in methampheta-
mine seizures in the Islamic Republic of Iran which 
reported by far the largest ATS seizures in the region. In 
the Islamic Republic of Iran, methamphetamine seizures 
have rapidly increased since 2007 and in 2011 almost tri-
pled reaching up to 4 tons. In spite of a slight drop in 2012, 
methamphetamine seizures in the Islamic Republic of Iran 
remained at high levels totaling around 3.4 tons.
There are no systematic ATS prevalence studies available 
for the Islamic Republic of Iran. However, the rise in meth-
amphetamine seizures and indications of growing domestic 
ATS use suggest that the Islamic Republic of Iran has an 
expanding domestic methamphetamine market.378 
According to expert perception, there was a large increase 
of methamphetamine use in the country in 2012.379 More-
over, there has been some increase in perceived ATS-related 
mortality and a rise in the number of people receiving 
treatment for ATS use in the Islamic Republic of Iran.380
Since only small quantities of ATS have been seized in 
Pakistan over the past years, the full extent of the ATS 
378 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Islamic Republic of Iran for 2012.
379 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Islamic Republic of Iran for 2012.
380 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Islamic Republic of Iran for 2012.
Fig. 38: Distribution of seized ATS reported in West-
ern and Central Asia, by drug type, 2005-
2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2012.
Fig. 39: Total ATS seizures reported in Western and  
Central Asia, 2005-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2005-2012.
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been investigations into the alleged diversion of large 
amounts of ephedrine since March 2012.384
In Kazakhstan, there are some indications of spreading 
ATS use among students. The results of a drug use survey 
among students aged 16 to 24 in 2012 display a lifetime 
prevalence of “ecstasy” use at 2.3 per cent and use of 
amphetamines (excluding “ecstasy”) at 1.0 per cent, both 
of which are higher than that of cocaine use at 0.8 per cent, 
but below cannabis use at 11.2 per cent.385 In addition, 
the survey results that year recorded a lifetime prevalence 
of tranquilisers and sedative use below that of “ecstasy” 
use, at 2.1 per cent.
Has methamphetamine manufacture 
spread across Western and Central Asia?
Illicit ATS manufacture in the region has predominantly 
been reported in the Islamic Republic of Iran, though there 
have been no official reports of methamphetamine labo-
ratories dismantled in the country for some years. The 
discovered manufacture of this substance was last reported 
in the Islamic Republic of Iran in 2009 when 6 metham-
phetamine laboratories were discovered, while another 4 
laboratories were dismantled prior to that in 2008.386 
However, high annual legitimate requirements for precur-
sor chemicals of ATS in the Islamic Republic of Iran might 
heighten the risk of their diversion. For instance, the coun-
try reported a required 55 tons of pseudoephedrine in 2012 
increasing from just 5 tons in 2006.387
Data with regards to methamphetamine in other parts of 
the region remain scarce. Since 2008 there have been indi-
cations that methamphetamine manufacture may have 
spread to other countries in Central Asia. In Kazakhstan, 
a methamphetamine laboratory was dismantled in 2008, 
while prior to that a methcathinone laboratory was dis-
mantled in Kyrgyzstan in 2007. However, no ATS labora-
tories have been discovered in these countries since then 
and over the years there have only been smaller seizures of 
less than 1 kg of amphetamine and methamphetamine in 
Kyrgyzstan. In 2012, a large seizure of almost 0.2 tons of 
non-specified ATS was reported in Kazakhstan.388
Recently, a report of methamphetamine manufacture in 
Afghanistan has been confirmed by forensic experts in 
384 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
385 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Kazakhstan 2012.
386 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for the Islamic Republic of Iran 2008-2009.
387 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
388 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Kazakhstan 2012.
market remains unclear. The first time that a survey in 
Pakistan included an analysis of ATS use revealed that ATS 
are indeed consumed in the country, albeit at much lower 
rates than opiates and cannabis. While the overall esti-
mated annual use of drugs under international control 
among people aged 15 to 64 stood at 6.0 per cent, annual 
methamphetamine use was 0.02 per cent and general 
annual ATS use was 0.08 per cent.381 Annual ATS preva-
lence was highest in the two western provinces bordering 
Afghanistan and the Islamic Republic of Iran. 
Given Pakistan’s high levels of legitimate requirements for 
ephedrine and pseudoephedrine, which have been increas-
ing over the past years, there is a risk that these two sub-
stances are diverted for illicit ATS manufacture in the 
region. The required amount of pseudoephedrine reported 
by the country rose to 48 tons in 2012 from 10 tons in 
2007.382 Moreover, in 2012, Pakistan had the world’s fifth 
highest legitimate requirements for ephedrine at 22 
tons.383 Seizure reports support the assumption that diver-
sion of precursors from licit trade could occur in the 
region. The Iranian Government reported a number of 
incidents to the International Narcotics Control Board 
(INCB) in 2011 involving more than 0.5 tons of ephed-
rine smuggled from Pakistan, while in Pakistan there have 
381 “Drug Use in Pakistan 2013”, collaborative study between the Minis-
try of Narcotics Control (MNC), the Pakistan Bureau of Statistics and 
the United Nations Office on Drugs and Crime (UNODC), Country 
Office Pakistan, 2013.
382 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
383 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
Fig. 40: Methamphetamine seizures reported in  
the Islamic Republic of Iran, 2005-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire for the Islamic Republic of Iran for 
2005-2012.
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Kabul (Afghanistan), with the discovery of a methampheta-
mine laboratory in Nimroz Province in Afghanistan in 
September 2013.389 Prior to this discovery, methampheta-
mine was believed to be trafficked to Afghanistan from 
neighbouring countries. However, in 2010, Pakistan 
reported the seizure of 12 kg of amphetamine that was 
perceived to have originated in Afghanistan.390 Since 2008, 
there have also been increasing reports of small quantity 
methamphetamine seizures in Afghanistan. This is reflected 
by the increasing number of methamphetamine samples 
analysed by the Counter Narcotics Police of Afghanistan 
(CNPA) forensics laboratory, which have tripled from 16 
in 2011 to 48 in 2012.391 According to the Ministry of 
Counter Narcotics Law Enforcement (MCN LE) Coordi-
nation Directorate, a large number of these seizures 
occurred in Western Afghanistan. Between March 2009 
and March 2013, around 92 per cent of methamphetamine 
samples analysed by the CNPA forensics laboratory were 
seized in Western Afghanistan, in Herat, Farah and Nimroz 
Province close to the Iranian border, as well as Faryab, 
389 Counter Narcotics Police of Afghanistan (CNPA), confirmed by the 
UNODC Office in Afghanistan.
390 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Pakistan 2010.
391 Islamic Republic of Afghanistan/Ministry of Counter Narcotics, 
Afghanistan Drug Report 2012, Kabul, Afghanistan, November 2013.
Kandahar, Balkh and Kabul Provinces.392 ATS manufac-
ture would be a worrying development to the Afghan drug 
situation, which continues to be the world’s leading opium 
producer and cultivator. In 2012, about 74 per cent of 
global illicit opium was produced in Afghanistan, while 
the global area under poppy cultivation rose by 15 per cent 
that year driven largely by increases in Afghanistan, includ-
ing Myanmar.393
There have been no further reports of ATS manufacture 
elsewhere in the region, though particularly large seizures 
totalling almost 65 kg of methamphetamine were reported 
in Tajikistan in 2012 and 20 kg of "ecstasy" were reported 
seized in Pakistan in 2007. Other than that, only some 
small quantities of ATS have been reported in Pakistan, 
Kazakhstan, Kyrgyzstan and Tajikistan over the years.
Contribution of Western Asia to the 
global methamphetamine market
It still remains unclear to what extent methamphetamine 
manufactured in the region is trafficked to other parts of 
the world. Between 2010 and 2012, all methamphetamine 
seized in Tajikistan was perceived to have originated from 
the Islamic Republic of Iran and trafficked via Uzbeki-
stan.394 In 2012, Armenia also reported that all metham-
phetamine seized in the country was perceived to have 
originated in the Islamic Republic of Iran.395
According to the Turkish authorities, Turkey serves as a 
transit point for methamphetamine smuggled from the 
Islamic Republic of Iran. Between 2009 and 2012, Turkey 
reported of methamphetamine seizures that were perceived 
to have originated in the Islamic Republic of Iran.396 
Within Turkey, most seizures of this drug of about 53 per 
cent occurred in Istanbul, particularly at Ataturk Airport, 
as well as provinces close to the Iranian border.397 Turkish 
customs officials have noted a particular increase in meth-
amphetamine seized at border crossing points along the 
border to the Islamic Republic of Iran.398 A growing 
number of Iranian nationals were also apprehended in 
392 Islamic Republic of Afghanistan/Ministry of Counter Narcotics, 
Afghanistan Drug Report 2012, Kabul, Afghanistan, November 2013.
393 United Nations Office on Drugs and Crime (UNODC), World Drug 
Report, New York, May 2013.
394 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Tajikistan 2012.
395 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Armenia 2012.
396 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Turkey 2009-2012.
397 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012; “2012 National 
Report (2011 data) to the EMCDDA by the Reitox National Focal 
Point” European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Turkey, 2012.
398 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
Map 18: Dismantled laboratories and significant 
methamphetamine seizures reported in 
Western and Central Asia, 2007-2012
Source: United Nations Office on Drugs and Crime (UNODC), 
Annual Report Questionnaire 2007-2012.
Note: The boundaries shown on this map do not imply official endorsement 
or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in 
Jammu and Kashmir agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the parties.
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Turkey in connection with methamphetamine 
trafficking.399  
From Turkey, methamphetamine is predominantly traf-
ficked onwards to East and South-East Asia as well as to 
countries in the Middle East, such as the Syrian Arab 
Republic by plane and via on-land routes.400 Between 
2009 and 2012, Turkey only reported of methampheta-
mine seizures that were perceived to have been destined 
for Indonesia, Japan, Malaysia, New Zealand and Thai-
land.401 The Turkish police reported in 2011, that 80 per 
cent of the air couriers trafficking methamphetamine from 
Turkey to Malaysia, Thailand, Japan, Indonesia and Aus-
tralia were Iranian nationals, whilst nationals of other 
countries included Nigeria, Germany, Belgium, Georgia, 
France, Italy, Romania, the United Kingdom, Japan, 
399 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
400 “2012 National Report (2011 data) to the EMCDDA by the Reitox 
National Focal Point” European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), Turkey, 2012.
401 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Turkey 2009-2012.
Turkey and Uzbekistan.402 Between 2010 and 2012, meth-
amphetamine seizures perceived to have originated in the 
Islamic Republic of Iran were reported by Thailand, Malay-
sia and Indonesia.403 According to the Malaysian Federal 
Narcotics Investigation Department, Iranian drug traffick-
ing networks have embarked on large-scale operations to 
meet the high demand for methamphetamine in the 
region.404
However, recently there has been an emergence of meth-
amphetamine trafficking from Western Asia to Europe, via 
Turkey. According to the Turkish National Police, there 
have been attempts to smuggle small quantities of meth-
amphetamine to Europe along road and railway routes.405 
402 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
403 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Thailand, Malaysia and Indonesia  2010-
2012.
404 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 7, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, March 2012.
405 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
Map 19: Methamphetamine flows as perceived by recipient country, 2008-2012
Source: United Nations Office on Drugs and Crime (UNODC), Annual Report Questionnaire 2008-2012; “Turkish Report of Anti-Smuggling 
and Organised Crime 2011”, Turkish National Police, Ankara, March 2012.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived 
by recipient countries. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent 
undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status 
of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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All methamphetamine seized in Bulgaria in 2011 was per-
ceived to have originated in the Islamic Republic of Iran.406 
Between 2010 and 2011, the Russian Federation and Ger-
many also reported seizures of methamphetamine that were 
perceived to have originated from the Islamic Republic of 
Iran.407
Increasing amounts of methamphetamine also appear to 
be trafficked to Turkey to supply the domestic market. 
Methamphetamine seizures in Turkey have been steadily 
rising annually from about 0.1 tons on 2009 to just over 
0.5 tons in 2012.408 Particularly in 2011, a considerable 
share of methamphetamine seized by the Turkish National 
Police had been apprehended in street operations, which 
indicates that this drug is also being trafficked into the 
country for domestic use.409
406 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Bulgaria 2011.
407 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Germany and the Russian Federation 2010-
2011.
408 United Nations Office on Drugs and Crime (UNODC), Annual 
Report Questionnaire for Turkey for 2009-2012.
409 “Turkish Report of Anti-Smuggling and Organised Crime 2011”, 
Turkish National Police, Ankara, March 2012.
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9. PRECURSOR TRENDS AND  
MANUFACTURING METHODS
Amphetamine-type-stimulants (ATS) comprise a number 
of substances under international control, primarily 
amphetamine, methamphetamine, ecstasy-group sub-
stances (3,4-methylenedioxymethamphetamine (MDMA), 
3,4-methylenedioxyamphetamine (MDA), 3,4-methylen-
edioxyethylamphetamine (MDE)) and methcathinone. 
There are numerous methods for the synthesis/manufac-
ture of these substances and a wide range of precursor 
chemicals can be used. However, it is possible to identify 
the most commonly used chemicals which are listed in 
Table I and Table II of the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988. 
The majority of the precursor chemicals that can be used 
in the illicit manufacture of ATS and synthetic drugs have 
widespread licit use in the chemical and pharmaceutical 
industries. As such, their diversion from licit trade by drug 
trafficking organizations is the primary source of precursor 
chemicals used in the illicit manufacture of synthetic drugs. 
The 1988 United Nations Convention provides measures 
to assist Member States in preventing the diversion of these 
chemicals and the International Narcotics Control Board 
(INCB) has a number of resources to monitor the licit/
illicit trade in precursor chemicals and developments/trends 
in the use of existing and novel precursor chemicals.
Data on the precursor chemicals and trends in their use is 
an invaluable source of information for law enforcement, 
forensic science and customs personnel in their respective 
roles in tackling the global trade in illicit drugs, the iden-
tification of the chemicals involved and prevention of their 
diversion. This chapter provides an overview of the recent 
trends with regard to the precursors used in the illicit man-
ufacture of ATS and  the responses of Member States and 
International Organizations in tackling the issue of the 
illicit manufacture of synthetic drugs
International responses to precursor 
trends in the manufacture of ATS
There have been a number of measures implemented by 
International Organisations and National Governments 
in recent years to tackle issues related to the diversion of 
precursor chemicals for use in the illicit manufacture of 
ATS. Precursor control initiatives initiated by the INCB 
including the establishment of the Precursor Incident 
Communication System (PICS) in 2012 revealed the con-
tinued emergence of phenylacetic acid as a precursor for 
the illicit manufacture of amphetamine and methampheta-
mine. The emergence of phenylacetic acid as an important 
precursor led to its rescheduling from Table II to Table I 
of the 1988 UN Convention as of 2011. While many 
countries had existing legislation to monitor transactions 
and shipments of this chemical, a number of countries 
have recently amended their national legislation or adopted 
stricter measures. These included Canada, China, countries 
of the European Union and the South and Central Ameri-
can countries, El Salvador, Guatemala, Mexico, Nicaragua 
and Paraguay.
Previous INCB initiatives had  revealed a shift from the 
use of pure ephedrine/pseudoephedrine to the use of phar-
maceutical preparations containing these precursor chemi-
cals. This trend follows the pattern of a response by drug 
traffickers to increased national awareness of and control 
measures on existing precursors. In recent years, a number 
of countries have also amended their legislation to more 
closely monitor pharmaceutical preparations containing 
ephedrine or pseudoephedrine. Over the 2010-2013 
period, such amendments to legislation have been adopted 
by Australia, China, India New Zealand, the Republic of 
Korea, the Russian Federation, Thailand and Uruguay 
among others.410, 411 A direct consequence of the increased 
awareness of the use of alternate precursors and the intro-
duction of new legislation is increased seizures of such 
substances in their various forms and thus a more clear 
picture of the methods used worldwide for the manufac-
ture of ATS is made possible. Another consequence of 
increased precursor controls in countries with significant 
illicit ATS manufacture is that traffickers target countries 
with less established control systems and shift their manu-
facture and purchase of precursors to these countries. Thus, 
illicit manufacture continues to spread in African countries 
such as Nigeria and in South and Central America.412
Trends in methamphetamine precursors: 
ephedrine and pseudoephedrine
Ephedrine and pseudoephedrine are attractive precursors 
as they are widely used in legitimate trade, and thus are 
more easily targeted for diversion. Also, their transforma-
410 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
411 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, 2014.
412 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
70
2014 GLOBAL SYNTHETIC DRUGS ASSESSMENT
pharmaceutical preparations containing ephedrine/ pseu-
doephedrine. In the years 2009-2012, over 46 tons were 
reported seized by Member States in addition to the seizure 
of over 62 million tablets in this time period. 
Within South and South East Asia, where there is consid-
erable legitimate manufacture of pharmaceutical prepara-
tions containing ephedrine and pseudoephedrine, 
significant seizures of these preparations have been increas-
ingly reported since 2010. Myanmar is one of the main 
destinations in the region for trafficked preparations which 
are primarily smuggled overland from China and India. 
According to a report presented at the Asia-Pacific Opera-
tional Drug Enforcement Conference (ADEC), 1.7 tons 
of pseudoephedrine primarily in the form of pharmaceuti-
cal preparations were seized in Myanmar in 2011 and over 
6.9 tons were seized in 2012.414 Seizures of pharmaceutical 
414 “Myanmar country report”, Central Committee for Drug Abuse Con-
tion to methamphetamine is a relatively straightforward 
procedure that can be mediated by a variety of chemicals. 
Multi-ton amounts of these chemicals are seized every year 
and as a result of increased awareness, the number of coun-
tries now reporting seizures has doubled in 10 years accord-
ing to the INCB.413 In the years 2009-2012, 141 tons of 
bulk ephedrine/ pseudoephedrine were reported to the 
INCB as having been seized. In 2010 for example, China, 
India, Mexico and the United States all with multi-ton 
seizures accounted for 84% of global seizures.
Despite the continued seizures of precursors in bulk form, 
it has become evident in recent years that the use of alter-
nate forms of these precursors also continues to increase 
in certain parts of the world. The first evidence of this is 
seen with the continued increase in use and seizures of 
413 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
Precursors for amphetamine  
 and methamphetamine
The primary precursor chemicals used in the 
manufacture of amphetamine and methampheta-
mine are ephedrine, pseudoephedrine and 1-phe-
nyl-2-propanone (P-2-P). Ephedrine and 
pseudoephedrine are widely used in the manufac-
ture of decongestants and bronchodilators, while 
the primary use of P-2-P is in the legitimate 
manufacture of amphetamine/methampheta-
mine by the pharmaceutical industry. Pheny-
lacetic acid is also an important precursor of 
P-2-P and norephedrine is another precursor that 
can be used for the synthesis of amphetamine
 Precursors for “ecstasy-type  
 substances”
The primary precursor chemicals used in the 
manufacture of MDMA and its analogues, MDA 
and MDEA, are safrole (including in the form of 
safrole rich oils), isosafrole, piperonal and 
3,4-methylenedioxyphenyl-2-propanone 
(3,4-MDP-2-P). Of these precursors, 3,4-MDP-
2-P has little legitimate use, while safrole, isosaf-
role and piperonal are used worldwide in the 
chemical and pharmaceutical industries and thus 
are more prone to diversion from licit trade. As 
with other ATS, the manufacture of ecstasy-
group substances is quite flexible given that the 
products themselves are analogues and also, that 
it is possible to convert MDA into both MDMA 
and MDE.
1-phenyl-2-propanone (P-2-P)
benzyl methyl ketone (BMK)
esters of 
phenylacec acid
alphaphenylacetoacetonitrile
(APAAN)
P-2-P bisulfite
phenylacec acid
norephedrine ephedrine / pseudo-
ephedrine
amphetamine methamphetamine
Precursors and pre-precursors
ATS
3,4-methylenedioxyphenyl-2-
propanone (3,4-MDP-2-P)
piperonal
isosafrole
safrole
MDA
MDMA
MDE
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preparations containing pseudoephedrine and ephedrine 
preparations have also been on the increase in other coun-
tries in the region including China, the Republic of Korea, 
Lao People’s Democratic Republic, Singapore and Thai-
land.415 The seizures have in some cases been destined for 
locations with the region, but also to Central America, 
either directly or via Europe. Within the Oceanic region, 
in both Australia and New Zealand there have also been 
increased reports of seizures of pharmaceutical preparations 
in the form of ContacNT416. New Zealand reported its 
highest seizure in 2010 (more than 0.9 tons) and a 1.3 ton 
seizure was made in Australia in 2012.417 Also, in 2012, 
Australia reported its second highest detection weight of 
ATS precursors (excluding MDMA) in a decade, at approx-
imately 1.8 tons.418 The majority of methamphetamine 
precursors seized in recent years in Australia, have been 
ephedrine and pseudoephedrine based, with P-2-P only 
accounting for 0.03 per cent of the total weight of precur-
sors seized.419 This statistic is in stark contrast to the situ-
ation in Europe, countries of Central America, Mexico and 
North America.
Trends in amphetamine and methamphet-
amine precursors: 1-phenyl-2-propanone 
(P-2-P) and phenylacetic acid
The flexibility of ATS manufacture is reflected in the 
number of precursor chemicals that can be used and indeed 
an even wider range of chemicals that can convert the pre-
cursors to the controlled drugs. The primary alternate pre-
cursor to pseudoephedrine and ephedrine in the 
manufacture of amphetamine and methamphetamine is 
1-phenyl-2-propanone (P-2-P). The second most notable 
trend  in recent years in the illicit manufacture of meth-
amphetamine is the increasing shift towards P-2-P based 
routes involving precursors and derivatives of P-2-P in 
certain regions of the world. In particular, phenylacetic 
acid (a direct precursor to P-2-P) and its derivatives have 
been used in increasing amounts in the illicit manufacture 
trol (CCDAC), presented at the Eighteenth Asia-Pacific Operational 
Drug Enforcement Conference (ADEC), Tokyo, 26-27 February 
2013.
415 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
416 ContacNT is distinct granular pharmaceutical formulation containing 
pseudoephedrine; International Narcotics Control Board (INCB), Pre-
cursors and chemicals frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances, New York, January 2013.
417 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2011; International Narcotics 
Control Board (INCB), Precursors and chemicals frequently used in the 
illicit manufacture of narcotic drugs and psychotropic substances, New 
York, 2014.
418 “Illicit Drug Data Report 2011-12”, Australian Crime Commission 
(ACC), Canberra, May 2013.
419 “Illicit Drug Data Report 2011-12”, Australian Crime Commission 
(ACC), Canberra, May 2013.
Fig. 41: Global seizures of methamphetamine  
precursors (bulk), 2009-2012
Fig. 42: Global seizures of pharmaceutical prepa-
rations of methamphetamine precursors, 
2009-2012
Fig. 43: Global seizures of 1-phenyl-2-propanone 
(P-2-P) and phenylacetic acid, 2009-2012
Source: International Narcotics Control Board (INCB), Precursors 
and chemicals frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances, for 2010, 2011, 2012, 2013.
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of amphetamine/methamphetamine. As a consequence, 
phenylacetic acid was rescheduled from Table II to Table 
I of the 1988 convention as of January 17, 2011.The use 
of such precursors has increased in recent years partly as a 
result of increased control measures and effective monitor-
ing of ephedrine and pseudoephedrine. Manufacturing 
routes based on P-2-P are historically preferred in Europe, 
where this precursor is mainly used to manufacture 
amphetamine. In 2011, half of the 5,312 litres of P-2-P 
seized worldwide was reported by European countries, 
although this decreased to 12 % of global seizures of P-2-P 
in 2012, with Mexico accounting for 4,699 (69 %)of the 
total of 6,818 litres seized.
It is, however, the increase in the seizures of phenylacetic 
acid in recent years that is most notable, particularly in the 
United States, Mexico and Central America. There were 
significant seizures in Mexico (56.1 tons in 2010) and the 
United States (122.7 tons in 2010 and 997 tons in 2011) 
providing evidence of the shift away from ephedrine/pseu-
doephedrine based manufacturing methods in the region. 
Despite the fact that seizures of both P-2-P and phenyl-
acetic acid decreased dramatically in 2012, forensic profil-
ing of seized methamphetamine in the United States 
confirmed that currently, nearly all of the analysed meth-
amphetamine is manufactured using phenylacetic acid or 
other P-2-P based methods (94 % of all samples tested in 
the second quarter of 2012, up from 69 % in 2010 and 
close to 1 % in 2007).420 This shift in manufacturing 
methods is also showing signs of spreading to Central 
American countries and in Guatemala declining seizures 
of ephedrine and pseudoephedrine have been reported in 
2013 coincident with the seizure of more than 1,000 litres 
of P-2-P in a clandestine laboratory in Tecun Uman, a 
border city between Guatemala and Mexico.421
Trends in ecstasy-group substance  
precursors
The main precursor chemicals used in the manufacture of 
ecstasy-group substances are included in Table 1 of the 
1988 Convention and their licit trade and reported diver-
sions to illicit manufacture are monitored by the INCB. 
Seizures of these precursors have increased in 2012- 2013 
following a number of years where there was a consider-
able discrepancy in the volume of seizures compared to the 
worldwide availability of the drugs themselves, in particular 
MDMA. While the amounts of 3,4-MDP-2-P and piper-
onal seized continue to be low, safrole and safrole rich oil 
seizures have increased with Cambodia, Malaysia, Mexico 
420 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York 2013, p. 16. 
421 United Nations Office on Drugs and Crime (UNODC), Global 
SMART Update Volume 10, Global Synthetics Monitoring: Analyses, 
Reporting and Trends (SMART) Programme, Vienna, September 
2013.
and the United States all reporting seizures greater than 
2,000 litres in 2011, while Australian authorites reported 
a seizure of 3.5 tons of safrole in 2012.422423 Within Cam-
bodia, a further 4,000 litres of safrole rich oils were seized 
in a clandestine laboratory in 2012.424 Within Europe, the 
Belgian authorities seized almost 10,000 litres of safrole 
rich oils in 2011 and in August and October 2013, two 
industrial scale clandestine MDMA laboratories were dis-
mantled in Belgium.425 In the first of these cases, several 
tons of safrole were seized and in the second 35 tons of as 
yet unidentified chemicals were found.
Non-controlled precursors used in  
the manufacture of amphetamine-type 
stimulants
Coincident with the increased use of phenylacetic acid in 
recent years, there has been a significant rise in the use of 
non-controlled precursor chemicals in the manufacture of 
amphetamine, methamphetamine and ecstasy-group sub-
stances. This development can also be attributed in part 
to increased control measures on listed precursor chemicals 
and successes in preventing their diversion to illicit manu-
facture forcing drug traffickers to seek alternative chemicals 
and/or masked precursors.
The use of such non-scheduled derivatives of known pre-
cursors is a continuing trend and Operation Phenylacetic 
Acid and its Derivatives (PAAD) initiated by the INCB in 
2011 revealed the extent to which derivatives of pheny-
lacetic acid were being used in Mexico and Central Ameri-
can countries. The initiative revealed a shift toward the use 
of non-controlled precursors in the region. The most com-
monly seized derivatives were the methyl and ethyl esters 
of phenylacetic acid and seizures of 526 tons and 430,000 
litres of these pre-precursors were reported in 2011 by 
Mexico and El Salvador and in 2012 Guatemala reported 
the seizure of 16,000 kg of ethyl phenylacetate.426 
 A number of other phenylacetic acid derivatives or pre-
cursors were also reported including phenylacetamide, 
benzyl chloride and benzylcyanide. These non-controlled 
precursors can be converted to phenylacetic acid and/or 
P-2-P by straightforward transformations, and while ana-
422 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, January 2013.
423 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, 2014.
424 Official communication with the National Authority for Combating 
Drugs (NACD), October 2012.
425 Europol (European Police Office), “Police discover largest synthetic 
drugs production side ever found in the EU”, the Hague, the Neth-
erlands, 23 October 2013, at https://www.europol.europa.eu/content/
police-discover-largest-synthetic-drugs-production-site-ever-found-eu.
426 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, 2014.
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Table 3: Most commonly used ATS manufacturing methods and the yields of the stated methods
* at 75% safrole.
Source: Drug Yield Calculator (V5.0), Royal Canadian Mounted Police and Health Canada; Suravina, L. G. and Voronenko, L. A. (1994). 
Forensics Investigation of Narcotic and Drastic Substances Obtained from Ephedra Grass Using Home Production Methods. Ministry of 
Justice of the Republic of Kazakhstan, Kazakhs Scientific Research Institute; DEA, Methamphetamine Synthesis #7 (1997).
logue legislation  in some countries can be used to control 
such deriviatives, the relationship between the controlled 
precursor and its masked derivative is sometimes not easily 
identified.
Another non-controlled precursor of P-2-P, alphapheny-
lacetoacetonitrile (APAAN) has emerged since 2011 in in 
a number of European countries in particular, where multi-
ton seizures of shipments from China to the Netherlands 
were reported. Seizures of APAAN increased in 2012 when 
a total of 17.5 tons were seized in Europe. Significant sei-
zures of APAAN has also been made in Canada in 2012, 
indicating the spread of its use to other ATS manufactur-
ing regions. As a consequence of the increased use of 
APAAN in the manufacture of ATS and its limited use in 
legitimate trade,427 APAAN was on the agenda of the fifty-
seventh session of the Commission on Narcotic Drugs 
(CND) for the inclusion in Table I of the United Nations 
427 European Monitoring Centre for Drugs and Drug Addiction, "Per-
spectives on Drugs; Synthetic Drug Production in Europe", 2013.
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 at the time of writing 
this report.
Evidence of the use of non-controlled precursors in the 
manufacture of ecstasy-group substances has also increased 
in recent years, with seizures of 1,200 kg of the methyl 
glycidate derivative of 3,4-MDP-2-P in 2010. This trend 
continued in 2011 with the discovery of helional in several 
clandestine laboratories in Australia and the United 
States.428 This non-controlled precursor chemical, widely 
used in the chemical industry as a fragrance agent, can be 
used in the manufacture of MDA and thus also MDMA 
and MDE.
428 Trotter Brendan, et.al. “Manufacture of 3,4-Methylenedioxyampheta-
mine From Helional Encountered in Australia” Journal of the Clandes-
tine Laboratory Investigating Chemist Association (23)(1) Jan. 2013: 4; 
Kovacs III, Edward J. and Dean A. Kirby, “Manufacture of 3,4-Meth-
ylenedioxyamphetamine From Helional Encountered in Australia” 
Journal of the Clandestine Laboratory Investigating Chemist Association 
(23)(1) Jan. 2013: 5-14.
End Product
Precursor 
(1 kg or 1 lt.)
Synthesis Method (Method)
Practical 
Yield
Amphetamine P-2-P (lt.) Ammonium formate (Leuckart) 55%
Amphetamine P-2-P (lt.) Formamide (Leuckart) 67%
d,l-Methamphetamine P-2-P (lt.) Formic acid (Leuckart) 60%
d-Methamphetamine Pseudo/ephedrine (kg) Red phosphorus / iodine 47%
d-Methamphetamine Pseudo/ephedrine (kg) Red phosphorus / hydriodic acid 54%
d-Methamphetamine Pseudo/ephedrine (kg) Lithium / ammonia (‘Birch’) 55%
d-Methamphetamine Pseudo/ephedrine (kg) Hypophosphorous acid / iodine 76%
d-Methamphetamine Pseudo/ephedrine (kg) Thionyl chloride (Emde) 70%
Methcathinone Pseudo/ephedrine (kg) Potassium permanganate 50%
MDA Sassafras oil* (lt.) Hydrogen peroxide / sodium  
cyanoborohydride
12%
MDA 3,4-MDP-2-P (lt.) Sodium cyanoborohydride 37%
MDA Piperonal Nitroethane 41%
MDMA Sassafras oil* (lt.) Hydrogen peroxide / aluminium amalgam 31%
MDMA Sassafras oil* (lt.) Hydrobromic acid 48%
MDMA 3,4-MDP-2-P (lt.) Formic acid (Leuckart) 66%
MDMA Sassafras oil* (lt.) Methyl nitrite / aluminium  
amalgam (Wacker)
68%
MDMA 3,4-MDP-2-P (lt.) Aluminium amalgam (reductive amination) 95%
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Glycidic acid derivatives of both P-2-P and 3,4-MDP-2-P 
have also emerged as novel ATS pre-precursors in 2012.429 
 The increasing use of non-controlled precursors reflects 
the increasing sophistication of ATS manufacture and the 
difficult challenges currently faced by Governments in their 
efforts to tackle the trafficking in precursor chemicals.
Manufacturing methods
The chemical transformations involved in the conversion 
of the precursor chemicals to illicit ATS products are 
mostly well known chemical reactions, described in the 
scientific literature and are also freely available on the inter-
net. Due to the similarity of the products, many methods 
can be adapted for the manufacture of different products. 
One example of this is the use of P-2-P to make ampheta-
mine or methamphetamine. The change in methampheta-
mine manufacturing methods in certain regions of the 
world to P-2-P based methods has resulted in dramatically 
increased seizures of methylamine (665 tons and 478,000 
litres were seized in 2011). This chemical can be used in 
429 International Narcotics Control Board (INCB), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, New York, 2014.
methamphetamine manufacture using P-2-P (also used in 
MDMA manufacture with 3,4 MDP-2-P). One notable 
difference between methamphetamine produced by P-2-P 
based routes compared with ephedrine/pseudoephedrine 
based routes is the nature of the product. Both ephedrine 
and pseudoephedrine produce the more potent d-meth-
amphetamine, whereas a mixture of d- and l-methamphet-
amine is produced from P-2-P. Therefore, in order to 
produce d-methamphetamine from P-2-P an extra step is 
required and certain other chemicals are required whose 
presence in a clandestine laboratory can indicate P-2-P 
based manufacture.
Manufacture methods using  
pre-precursors
Considering the recent developments in the increasing use 
of phenylacetic acid, its derivatives and  other non-sched-
uled precursor chemicals for the manufacture of ATS, it 
should be noted that with such precursors, extra chemical 
steps can be required to manufacture the final ATS prod-
uct. For example, chemicals such as acetic anhydride or 
lead acetate are used to convert phenylacetic acid to P-2-P 
and recently seizures of acetic anhydride, typically regarded 
as a precursor for the production of heroin, have increased 
Chemical structures of typical synthetic cannabinoids
JWH-018 (1-pentyl-3-(1-naphthoyl)indole) (A),
APINACA (1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide) (B)
PB-22 (1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid ester) (C)
Manufacture of 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25C-NBOMe) (E)  
using 2C-B (4-bromo-2,5-dimethoxyphenethylamine) (D)
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in Mexico.430 The conversion of phenylacetic acid esters 
to P-2-P can also require an intermediate step.
Similarly, the use of APAAN in the manufacture of 
amphetamine or methamphetamine requires its interme-
diary conversion to P-2-P. However, despite the extra steps 
that are required when using non-scheduled precursors, 
their eventual conversion to illicit drugs is relatively 
straightforward and the benefits of their use to traffickers 
are obvious compared to the more tightly controlled well 
known precursors. Another consequence of the increased 
sophistication of ATS manufacturing methods, is the 
improved efficiency of the manufacturers. For example, it 
was reported that the use of larger scale industrial equip-
ment has enabled amphetamine manufacturing facilities 
in Belgium and the Netherlands to increase their yields per 
batch from 5-8 kg several years ago to a current 40 kg per 
batch.431
Manufacture of New Psychoactive  
Substances (NPS)
By December 2013, over 348 NPS had been reported to 
the UNODC early warning advisory432. It is possible to 
classify the majority of these molecules into the following 
substance groups based on structural similarities: aminoin-
danes, synthetic cannabinoids, synthetic cathinones, keta-
mine and phencyclidine-type substances, phenethylamines, 
piperazines, plant-based substances, tryptamines plus a 
group of miscellaneous substances. As a consequence of 
the number and diverse chemical structure of the new psy-
choactive substances, it has not been possible to compre-
hensively examine their methods of manufacture and 
identify and prioritise key precursor chemicals. However, 
within certain substance groups, it is possible to see 
common approaches to synthetic methods. Based on the 
recent trends  in the appearance of new substances, it is 
also possible to understand what approaches are used in 
their manufacture to by-pass legislative responses of 
Member States to the emergence of NPS. Examples of the 
manufacture of selected NPS are provided in the following 
sections.
Synthetic cathinones
The synthetic cathinone most commonly reported to the 
UNODC is mephedrone (4-methylmethcathinone), which 
can be manufactured by a two-step process using 4-meth-
ylpropiophenone as one of the main precursors. This com-
pound can be brominated and then reacted with another 
430 United Nations Office on Drugs and Crime (UNODC) and Organi-
zation of American States (OAS), Amphetamine-Type Stimulants in 
Latin America, February 2014.
431 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), “Perspectives on drugs: Synthetic drug production in 
Europe”, 2013.
432 For more information on the Early Warning Advisory (EWA) see www.
unodc.org/nps.
precursor, methylamine to give mephedrone. This syn-
thetic route is flexible and a number of cathinone deriva-
tives can be manufactured by slight modifications to the 
precursors. For example, changing the position and/or 
identity of the alkyl group in 4-methylpropiophenone can 
produce a number of known cathinone compounds; e.g 
3-methylpropiophenone generates 3-methylmethcathi-
none and 4-ethylpropiophenone enables the manufacture 
of 4-ethylmethcathinone. In a similar manner, substituting 
methylamine with another amine such as ethylamine ena-
bles the manufacture of a series of ethcathinone 
derivatives. 
Synthetic cannabinoids
The identification of methods/precursors for the manu-
facture of synthetic cannabinoids is complicated by the 
fact that this group of NPS contains a large number of 
structurally diverse substances. The synthetic cannabinoids 
can to some extent be subdivided into certain structural 
classes, however as new derivatives continue to appear on 
the market, new classifications are required. Naphthoylin-
doles are one of the main sub-groups of synthetic cannabi-
noids and JWH-018 (1-pentyl-3-(1-naphthoyl)indole) (see 
figure) is one of the most commonly reported substances. 
JWH-018 can be manufactured in two steps with indole 
as one of the primary precursors. Alkylation of indole with 
n-pentylbromide followed by reaction with 1-naphthoyl 
chloride produces JWH-018.433 Altering the precursors 
by adding/varying  substitutents can produce a wide vari-
ety of possible synthetic cannabinoids and other structural 
classes of synthetic cannabinoids can be obtained by chang-
ing the naphthoyl group to a benzoyl or a phenacetyl 
group.
Examination of synthetic cannabinoids that have appeared 
recently reveals some common approaches used to manu-
facture new compounds. These approaches have included: 
(see diagram)
 • the replacement of a hydrogen in the terminal carbon 
of the alkyl chain with fluorine or chlorine. 
 • the use of indazole instead of indole as a starting mate-
rial e.g APINACA (1-pentyl-N-tricyclo[3.3.1.13,7]
dec-1-yl-1H-indazole-3-carboxamide) 
 • the use of different linkages. JWH-018 has a  
ketone linkage, whereas PB-22 (1-pentyl-8-quinolinyl 
ester-1H-indole-3-carboxylic acid ester) has an ester 
linkage and MN-24 (N-1-naphthalenyl-1-pentyl-1H-
indole-3-carboxamide) has an amide linkage group.
433 Huffman, J.W., et.al., “Structure–activity relationships for 1-alkyl-
3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: 
steric and electronic effects of naphthoyl substituents. New highly 
selective CB2 receptor agonists”, Biorganic and Medicinal Chemistry 
(13)(1) Jan. 2005: 89-112.
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Phenethylamines
Phenethylamines are a group of NPS consisting of com-
pounds that all contain the 2-phenyl-2-ethanamine group 
but also can have a variety of substituents in a number of 
different positions. As with the other NPS mentioned, the 
methods for the manufacture of phenethylamines are 
diverse and varied, thus it is difficult to identify key manu-
facturing methods or precursors. However, the approach 
of the manufacturers of NPS to the development of new 
substances can be illustrated with an example from the 
phenethylamine group of substances.
2C-B (4-bromo-2,5-dimethoxyphenethylamine), a sub-
stance controlled under schedule II of the United Nations 
convention on Psychotropic Substance 1971 is a member 
of the 2C class of phenethylamines of which there are 
approximately 27 members. 2C-B itself can be used as a 
precursor for manufacture of the hallucinogenic 
2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine 
(25C-NBOMe) (see diagram). In a similar manner, reac-
tion of any 2C drug with 2-methoxybenzaldehyde pro-
duces the corresponding NBOMe compound. In recent 
years, a number of NBOMe compounds have appeared in 
NPS markets and in the last 6 months more novel derivi-
atives of NBOMe compounds have been reported to 
UNODC.
 
